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Adhesion of sickle erythrocytes to vascular 
endothelium may initiate or propagate occlusive events in 
sickle cell anemia, many of which are accompanied by 
infection and the associated inflammatory response.  
Inflammatory markers are also present in sickle patients 
during asymptomatic periods.  Inflammatory cytokines 
upregulate expression of endothelial adhesion molecules 
that promote adhesion of sickle erythrocytes.  The data in 
this work demonstrate that after 2 hrs of stimulation with 
the cytokine TNF-α, E-selectin, but not VCAM-1 is 
upregulated on human dermal microvascular endothelial 
cells.  After 6 hrs of TNF-α stimulation, both VCAM-1 and 
E-selectin expression are upregulated on MECs, and sickle 
erythrocytes bind to both receptors.  Because strategies to 
control inflammation-associated adhesion in vivo may need 
to account for both VCAM-1 and E-selectin mediated events, 
control of intracellular signaling pathways leading to 
receptor expression is an attractive strategy for 
inhibiting adhesion.  Cyclic AMP and nitric oxide are two 
xxvi 
intracellular signaling molecules important to cytokine-
induced receptor expression.  The data in this work 
demonstrate that TNF-α induced VCAM-1 and E-selectin 
expression on endothelial cells and sickle erythrocyte 
adhesion are abated by increasing endothelial cyclic AMP 
concentrations using Forskolin, IBMX, or Bt2cAMP.  
Conversely, when sickle erythrocytes, rather than 
endothelial cells, are treated with reagents that increase 
intracellular cAMP, adhesion to unstimulated endothelial 
cells is increased in some patients.  Treatment of 
endothelial cells with reagents such as SNP and DETA-NO 
that increase nitric oxide significantly inhibits VCAM-1, 
but not E-selectin expression, induced by TNF-α stimulation 
and significantly inhibits sickle erythrocyte adhesion.  
Treatment of sickle erythrocytes directly with these 
reagents may also inhibit adhesion.  Together these data 
suggest that cAMP- and nitric oxide-dependent signaling are 
useful therapeutic targets to inhibit cytokine-induced 

















 Sickle cell anemia is a genetic disorder estimated to 
affect 70,000 Americans, primarily of African descent.  It 
is caused by the homozygous inheritance of the sickle β 
hemoglobin gene, which codes for the amino acid valine in 
the 6th position rather than glutamic acid.  This 
substitution of a hydrophobic amino acid for a normally 
hydrophilic one results in the ability of the hemoglobin 
molecules to aggregate upon deoxygenation. Hemoglobin 
gelation is the cause of the rigid, “sickle”-shaped 
erythrocytes for which the condition is named.   
Complications associated with sickle cell anemia are 
systemic, as bones, lungs, brain, spleen, kidneys, heart, 
eyes, and other organs may be affected in some patients.  
Vascular complications in sickle cell anemia are 
multifactorial and complex, affecting both large and small 
vessels.  The most common microvascular problem in tissues 
is the vaso-occlusive pain episode caused by blood flow 
2 
blockage leading to tissue ischemia and severe pain.  The 
abnormal adhesion of sickle erythrocytes to vascular 
endothelium may initiate or propagate vaso-occlusion.  This 
adherence may slow down blood flow, allowing subsequent 
entrapment of non-deformable, sickled cells and propagation 
of the pain episode. 
At a post-capillary venular shear stress of 1 dyne/cm2, 
sickle erythrocyte adherence to endothelium occurs via 
binding of specific receptors and ligands on erythrocytes 
and endothelial cells.  Inflammatory mediators (cytokines, 
chemokines) and thrombotic factors (vWF, etc.) contribute 
to the development of these high affinity receptor/ligand 
interactions in vitro by increasing cell adhesion molecule 
expression, receptor affinity, and adhesive protein 
concentration in the microcirculation.  The presence of 
cytokines and activated monocytes, neutrophils, and 
platelets in sickle blood during asyptomatic periods and 
pain events provides in vivo support for the roles of 
inflammation and thrombosis in the pathogenesis of pain 






1.1  Thesis Rationale 
 
The cytokine tumor necrosis factor (TNF-α) induces 
expression of endothelial receptors VCAM-1, E-selectin, and 
ICAM-1.  VCAM-1 and E-selectin bind specifically to ligands 
on sickle erythrocytes (ICAM-1 does not), suggesting that 
strategies to inhibit interactions between sickle 
erythrocytes and VCAM-1 and E-selectin may be of potential 
benefit to sickle patients.  It is hypothesized that sickle 
erythrocyte adherence induced by inflammatory mediators 
such as TNF-α is abated by interruption of endothelial cell 
signaling cascades normally associated with cytokine 
stimulation.  Specifically, the aims outlined below probe 
the roles of secondary messengers cyclic 3’5’-adenosine 
monophosphate (cAMP) and nitric oxide (NO) in interruption 
of signaling normally leading to expression of adhesion 
molecules VCAM-1 and E-selectin in microvascular 
endothelial cells.  These studies suggest therapeutic 
strategies to reduce erythrocyte adherence and control 




1.1.1  Specific Aim #1:  Regulate Endothelial Cell Adhesion 
Molecule Expression and Sickle Erythrocyte Adhesion by 
Modulation of Intracellular cAMP 
Literature suggests that increasing intracellular cAMP 
in endothelial cells decreases TNF-α induced VCAM-1 and E-
selectin expression.  Studies in this aim test the effect 
of forskolin, an activator of the adenylate cyclase enzyme 
that makes cAMP, isobutylmethylxanthine, an inhibitor of 
the phosphodiesterases that break down cAMP, and dibutyryl 
cAMP, a cell-permeable cAMP analogue, on TNF-α induced 
expression of these adhesion molecules and on sickle 
erythrocyte adhesion to microvascular endothelium.  
Specifically, the time course and dose dependent effects of 
forskolin on endothelial cAMP concentration and adhesion 
molecule expression are measured using ELISA, and 
conditions corresponding to maximal effect on adhesion 
molecule expression are used to test the effect on sickle 
erythrocyte adherence in flow assays in vitro.  Antibody 
blocking of VCAM-1 and E-selectin confirms the roles of 
these molecules in TNF-α induced adhesion of sickle 
erythrocytes.  The effect of these reagents on sickle 
erythrocyte adhesion when the erythrocytes, rather than the 
endothelial cells, are treated is also documented.  
5 
Completion of these studies results in 1) establishment of 
the time course of the relative contributions of VCAM-1 and 
E-selectin in the promotion of sickle erythrocyte adhesion 
to TNF-α stimulated microvascular endothelium, 2) 
demonstration that increasing endothelial intracellular 
cAMP is effective at reducing cytokine-induced expression 
of VCAM-1 and E-selectin and adhesion of sickle 
erythrocytes, and 3) addition of evidence that targeting of 
intracellular pathways may be useful therapies in 
controlling vaso-occlusive complications in sickle 
patients. 
 
1.1.2  Specific Aim #2:  Regulate Adhesion Molecule 
Expression and Sickle Erythrocyte Adhesion to Endothelial 
Cells by Modulation of Intracellular Nitric Oxide. 
Despite its emerging role as an important mediator of 
several clinical phenomena relevant to sickle cell anemia, 
little is known about the specific effects of nitric oxide 
(NO) on sickle cell adherence to endothelial cells.  One 
important potential effect of NO is its ability to 
interrupt cytokine-induced expression of adhesion molecules 
on endothelial cells.  One goal of the studies in this aim 
is to harness the ability of NO to regulate adhesion 
6 
molecule expression to reduce adhesion of sickle 
erythrocytes to endothelial cells.  Experiments in this aim 
characterize the effect of the NO donors sodium 
nitroprusside and 2,2'-(Hydroxynitrosohydrazono)bis-
ethanimine (DETA-NO) on TNF-α induced VCAM-1 and E-selectin 
expression on microvascular endothelium (ELISA) and 
demonstrate that increasing endothelial NO is effective at 
reducing adhesion of sickle erythrocytes (flow assays). 
These experiments also show the effect of treatment of 










2.1  Sickle Cell Anemia 
 
2.1.1  Etiology 
 Sickle cell hemoglobinopathies are caused by the 
genetic inheritance of hemoglobin of altered structure.  
Hemoglobin protein is comprised of two α subunits, the 
structures of which are determined by four α globin genes 
on the 16th chromosome, and two ß subunits, the structures 
of which are determined by two ß globin genes on chromosome 
11 (S. H.  Embury et al., 1994).  Sickle 
hemoglobinopathies, two of the most common of which in the 
United States are sickle cell anemia (HbSS) and sickle ß 
thalassemia (Hbßthal), result from altered ß globin 
structure (Bunn & Forget, 1986).   
Sickle cell anemia results from the substitution of 
valine for glutamic acid in the sixth amino acid of the ß 
globin chains (Pauling et al., 1949).  Homozygous 
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inheritance of this hemoglobin results in sickle cell 
anemia and clinical symptoms, while heterozygous 
inheritance results in sickle cell trait (HbSA) and 
generally few clinical complications (Stark et al., 1980).  
Sickle ß thalassemia disorders result from inheritance of 
one sickle ß gene and one ß thalassemia gene.  Other common 
hemoglobinopathies result from inheritance of one sickle ß 
globin gene and one other mutated ß globin gene.  In total, 
more than 400 abnormal hemoglobin variants are known to 
exist (Bunn & Forget, 1986), and clinical symptoms may 
range from non-existent to quite severe.  While many 
clinical similarities exist between the different 
hemoglobinopathies, the studies presented in this document 
involve only patients with homozygous sickle cell anemia 
(SCA). 
 
2.1.2  Natural and Medical History 
 Origin of the sickle hemoglobin gene and sickle cell 
anemia has been traced to three regions in Africa:  Benin, 
Senegal, and the Central African Republic (Pagnier et al., 
1984).  While the time at which the mutation occurred is 
not known exactly, it likely happened 2,000 to 3,000 years 
ago, coinciding with the introduction of iron tools, 
destruction of forests, and the endemicity of the 
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Plasmodium falciparum malarial parasite (Livingstone, 
1958).  The inheritance of sickle trait is thought to 
protect individuals against malarial infections, thus 
allowing the gene to be passed to future generations 
(Allison, 1954).   
 While some evidence points to the recognition by 
indigenous people of familial pain patterns (Konotey-Ahulu, 
1974), little was known about causes of pain or sickle cell 
anemia until the 20th century.  Sickled erythrocytes were 
first documented in 1910 by Dr. J.B. Herrick, a physician 
studying the abnormal blood smear of a dental student from 
Grenada who later experienced a painful crisis (Herrick, 
mp;list_uids=8919662 </url></related-
he abnormal hemoglobin protein structure of sickle cell 
anemia by electrophoresis in 1949 (Pauling et al., 1949), 
but the exact amino acid substitution was not known until 
1956 (Ingram, 1956).  Studies explaining how altered 
hemoglobin structure is linked to erythrocyte sickling and 







2.2  Clinical Symptoms 
 
2.2.1  Hemoglobin Aggregation 
 Unlike normal hemoglobin, sickle hemoglobin has a net 
positive charge which results in reduced solubility (Perutz 
& Mitchison, 1950).  Upon deoxygenation in the 
microcirculation, sickle hemoglobin molecules reversibly 
aggregate into paracrystalline polymers (Magdoff-Fairchild 
et al., 1976; Noguchi & Schechter, 1981).  These aggregates 
can form long fiber bundles (Dykes et al., 1978), which 
distort the erythrocyte into the characteristic “sickle” 
shape described by Herrick (Herrick, 1910).   
 Aggregation of sickle hemoglobin depends on sickle 
hemoglobin concentration, oxygen saturation, blood pH, and 
temperature.  Heterozygous sickle cell trait carriers, 
whose erythrocytes contain a mixture of sickle and non-
sickle hemoglobin, exhibit few clinical symptoms and their 
hemoglobin does not aggregate at physiologic oxygen 
saturations of 80% (venous circulation) to 95% (arterial 
circulation) (Ferrone, 1989; Ferrone et al., 1985a, 1985b; 
Noguchi et al., 1989).  However, sickle hemoglobin 
aggregates are evident at 90% oxygen saturation when 
hemoglobin concentrations are 42 g/dL, such as are found in 
dense sickle erythrocytes from homozygous sickle patients 
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(Noguchi et al., 1989).  Hemoglobin aggregation also 
increases with decreasing pH and increasing temperature 
(Ferrone et al., 1985a).  
 Hemoglobin aggregation and erythrocyte sickling upon 
deoxygenation are not instantaneous.  Rather, a delay 
exists between the time of deoxygenation and the time of 
hemoglobin aggregation and erythrocyte sickling (Eaton et 
al., 1976b; Hofrichter et al., 1974).  Under normal 
physiologic circumstances the time required for an 
erythrocyte to pass through the microcirculation is roughly 
1 second (Eaton et al., 1976a), and the delay time is 
longer, suggesting that most sickle erythrocytes can 
traverse the microcirculation before becoming stiff and 
sickled and without occluding microvessels (Mozzarelli et 
al., 1987). However, factors that either decrease the delay 
time before onset of hemoglobin aggregation or increase the 
time for erythrocytes to pass through microvessels could 
lead to red cell sickling and occlusion in microvessels. 
Two factors that change the delay time before hemoglobin 
aggregation are deoxy-sickle hemoglobin concentration and 
temperature.  The delay time is proportional to the 
negative 30th power of the deoxyhemoglobin concentration.  
Also, a change of temperature of 1°C in the physiologic 
temperature range cuts the delay time by nearly half 
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(Hofrichter et al., 1974).  One factor that might result in 
increased time for erythrocytes to traverse the 
microcirculation is sludging blood flow due to adhesion of 
sickle erythrocytes to the vascular endothelium.  This is 
discussed in more detail in Section 2.4. 
    
2.2.2  Hemolytic Anemia 
 Repeated reversible sickling of erythrocytes due to 
hemoglobin aggregation increases the membrane rigidity of 
the erythrocytes due to binding of spectrin to membrane 
proteins (Lux et al., 1976; Usami et al., 1975).  The 
limited deformability of sickle erythrocytes as they 
traverse the microcirculation results in mechanical stress 
and damage to the erythrocytes (Weed, 1975), as evidenced 
by increased phosphatidylserine presence on the outer 
leaflet of the erythrocyte membrane (Setty et al., 2002; 
Yasin et al., 2003).  Membrane damage shortens the life-
span of sickle erythrocytes from the normal average of 120 
days to only 12 to 15 days, resulting in chronic hemolytic 
anemia (G.R. Serjeant, 1985).  
 
2.2.3  Vaso-Occlusion 
 Vaso-occlusion occurs when micro or macro vessels are 
plugged and is the source of many of the clinical symptoms 
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associated with sickle cell anemia.  Vessels may be blocked 
by several cell types, the most well documented of which 
include sickle erythrocytes (S. H. Embury et al., 2004; 
Hebbel, 1997) and leukocytes (Kaul et al., 2004) that 
abnormally adhere to the endothelial cells lining the 
vascular wall and stiff, morphologically sickled 
erythrocytes that lack the flexibility to traverse the 
microcirculation without entrapment (Ferrone et al., 
1985b).  The occlusion of vessels with these cell types 
leads to tissue ischemia, organ damage, and the most 
serious clinical complications of sickle cell anemia.  
These clinical complications include pain crises, stroke, 
acute chest syndrome, retinopathy, and priapism, each of 
which is described more fully below (Edwards et al., 2005; 
Maples & Hagemann, 2004; Rogers, 2005). 
 Pain episodes are periods of diffuse, reversible pain 
in the back, chest, abdomen, and extremities, especially in 
the bones.  These episodes can last anywhere from a few 
hours to several weeks, with duration depending on levels 
of fetal hemoglobin, overall physical condition, 
psychological and social factors, and the presence or 
absence of underlying infection (A. Platt et al., 2002).  
Although pain crises often manifest without apparent 
precipitants, several factors are known to contribute to 
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onset of these episodes.  These may include physical states 
such as pregnancy, environmental conditions such as cold 
temperature or high altitude, psychological states of 
stress, anxiety, or depression, and pathological states of 
infection or hypoxia (O. S. Platt et al., 1991).   
One of the clearest precipitants of pain episodes and 
mortality among sickle patients is bacterial infection 
(Barrett-Connor, 1971; S. H.  Embury et al., 1994; Manci et 
al., 2003; C. Taylor et al., 2004).  While the link between 
infection, the associated inflammatory response, and sickle 
pain events is not concretely established, evidence 
presented in Section 2.3 suggests that inflammation 
contributes to abnormal adhesion of sickle blood cells to 
the endothelium, which may in turn lead to vacular 
occlusion and pain. 
 It is estimated that 10% to 15% of sickle 
patients suffer some sort of cerebral vascular event (Koshy 
et al., 1990; Ohene-Frempong et al., 1998) during their 
lives.  Children and older patients are more likely to 
suffer from infarctive strokes, whereas young adults are 
more likely to suffer from hemorrhagic strokes (Ohene-
Frempong et al., 1998).  Strokes represent the second most 
common cause of death among children with sickle cell 
anemia (Leikin et al., 1989), and pediatric sickle cell 
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patients are more than 300 times more likely than non-
sickle patients to suffer a stroke (Ohene-Frempong et al., 
1998).  The mechanisms of stroke in sickle cell anemia are 
not well understood or documented in the literature.  Major 
risk factors for childhood stroke include anemia, silent 
infarcts, incidence of acute chest syndrome (C. Hoppe, 
2005), and blood velocities of 200 cm/s or higher in the 
middle cerebral artery or internal carotid artery as 
determined by transcranial doppler (TCD) (Adams et al., 
1997).  Autopsies from sickle patients whose cause of death 
was determined to be from neurologic complications show 
infarcts and/or hemorrhages in the cerebral hemispheres, 
thrombosis at major branches of large vessels such as the 
Circle of Willis or the internal carotid artery, vascular 
occlusion, and scars from previous microinfarcts (Koshy et 
al., 1990). Chronic transfusion therapy to decrease sickle 
hematocrit counts lessens the incidence of stroke in some 
patients (Pegelow, 2001; Pegelow et al., 2001). 
Acute chest syndrome is characterized by chest pain, 
fever, coughing, and increased respiration (Siddiqui & 
Ahmed, 2003).  It occurs in up to 43% of sickle patients, 
and 25% of deaths in sickle cell anemia result from acute 
chest syndrome (Castro et al., 1994; Vichinsky et al., 
2000; Vichinsky et al., 1997).  Risk factors include age, 
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high leukocyte counts, low fetal hemoglobin levels, 
previous history of pulmonary events, and stroke (Castro et 
al., 1994; C. Hoppe, 2005; Siddiqui & Ahmed, 2003).  Known 
causes of acute chest syndrome include infection, vaso-
occlusion, fat embolism, and thrombosis.  However, in a 
study of 537 sickle cell patients who experienced acute 
chest events, 45% of events occurred with no known cause 
(Castro et al., 1994; Walker et al., 1979). 
Retinopathy in sickle cell anemia occurs due to 
arteriolar occlusion and ischemia of the peripheral retinal 
vasculature (Galinos et al., 1975; Talbot et al., 1982).  
It is estimated that 10 to 20% of sickle patients 
experience retinopathy and transient visual loss (Moriarty 
et al., 1988).  Permanent vision loss is rare, with one 
study reporting permanent loss in only one out of 82 eyes 
affected with retinopathy (Downes et al., 2005). 
Priapism, or painful involuntary erection of the 
penis, occurs in up to half of men with sickle cell anemia 
(Chinegwundoh & Anie, 2004).  There are two types of 
priapism, stuttering attacks which occur intermittently and 
range from several minutes to hours in duration and acute 
attacks which last from hours to days (Mantadakis et al., 
1999; Maples & Hagemann, 2004; Rogers, 2005).  Most 
incidences of priapism in sickle cell anemia are 
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characterized by low blood flow and decreased outflow from 
penile veins.  This may be due to sickling of erythrocytes 
within the corpora cavernosa of the penis and subsequent 
venous stasis (Maples & Hagemann, 2004).  However, some 
cases of priapism in sickle cell patients are characterized 
by high blood flow as well (Ramos et al., 1995).  Priapism 
lasting for many hours can result in irreversible cell 
damage and impotence (Rogers, 2005).  Treatment options for 
low-flow priapism are generally pharmacologic in nature, 
with adrenergic agents representing one major category.  
High-flow priapism tends to require arterial embolization 
or ligation (Maples & Hagemann, 2004). 
Hemoglobin aggregation, anemia, and vaso-occlusion are 
the three major physiologic factors affecting sickle cell 
anemia patients.  In general, the anemia is relatively 
well-tolerated, whereas vaso-occlusion is responsible for 
most clinical disease manifestations and the morbidity and 
mortality associated with the disorder (G. R. Serjeant, 
1993).  The role of the endothelium in the progression of 






2.3  The Endothelium in Sickle Cell Anemia 
 
The vascular endothelium plays an important part in 
the physiology and progression of clinical events in sickle 
cell anemia.  The endothelium is responsible for regulating 
vascular tone and providing a barrier between blood and 
tissue.  In addition, the endothelium is a critical 
mediator of the inflammatory response, expressing receptors 
for leukocyte recruitment, attachment, and infiltration.  
Finally, the endothelium produces plasma proteins that are 
critical to the coagulation cascade.  The endothelium in 
sickle patients is unique in that it is abnormally 
activated to express receptors and proteins involved in 
inflammation and coagulation and has diminished capacity to 
regulate vascular tone (Hebbel et al., 2004).  These 
aspects of sickle biology are discussed in more detail 
below. 
 
2.3.1  Vasoregulation 
 The endothelium regulates vascular tone by producing 
vaso-active substances including dilators such as nitric 
oxide (NO) and prostaglandins as well as contrictors such 
as endothelin-1.  The sickle circulation is characterized 
by hypoperfusion leading to tissue ischemia in the 
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microcirculation (Kaul et al., 1996; Kaul et al., 2000; 
Nath et al., 2004; Osarogiagbon et al., 2000), but 
hyperperfusion in the macrocirculation (Gladwin et al., 
2003; Hatch et al., 1989; Nath et al., 2004), suggesting 
overall vascular instability and inability to regulate 
vascular tone. 
 While mechanisms for this vascular instability are not 
well-understood, it appears that one major contributing 
factor is decreased bioavailability of nitric oxide (Morris 
et al., 2000a; Morris et al., 2000b).  Nitric oxide is 
produced by nitric oxide synthases (NOS) in endothelial 
cells, then diffuses to smooth muscle cells where it 
initiates cell signaling eventually resulting in calcium 
sequestration and vessel relaxation (Nath et al., 2004).  
The bioavailability of and responsiveness to nitric oxide 
appears greater in women with sickle cell anemia than men 
with the condition (Gladwin et al., 2003).  Nitric oxide 
deficiency is a multifaceted problem that may be caused by 
several factors loosely grouped as oxidative damage but 
more specifically including the following: 
 
• Consumption of nitric oxide by the elevated amounts of 
hemoglobin in sickle plasma (Reiter et al., 2002) 
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• Consumption of nitric oxide from excessive superoxide 
generation (Osarogiagbon et al., 2000) 
• Uncoupling of endothelial NOS by oxidation of 
tetrahydrobiopterin (Landmesser et al., 2003) 
• Activation of xanthine oxidase (Aslan et al., 2001; 
Nath et al., 2004) 
 
In addition to serving as a vasoregulator, nitric 
oxide may significantly affect other biological phenomena 
important to sickle cell anemia, such as receptor 
expression and cell adhesion (De Caterina et al., 1995; 
Gladwin & Schechter, 2001).  These are discussed in more 
detail in Section 2.7 below. 
 
2.3.2  Coagulation 
 Unlike quiescent endothelium of non-sickle patients, 
which is generally nonthrombogenic, endothelium of sickle 
patients shows signs of chronic hypercoagulability that is 
further exacerbated during clinical events (S. H.  Embury 
et al., 1994).  Sickle cell anemia patients exhibit 
increased rates of thrombin and fibrin formation (Francis, 
1989; Leslie et al., 1975) and consumption of anti-
thrombogenic substances such as antithrombin 2I, protein C, 
and protein S (Cacciola et al., 1989; Francis, 1988; Green 
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& Scott, 1986; Karayalcin & Lanzkowsky, 1989).  Tissue 
factor, the trigger for onset of coagulation, is elevated 
on circulating endothelial cells of sickle patients (Key et 
al., 1998; A. Solovey et al., 1998), and platelet counts 
are slightly elevated in sickle patients (Westwick et al., 
1983).   
 Hypercoagulation promotes platelet adhesion, 
aggregation, and thrombus formation and may contribute to 
vaso-occlusive events in sickle cell patients.  While many 
aspects of clinical events in sickle cell anemia are not 
well understood, some studies suggest a link between 
thrombosis and occurrence of stroke in sickle patients 
(Prengler et al., 2002).   
 
2.3.3  Inflammation 
 Sickle cell anemia patients experience chronic 
inflammation that may be exacerbated further during 
clinical events.  The causes of inflammation remain 
unclear, but likely include the following: 
 
• Infection.  Clinical events in sickle cell anemia 
are often preceded or accompanied by infection (S. 
H.  Embury et al., 1994; Manci et al., 2003; C. 
Taylor et al., 2004).  Infections induce 
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inflammatory signaling cascades, leading to the 
signs of inflammation noted below. 
• Adhesion of Sickle Erythrocytes to Vascular 
Endothelium.  Sickle erythrocytes can induce 
endothelial activation and expression of adhesion 
molecules normally associated with inflammation, 
such as VCAM-1, E-selectin, and ICAM-1 in vitro (M. 
D. Brown et al., 2001; Shiu et al., 2000). 
• Clinical events resulting in tissue ischemia and 
damage.  While inflammation likely contributes to 
the onset of occlusion and clinical events, it is 
also likely that occlusive events exacerbate 
inflammation, creating a vicious cycle for sickle 
patients (Hebbel et al., 2004).  The process of 
reperfusion during resolution of occlusion damages 
the endothelium and triggers inflammatory signaling 
characteristic of ischemia/reperfusion injuries.  
Transgenic sickle mice provide in vivo evidence that 
hypoxia/reoxygenation induces inflammation, as they 
display increased adhesion of leukocytes to vascular 
endothelial cells (Kaul & Hebbel, 2000). 
 
Much evidence exists to suggest that the sickle 
endothelium exists in a persistently activated state.  
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Sickle subjects display elevated levels of inflammatory 
cytokines such as TNF-α and various interleukins (IL1ß, 
IL4, IL6, and IL10) (Hibbert et al., 2005; Malave et al., 
1993; Pathare et al., 2004; S. C. Taylor et al., 1995; S. 
C. Taylor et al., 1997).  Circulating endothelial cells 
from sickle patients show presence of inflammatory response 
receptors including VCAM-1, E-selectin, ICAM-1, and P-
selectin (A. Solovey et al., 1997).  Soluble VCAM-1, E-
selectin, and ICAM-1 levels are also elevated (Conran et 
al., 2004; Duits et al., 1996; Mohan et al., 2005b; 
Sakhalkar et al., 2004).  Other signs of inflammation 
include increased leukocyte (Awogu, 2000; Okpala, 2004) and 
platelet counts (Mohan et al., 2005a) and activated 
monocytes (Belcher et al., 2000; Lard et al., 1999; Wun et 
al., 2002).   
Transgenic sickle mice also appear to exhibit an 
inflammatory phenotype, expressing increased amounts of IL-
6, VCAM-1, ICAM-1, E-selectin, P-selectin, and tissue 
factor (Belcher et al., 2003; S. H. Embury et al., 2004; A. 
Solovey et al., 2004; K. Wood et al., 2004a; K. C. Wood et 
al., 2004b).  In addition, sickle mice demonstrate 
increased adhesion of sickle erythrocytes to endothelium 
(S. H. Embury et al., 2004) and rolling and adhesion of 
leukocytes than non-sickle controls (K. C. Wood et al., 
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2004b).  The anti-inflammatory drug sulfasalazine inhibits 
leukocyte adhesion and improves microvascular flow in 
transgenic sickle mice (Kaul et al., 2004), suggesting that 
transgenic sickle mice are useful for testing therapeutics 
(Hebbel et al., 2004) and that anti-inflammatory drugs may 
benefit sickle patients. 
 
2.4  Sickle Erythrocytes 
 
2.4.1  Sickle Erythrocyte Abnormalities 
 As established in Sections 2.2 and 2.3, both sickle 
erythrocytes and endothelial cells from sickle patients are 
abnormal.  The erythrocyte population in sickle patients is 
quite heterogeneous.  Some erythrocytes are irreversibly 
sickled and do not assume the normal biconcave shape upon 
reoxygenation.  Irreversible sickling is attributed to 
spectrin-actin cytoskeletal rearrangement and increased 
binding of sickle hemoglobin to the erythrocyte membrane 
(Evans & Mohandas, 1987; Lux et al., 1976). Other 
erythrocytes containing sickle hemoglobin reversibly become 
stiff and sickled upon deoxygenation (Magdoff-Fairchild et 
al., 1976; Noguchi et al., 1989; Noguchi & Schechter, 1981) 
and may occlude microvessels if the delay time between 
hemoglobin aggregation and erythrocyte sickling is shorter 
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than the transit time through the microcirculation (Eaton 
et al., 1976a; Mozzarelli et al., 1987).   In addition, the 
membranes of some erythrocytes are damaged by repeated 
sickling, altering the lipid organization of the membranes 
and resulting in exposure of phosphatidylserine (PS) on the 
outer leaflet (Yasin et al., 2003).  This abnormal exposure 
of PS creates a negatively charged and pro-thrombogenic 
cell surface (Zwaal et al., 1989).  Other membrane 
glycoproteins such as band 3 and glycophorin A were found 
to be aggregated on the surface of some sickle erythrocytes 
(Corbett & Golan, 1993; Liu et al., 1996; Thevenin et al., 
1997).   
 One other important group of erythrocytes in sickle 
blood is reticulocytes, or immature erythrocytes recently 
released from the bone marrow.  By age 5, sickle patients 
average a reticulocyte count of 12% (A. K. Brown et al., 
1994; el Sayed & Tawfik, 1994), whereas non-sickle subjects 
average a reticulocyte count of about 1%.  The increase is 
likely an attempt to compensate for the shortened 
erythrocyte lifespan and overall reduced erythrocyte counts 
and anemia experienced by sickle patients.  Maturation of 
reticulocytes occurs after release from bone marrow, and 
until this happens, the membranes of these cells contain 
transferrin (de Jong et al., 2001) and fibronectin (Patel 
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et al., 1985) receptors that older cells do not.  In 
addition, sickle reticulocytes have been shown to express 
α4β1 (Swerlick et al., 1993) as well as CD36 (Joneckis et 
al., 1993).   
  
2.4.2  Mechanisms of Sickle Erythrocyte Adhesion to 
Endothelium 
 Sickle erythrocytes are abnormally adherent to 
vascular endothelium.  Adhesion has been demonstrated in 
vivo in sickle transgenic mice as well as in numerous in 
vitro studies elucidating specific adhesion mechanisms (S. 
H. Embury et al., 2004; Hebbel et al., 1980; Hoover et al., 
1979; Kaul et al., 1995).  Erythrocyte adhesion is likely 
important to the clinical course of sickle cell anemia in 
that it is thought to increase the transit time of 
erythrocytes through the microcirculation, allowing 
sickling of erythrocytes in the microcirculation and 
initiating vaso-occlusion (Eaton et al., 1976a; Hofrichter 
et al., 1974).  Sickle erythrocytes may be more adherent to 
the endothelium of sickle patients because the endothelium 
may be abnormally activated to express higher levels of 
adhesion molecules as discussed in Section 2.3 and because 
the sickle erythrocytes abnormally display ligands as 
discussed in Section 2.4.1 that bind to these receptors.  
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Specific receptor/ligand interactions supporting adhesion 
of sickle erythrocytes have been identified using in vitro 
assays where variables such as flow conditions and cell 
activation states are easily controlled.  A summary of 
these interactions is provided below. 
 
2.4.2.1  Direct Adhesion of Sickle Erythrocytes to 
Endothelial Cells.  The adhesion of sickle erythrocytes to 
vascular endothelium may occur by direct interaction of 
erythrocyte ligands with endothelial adhesion molecules or 
through interactions of sickle erythrocyte ligands and 
endothelial adhesion molecules with bridging molecules.  
Mechanisms of binding of sickle erythrocytes directly to 
endothelial cells (without bridging molecules) are listed 
below. 
• The best-characterized example of direct adhesion of 
sickle erythrocytes to endothelial cells occurs via 
binding of α4β1 on sickle erythrocytes to endothelial 
VCAM-1.  VCAM-1 expression on endothelial cells is 
stimulated by inflammatory cytokines such as TNF-α 
(Swerlick et al., 1993). 
• When α4β1 on sickle erythrocytes is activated by 
phorbol ester or IL8, it binds to surface associated 
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fibronectin (FN) on endothelial cells (Kumar et al., 
1996a). 
• Externalized phosphatidylserine on sickle erythrocytes 
binds to microvascular endothelial CD36 (Closse et 
al., 1999; Setty et al., 2002).  CD36 is not expressed 
on large vessel endothelium (H. A. Brittain et al., 
1992). 
• Aggregated band 3 on sickle erythrocytes binds to 
unknown receptor(s) on endothelial cells (Thevenin et 
al., 1997). 
• Unknown ligands on sickle erythrocytes bind to 
endothelial P-selectin and E-selectin.  P-selectin is 
upregulated on endothelial cells by stimulation with 
histamine or thrombin, and E-selectin is upregulated 
by stimulation with inflammatory cytokines such as 
TNF-α (Matsui et al., 2001; Natarajan et al., 1996). 
• Stimulation of sickle erythrocytes with epinephrine 
activates ICAM-4, which binds to endothelial αςβ3 
(Zennadi et al., 2004). 
 
2.4.2.2  Adhesion of Sickle Erythrocytes to Endothelial 
Cells via Bridging Molecules.  In addition to binding 
directly to endothelial cells, sickle erythrocytes may also 
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bind via a mediator, or bridging molecule.  Thrombospondin 
and unusually large molecular weight von Willebrand factor 
are two plasma proteins serving important mediating roles 
in sickle erythrocyte/endothelial interactions.  The 
contribution of each to sickle cell adhesion is discussed 
in this section. 
• Thrombospondin (TSP) is a large glycoprotein secreted 
by platelets (Lawler et al., 1978) and endothelial 
cells (Kramer et al., 1985) that interacts with cell 
surface receptors on both endothelial cells and sickle 
erythrocytes via its multiple binding sites (Gupta et 
al., 1999).  TSP receptors on sickle erythrocytes 
include CD36 (Sugihara et al., 1992), sulfated 
glycolipids (SGL) (Hillery et al., 1996), 
phosphatidylserine (Setty et al., 2002), and integrin 
associated protein (IAP) (J. E. Brittain et al., 
2001a, 2001b).  Endothelial receptors include CD36 (H. 
A. Brittain et al., 1993; Sugihara et al., 1992), αςβ3 
(H. A. Brittain et al., 1993; Kumar et al., 1996b), 
and sulfated heparin (Gupta et al., 1999).   
• Unusually large molecular weight von Willebrand factor 
(vWF) multimers bridge GPIb-like and integrin 
receptors on sickle red cells and similar receptors on 
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endothelial cells (Wick et al., 1987; Wick et al., 
1993). 
 
2.4.2.3.  Adhesion of Sickle Erythrocytes to Sub-
endothelial Matrix Proteins.  In addition to adhering to 
endothelial cells, sickle erythrocytes can also bind to 
endothelial matrix proteins.  This binding may be relevant 
in vivo, since the endothelium is thought to be damaged in 
sickle patients, and, thus, the underlying matrix may be 
exposed (Hines et al., 2003; Kasschau et al., 1996; A. 
Solovey et al., 1997).  Mechanisms of binding of 
erythrocytes to matrix proteins are listed below. 
• Sickle erythrocytes adhere to immobilized FN via α4β1 
(Kasschau et al., 1996). 
• Sickle erythrocytes adhere to immobilized laminin via 
BCAM/Lutheran protein that is activated by epinephrine 
stimulation (Hines et al., 2003). 
 
Sickle erythrocytes are abnormally adherent to 
vascular endothelium.  Adhesion occurs via direct contact 
of endothelial adhesion molecules with ligands on sickle 
erythrocytes or via contact of endothelial adhesion 
molecules and sickle erythrocyte ligands with bridging 
proteins.  Sickle erythrocytes are also abnormally adherent 
31 
to endothelial matrix proteins.  A summary of the molecular 
interactions between sickle erythrocytes and endothelial 
cells and matrix proteins is given in Figure 2.1 below.   
The mechanisms of adhesion outlined above have been 
identified under a variety of flow conditions.  A 
decription of the flow environment of the sickle 
microvasculature as well and how this may affect sickle 




































Figure 2.1  Mechanisms of adhesion between sickle 
erythrocytes and endothelial cells and matrix.  Sickle 
erythrocytes adhere to endothelial cells directly or via 



















































































2.4.3  Hemodynamics of Sickle Erythrocyte Adhesion 
 Sickle erythrocyte adhesion is thought to occur 
primarily in the post-capillary venules (Kaul et al., 
1989).  The shear stress in these venules for non-sickle 
patients is estimated to be 1 dyne/cm2 (Turitto, 1982).  
Many in vitro assays have shown minimal adhesion of non-
sickle erythrocytes at this shear stress, but increased 
adhesion of sickle erythrocytes (Barabino et al., 1987; 
Wick et al., 1987).  These assays have proven quite useful 
at identifying specific adhesion molecule/ligand 
interactions that support sickle erythrocyte adhesion.  
However, some studies suggest that this flow condition may 
not be the prevalent one in the sickle microvasculature.  
Rather, conditions of oscillatory flow and frequent stasis 
have been demonstrated (Lipowsky et al., 1987; Rodgers et 
al., 1984).   
 Differences between hemodynamics in sickle and non-
sickle patients are further exemplified by erythrocyte 
velocity profiles.  Sickle patients show broad histograms 
of red cell velocities through the microcirculation, where 
non-sickle patients show narrower histograms (Lipowsky et 
al., 1987), meaning that some sickle erythrocytes move 
through the microcirculation slowly.  These results are 
mimicked in parallel plate flow chambers in vitro, which 
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demonstrate a population of erythrocytes that “slide” or 
“roll” along the endothelial surface (Matsui et al., 2001; 
Matsui et al., 2002).  P-selectin induces this sliding 
effect, but it is not known if other adhesion molecules are 
also responsible.  Also unknown is whether or not the 
sliding results in increased capture and firm adhesion of 
sickle erythrocytes, just as rolling of leukocytes aids in 
their capture (Hebbel et al., 2004). 
 In order for sickle erythrocytes to firmly adhere to 
the endothelium, the bonding force must be stronger than 
the detaching forces of fluid shear stress and peeling 
torque.  The strength of the bonding force depends on both 
the number of bonds between erythrocyte and endothelial 
cell molecules as well as the strength of each individual 
bond (Hebbel, 1997; Hebbel et al., 2004).  Under fluid flow 
at the typical post-capillary venule shear stress of 1 
dyne/cm2, sickle cell adherence requires the presence of 
specific, high-affinity bonds between endothelial adhesion 
molecules and sickle erythrocyte ligands such as those 
outlined in Section 2.4.2.  These bonds are strong enough 
collectively to withstand the opposing shear forces.  Thus 
at venular shear stresses, sickle cell adhesion is said to 
be “affinity-controlled.”  Under conditions of low flow 
(0.1 dyne/cm2), however, fluid flow opposing adhesion is low 
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and, thus, low-affinity bonds, the identities of which are 
not well-characterized, are sufficient to support 
significant sickle erythrocyte adhesion.  Adhesion under 
low flow conditions is said to be “transport-controlled,” 
because the level of adherence depends primarily on the 
contact time between sickle erythrocytes and endothelial 
cells (Montes et al., 2002; Wagner et al., 2004). 
 
 Whether high-affinity or low-affinity, sickle 
erythrocyte adhesion to endothelial cells is important as a 
likely initiator of vaso-occlusion in sickle cell anemia.  
Thus strategies to control or eliminate abnormal adhesion 
represent an attractive therapeutic prospect for sickle 
cell anemia patients.  To date, no such therapies exist.  
The following section outlines current cures and therapies 
available for sickle cell patients and also addresses 
potential future therapies, including strategies to prevent 
sickle erythrocyte adhesion. 
  
2.5  Current and Future Therapies 
 
Despite the significant collective body of knowledge 
regarding sickle cell syndromes, treatment options are 
still quite limited, owing to the complex pathology of the 
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condition. For most patients, the primary treatments are 
merely preventative and supportive.  Treatment of acute 
pain episodes generally includes control of pain with 
opiates such as morphine, intracellular hydration with oral 
or intravenous fluids, correction of hypoxia and acidosis, 
bed rest, and treatment of underlying infection or other 
complications (A. Platt et al., 2002).  However, for those 
with severe complications, three major therapeutic options 
are currently available. 
 
2.5.1  Bone Marrow Transplant  
Bone marrow transplant is currently the only available 
curative therapy for sickle cell anemia.  While the 
survival rate from this procedure is roughly 91% and the 
cure rate is 82% (C. C. Hoppe & Walters, 2001), the option 
of bone marrow transplantation is currently limited 
primarily to children under 16 years of age with severe, 
pre-existing complications.  One major barrier to 
transplants is the lack of a suitable donor for the vast 
majority of patients; it is estimated that only 14% of 
patients have a human leukocyte antigen (HLA)-matched 
sibling donor (C. C. Hoppe & Walters, 2001).  Another 
obstacle is the potential for short and long-term 
complications after transplantation including intracerebral 
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hemorrhage, graft-versus-host disease (GVHD), seizure, and 
gonadal dysfunction (Amrolia et al., 2003; C. C. Hoppe & 
Walters, 2001). 
 
2.5.2  Blood Transfusion 
Blood transfusion is widely used in the treatment of 
sickle cell anemia.  It is estimated that 50% of all 
patients receive a red cell transfusion at some point in 
their lives and that 5% receive chronic transfusions (Rosse 
et al., 1990).  Serious complications associated with this 
therapy include iron overload, allo-immunization, and risk 
of transmitted infection (Amrolia et al., 2003). 
 
2.5.3  Hydroxyurea 
Hydroxyurea is a therapeutic agent administered to 
patients with severe sickle cell symptoms.  It was 
originally administered due to its ability to increase 
fetal hemoglobin (HbF) concentrations, which interferes 
with sickle hemoglobin (HbS) aggregation and red cell 
sickling both by preventing effective contact between 
adjacent HbS molecules and by forming mixed HbF-HbS hybrids 
which are more soluble than HbS aggregates (Halsey & 
Roberts, 2003).  Additionally, hydroxyurea reduces sickle 
erythrocyte expression of α4β1 and CD36 (Styles et al., 
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1997) and in vitro adhesion to endothelial thrombospondin 
and laminin (Hillery et al., 2000).  The drug also 
increases erythrocyte hydration and deformability (Ballas 
et al., 1989) and decreases neutrophil counts (O. S. Platt 
et al., 1994).  Recently, hydroxyurea metabolism has been 
shown to lead to nitric oxide (NO) release (J. Jiang et 
al., 1997), and it is possible that some of the drug’s 
effects may be mediated by this release.  Although the 
effects of hydroxyurea are of broad scope in vitro, many of 
these effects have not yet been linked directly to patient 
benefit, and it is unclear which effects are most relevant 
to sickle cell anemia pathology.  Common short-term side 
effects of hydroxyurea usage include dose-dependent 
myelosuppression, nausea, vomiting, and skin rashes.  The 
most troublesome long-term potential risk may be 
leukemogenicity (Amrolia et al., 2003). 
 
2.5.4  Gene Therapy 
As noted earlier, currently the only cure for sickle 
cell anemia is bone marrow transplant, which works by 
ablating the patient’s hematopoeitic stem cells and 
replacing them with those from a donor.  Since most sickle 
cell patients do not have a suitable donor, gene therapy 
represents an attractive curative therapy.  It is 
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different, in that autologous bone marrow cells are used.  
The process involves removing bone marrow from the patient, 
transferring viral vectors containing normal β-globin into 
the cells, selecting out the cells that are successfully 
corrected, and then transplanting the corrected cells back 
into the patient.  The biggest challenge for this therapy 
is developing more efficient levels of gene transfer and 
increasing the levels of gene expression (Bank et al., 
1989).  Recently, results from murine studies of β-
thalessemia in which a lentivirus vector was used to 
transfect cells showed such positive results in terms of 
high gene transfer and expression rates, that a Phase I/II 
clinical trial is currently under way (Bank et al., 2005). 
 
2.5.5  Anti-sickling Agents 
Another potential therapy for sickle cell anemia 
patients is inhibition of sickle hemoglobin aggregation and 
erythrocyte sickling.  Prevention of sickling may reduce 
the erythrocyte damage and death that leads to chronic 
anemia and prevent occlusion of vessels with sickled cells.  
As noted in Section 2.2.1, hemoglobin aggregation and onset 
of sickling are strongly dependent on sickle hemoglobin 
concentration (Hofrichter et al., 1974).  Thus two main 
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strategies are used to decrease sickle hemoglobin 
concentration and erythrocyte sickling.   
One strategy is to increase the concentration of fetal 
hemoglobin in erythrocytes, since fetal hemoglobin does not 
form aggregates.  Fetal hemoglobin levels are inversely 
correlated with vaso-occlusive complications in sickle cell 
patients.  It is estimated that a fetal hemoglobin 
concentration of 10% ameliorates major organ failure, while 
a concentration of 20% is required to ameliorate vaso-
occlusive crisis, pulmonary disorders, and other recurrent 
symptoms (Powars et al., 1984).  As noted in Section 2.3.3, 
one effect of hydroxyurea is increased fetal hemoglobin 
production (Halsey & Roberts, 2003).  However, the 
potentially cytotoxic, clastogenic (breaking of 
chromosomes), carcinogenic, and mutagenic properties of the 
drug mean that it cannot be administered to all patients 
(Amrolia et al., 2003; Charache et al., 1987).  Another, 
less cytotoxic drug, Decitibine, has also been shown to 
increase fetal hemoglobin concentrations from 6.5% to 20.4% 
and reduce reticulocyte counts from 231 to 163 x 109 cells 
per L in a small sample of patients (Buchanan et al., 2004; 
Saunthararajah et al., 2003).  However, one animal study 
suggests that the drug may also be carcinogenic 
(Saunthararajah & DeSimone, 2004).  Other fetal hemoglobin 
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inducing compounds include short chain fatty acids, which 
inhibit histone deacetylase, causing histone 
hyperacetylation, changes in chromatin structure, and 
enhancement of fetal hemoglobin gene expression in sickle 
cell patients.  In Phase II clinical trials, administration 
of arginine butyrate increased fetal hemoglobin levels from 
7% to 21% in 11 of 15 patients studied (Atweh et al., 1999; 
Buchanan et al., 2004). 
The other main strategy for decreasing sickle 
hemoglobin concentrations in erythrocytes and inhibiting 
hemoglobin aggregation and erythrocyte sickling is 
hydration of erythrocytes.  Sickle erythrocytes are 
dehydrated due to loss of potassium (K+) and chloride (Cl-) 
ions as well as water (Glader et al., 1978; Glader & 
Nathan, 1978).  Oral magnesium supplements have been shown 
to inhibit co-transport of K+ and Cl- ions in vivo, and a 
clinical trial demonstrates that magnesium improves 
erythrocyte hydration and reduces the percentage of days 
that sickle cell anemia patients experience pain (Buchanan 
et al., 2004; De Franceschi et al., 2000).  The efflux of K+ 
ions from erythrocytes also occurs through Ca2+-activated 
“Gardos” channels (Gardos, 1958).  A recent study 
demonstrated that blocking of these channels by ICA 17043, 
a more potent and less toxic derivative of the drug 
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Clotrimazole, resulted in decreased sickle erythrocyte 
density and hemolysis.  Clinical benefit from the treatment 
was not established (Brugnara, 2003; Buchanan et al., 2004; 
Stocker et al., 2003). 
 
2.5.6  Anti-coagulation Therapy 
As established in Sections 2.3.2 and 2.4, sickle cell 
anemia patients exhibit activated coagulation systems that 
may result in increased sickle erythrocyte adhesion to 
vascular endothelium.  Thus some have hypothesized that 
therapies which inhibit thrombosis or coagulation may 
benefit sickle cell patients.  Early reports indicate that 
ticlopidine (Cabannes et al., 1984; Lonsdorfer et al., 
1984), warfarin (Ahmed et al., 2004; Salvaggio et al., 
1963), and minidose heparin (Chaplin et al., 1989) may 
benefit sickle patients experiencing pain episodes, while 
low-intensity coumadin (Schnog et al., 2002; Wolters et 
al., 1995) and aspirin (Greenberg et al., 1983; Zago et 
al., 1984) do not (Hebbel et al., 2004). 
 
2.5.7  Anti-inflammatory Therapy 
Given that in addition to coagulation, sickle patients 
also experience chronic inflammation that may contribute to 
increased sickle erythrocyte adhesion and clinical 
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symptoms, anti-inflammatory therapies may benefit sickle 
patients.  The Hebbel group recently demonstrated that 
patients taking sulfasalazine, an anti-inflammatory agent 
that inhibits transcription factor nuclear factor kappa B 
(NF-κB) that is necessary for transcription of many 
inflammation-induced proteins (Ghersa et al., 1994), showed 
decreased expression of adhesion molecules VCAM-1, E-
selectin, and ICAM-1 on their circulating endothelial cells 
(A. A. Solovey et al., 2001).  Given this success, the 
group proposes a clinical trial combining the use of 
sulfasalazine and statins (Hebbel et al., 2004), which 
provide anti-inflammatory benefits and improve NO 
availability in non-sickle models (Koh, 2000).  To date, no 
such trial has been conducted.   
 The studies presented in the following chapters 
explore the effects of anti-inflammatory compounds on 
adhesion molecule expression and adhesion of sickle 
erythrocytes to vascular endothelium.  Cyclic AMP and 
nitric oxide are two important cell signaling molecules 
that regulate inflammatory responses in endothelial cells.  
The roles of these molecules in cell signaling, endothelial 
biology, and sickle cell anemia are discussed in Sections 
2.6 and 2.7 below, and their effect on sickle erythrocyte 
adhesion is the subject of Chapters 5 and 6. 
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2.6  The Role of cAMP in Endothelial Biology and Cell 
Signaling 
 
Cyclic AMP is an important and widespread mediator of 
the conversion of extracellular signals into intracellular 
events (Galea & Feinstein, 1999).  The mechanism of its 
action has been well-studied, and many key components of 
the signaling pathway have been identified.  The binding of 
extracellular ligands to some G-protein-coupled receptors 
results in release of G-proteins that activate the enzyme 
adenylate cyclase.  Adenylate cyclase converts bound ATP to 
cAMP (Iyengar, 1993).  The cAMP activates protein kinase A 
(PKA), a tetramer of two catalytic (C) and two regulatory 
(R) subunits.  In the absence of cAMP the R2C2 protein is 
catalytically inactive.  Upon binding of cAMP to the R 
subunits, the R and C subunits dissociate, and the C 
subunits become catalytically active.  The active C 
subunits of PKA phosphorylate a wide variety of 
intracellular proteins (Habener).  Active C subunits may 
also enter the nucleus (Nigg et al., 1985), where they 
phosphorylate and activate transcription factors (Montminy, 
1997).  Cyclic AMP-mediated signaling is generally 
transient and followed by a refractory period (Armstrong et 
al., 1995).  Deactivation of cAMP signaling may occur by 
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desensitization of G-coupled receptors, degradation of cAMP 
by phosphodiesterases, inhibition of PKA, and/or activation 
of dephosphorylating phosphatase enzymes (Bushnik & Conti, 
1996; Frohman et al., 1988; Iyengar, 1993). 
In experiments, activation of cAMP-dependent signaling 
has traditionally been achieved by several methods 
including 1) activation of G-coupled receptors, 2) direct 
activation of adenylate cyclase by forskolin, 3) inhibition 
of cAMP degradation using phosphodiesterase inhibitors such 
as rolipram, 4) administration of membrane-permeable cAMP 
analogs (dibutyryl cAMP and 8-bromo-cAMP) that are 
resistant to degradation by phosphodiesterases, and 5) 
inhibition of phosphatases with okadaic acid (Galea & 
Feinstein, 1999).   
Several studies point to the role of cAMP as a 
ubiquitous regulator of inflammatory and immunological 
reactions.  Increases in cAMP have been shown to block T 
lymphocyte activation (Birch & Polmar, 1982), inhibit 
interleukin 1β (IL-1β) and TNF-α release from macrophages 
(Knudsen et al., 1986; Kunkel et al., 1988), and reduce 
expression of adhesion molecules in endothelial cells 
(Pober et al., 1993).  Specifically, increasing cAMP 
reduces expression of VCAM-1 and E-selectin, but not ICAM-
1, on TNF-α stimulated endothelial cells (Otsuki et al., 
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2001; Pober et al., 1993).  These and other studies have 
led to the notion that one physiological role of cAMP-
dependent signaling is suppression of immune responses 
(Galea & Feinstein, 1999). 
The exact mechanism by which inhibition of adhesion 
molecule expression by cAMP occurs is not completely 
understood.  It has been shown that raising cAMP levels 
inhibits transcription of VCAM-1 and E-selectin mRNA 
(Ollivier et al., 1996; Otsuki et al., 2001).  Literature 
suggests that nuclear factor κB (NF-κB) is a transcription 
factor important to both VCAM-1 and E-selectin expression.  
NF-κB is normally stored in an inactivated state (that is, 
bound to the inhibitory protein IκBα) outside the cell 
nucleus, but is dissociated from IκBα and is translocated to 
the nucleus upon stimulation with cytokines such as TNF-α 
(Ollivier et al., 1996).  One study suggests that raising 
cAMP levels does not prevent nuclear translocation of NF-κB, 
but it does prevent NF-κB from binding to the VCAM-1 
promoter region (Ollivier et al., 1996; Otsuki et al., 
2001).  Figure 2.2 shows a proposed pathway for VCAM-1 and 
E-selectin gene transcription and how cAMP interrupts this 
pathway. 
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Given the ubiquitous nature of cAMP, it is not 
surprising that it affects expression of other receptors 
and ligands important to sickle cell anemia.  Treatment of 
sickle erythrocytes with reagents that increase cAMP 
activates erythrocyte BCAM/Lutheran protein for some 
patients, allowing it to bind to the endothelial matrix 
protein laminin (Hines et al., 2003).  cAMP appears to act 
through activation of Rap 1, a small guanosine 
triphosphatase that promotes integrin-mediated adhesion 
(Murphy et al., 2004), and results in phosphorylation of 
Lutheran glycoproteins (Gauthier et al., 2005).  cAMP-
mediated signaling in sickle erythrocytes also induces 
serine phosphorylation of ICAM-4, which increases 
erythrocyte adhesion to endothelial αVβ3 (Zennadi et al., 
2004).   
In addition to regulating transcription and expression 
of endothelial receptors and erythrocyte ligands, elevated 
cAMP also causes vasodilation in rabbit spinal arterioles 
(Yashiro & Ohhashi, 2002) and transgenic sickle mice (Kaul 
et al., 2000).  As vasodilation is a vascular response 
generally attributed to production of endothelial nitric 
oxide (NO), subsequent studies revealed that cAMP elevating 
agents also increase NO concentration (X. Zhang & Hintze, 
2001; X. P. Zhang et al., 2002).  cAMP induces 
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transcription of both endothelial and inducible nitric 
oxide synthases (eNOS and iNOS, respectively), the enzymes 
responsible for producing NO (Galea & Feinstein, 1999; 
Niwano et al., 2003).  Additionally, cAMP-dependent protein 
kinase (PKA) activates eNOS by phosporylating Serine-1177 
(Michell et al., 2001).  The production of cAMP and NO are 
closely linked, as increasing NO has also been reported to 
increase cAMP in platelets (Aktas et al., 2003), and NO 
shows much of the same potential as cAMP for regulating 
inflammatory gene expression (De Caterina et al., 1995; 
Khan et al., 1996; Spiecker et al., 1997).  The role of NO 
in vascular biology and sickle cell anemia is outlined in 































Figure 2.2  Intracellular cAMP and nitric oxide signaling 
in cytokine-induced sickle cell adherence.  Forskolin 
(orange pathway) increases endothelial cAMP, which inhibits 
NF-κB from binding to its recognition sequence on VCAM-1 and 
E-selectin genes.   Nitric oxide (blue pathway) inhibits 
VCAM-1 expression by increasing the expression and nuclear 
translocation of IkB.   
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2.7  The Role of Nitric Oxide in Sickle Cell Anemia and 
Endothelial Biology 
 
Nitric oxide is a soluble gas synthesized in endothelial 
cells upon activation of the family of nitric oxide 
synthase enzymes.  One of its primary physiological roles 
is the regulation of vascular tone.  Once synthesized, NO 
is released from the endothelium as a gas or attached to 
transport molecules and activates soluble guanylyl cylase 
in smooth muscle cells, resulting in increased cyclic 
guanosine monophosphate (cGMP) in smooth muscle cells.  The 
cGMP activates GMP-dependent kinases that decrease 
intracellular calcium concentrations, producing overall 
muscle relaxation and vasodilation (Gladwin & Schechter, 
2001). 
In addition to the important vasodilatory actions of NO, 
the molecule provides several other potentially beneficial 
effects to sickle patients.  These effects, recently 
summarized by Gladwin and Schechter (Gladwin & Schechter, 
2001), are wide in scope and target many of the elements of 
interest in sickle cell anemia: 
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• Inhaled NO acts on the pulmonary vasculature to reduce 
artery pressures, increase oxygenation, and improve 
ventilation. 
• NO inhalation increases nitrosylated hemoglobin, which 
may affect oxygen affinity as well as delivery of NO 
to the peripheral vasculature. 
• NO generated by hydroxyurea may contribute to the 
induction of fetal hemoglobin synthesis and reduced 
sickling of erythrocytes. 
• NO may improve microvascular perfusion. 
• NO inhibits platelet aggregation and may prevent 
thrombotic complications associated with sickle cell 
anemia. 
• NO downregulates endothelial adhesion molecule 
expression. 
 
Increased endothelial nitric oxide levels reduce 
cytokine-induced expression of the adhesion molecule VCAM-1 
in a manner that appears independent of cGMP (De Caterina 
et al., 1995). Whether or not NO inhibits E-selectin and 
ICAM-1 expression is debatable (De Caterina et al., 1995; 
Khan et al., 1996). Inhibition of adhesion molecule 
expression is paralleled by reduced adhesion of monocytes 
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(De Caterina et al., 1995).  Others have shown that 
increasing nitric oxide can inhibit neutrophil migration 
(Elferink & VanUffelen, 1996), platelet aggregation 
(Geiger, 2001), and adhesion of Plasmodium falciparum-
infected erythrocytes (Serirom et al., 2003).  
Additionally, increased NO decreases adhesion of nonsickle 
erythrocytes to TNF-α stimulated endothelium and adhesion 
of sickle erythrocytes to unstimulated endothelium (Space 
et al., 2000).  Conversely, decreasing endothelial NO 
content induces expression of VCAM-1 on otherwise 
unstimulated endothelium (De Caterina et al., 1995), and 
increases adhesion of uninfected (Space et al., 2000) and 
Plasmodium falciparum-infected nonsickle erythrocytes 
(Serirom et al., 2003).  Reduction of NO in neutrophils has 
also been shown to induce surface expression of the VCAM-1 
binding ligand α4β1, resulting in increased adhesion of 
neutrophils to fibronectin (Conran et al., 2003). 
The mechanisms by which NO inhibits VCAM-1 expression are 
complex and are not fully understood.  NO has been shown to 
stabilize the NF-κB-IκBα complex, preventing dissociation, 
activation, and nuclear translocation of NF-κB.  It also 
increases mRNA expression of IκBα (Peng et al., 1995).  
Furthermore, NO increases the concentration of IκBα in the 
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nucleus, where it could displace NF-κB from its cognate DNA 
(Spiecker et al., 1997).  Figure 2.2 summarizes potential 
mechanisms by which NO inhibits endothelial VCAM-1 
expression.   
 
2.8  Chapter Summary 
 
 Sickle cell anemia is caused by the homozygous 
inheritance of the sickle β hemoglobin gene.  Symptoms of 
the conditions include reversible aggregation of hemoglobin 
inside erythrocytes upon deoxygenation, hemolytic anemia, 
and vaso-occlusion resulting in painful crises, acute chest 
syndrome, stroke, retinopathy, priapism, and other 
complications.  In sickle patients, both endothelial cells 
and erythrocytes exhibit abnormalities that likely 
contribute to clinical symptoms.  The endothelium of sickle 
patients shows dimished capacity to regulate vascular tone 
and is also chronically activated to express proteins and 
receptors involved in coagulation and inflammation.  One of 
the most important sickle erythrocyte abnormalities is 
increased adhesion to endothelial cells and endothelial 
matrix proteins, which likely initiates or propagates vaso-
occlusion.  Strategies to inhibit abnormal erythrocyte 
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adhesion to endothelial cells may benefit sickle patients, 
but current therapies for sickle cell anemia patients do 
not directly address adhesion.  Since inflammation leads to 
endothelial expression of receptors VCAM-1 and E-selectin 
and sickle erythrocyte adhesion, anti-inflammatory reagents 
may help control adhesion and clinical complications in 
sickle cell anemia.  Cyclic AMP and nitric oxide are two 
signaling molecules with anti-inflammatory properties.  The 
ability of these molecules to prevent receptor expression 








MATERIALS AND METHODS 
 
3.1  Endothelial Cells 
 
3.1.1  Obtaining Cells 
 Human dermal microvascular endothelial cells (MECs) 
were purchased at 2nd or 3rd passage from the Department of 
Dermatology at Emory University School of Medicine.  Cells 
were received as frozen cell suspensions in cryovials or as 
confluent monolayers grown on T75 flasks.   
Frozen cell suspensions were thawed in a water bath at 
37°C, the cell suspension was centrifuged at 100g for 10 
minutes, the supernatant was removed, and the cells were 
resuspended in 15 mL microvascular endothelial growth media 
(EGM-MV) purchased as a proprietary formula from Cambrex.  
Hydrocortisone supplements provided by Cambrex as part of 
the media formulation were not added to the media to avoid 
endothelial cell activation.  The cells in media were 
placed in a T75 flask (Corning) coated overnight with 0.1% 
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porcine gelatin (Sigma) in Dulbecco’s phosphate-buffered 
saline (DPBS, Sigma) and incubated at 37°C until cells 
reached confluency.  Media was changed every 48 hours. 
Human umbilical vein endothelial cells (HUVECs) were 
purchased at 3rd passage as confluent monolayers in T75 
flasks from the Department of Dermatology at Emory 
University School of Medicine.  All cells were passaged as 
described below. 
 
3.1.2  Passaging 
 All endothelial cells were sterilly passaged by 
trypsin digestion.  For MECs, confluent monolayers were 
washed two times with 6 mL MCDB131 (Media Tech) to remove 
any serum-containing growth media.  After rinsing with MCDB 
131, cells were quickly rinsed with 3 mL 0.05% trypsin/EDTA 
(Gibco) at 37°C, then treated with another 4 mL 
trypsin/EDTA.  The flasks were gently tapped and observed 
under light microscopy to ensure cell detachment.  To 
inactivate the trypsin, 6 mL EGM-MV was added to the flask.  
The cell suspension was removed from the flask and 
centrifuged at 100g for 10 minutes.  The cell pellet was 
resuspended in EGM-MV and split 1:3.  That is, the cells 
were placed in 3 gelatin-coated T75 flasks for further 
culture.  The passage number was increased by one after 
57 
this and subsequent trypsin digestions.  Cells were 
cultured at 37°C in a 95% air and 5% CO2 incubator.  
Passaging of HUVECs was similar, but M199 (Sigma) was used 
instead of MCDB131 and HUVEC media was used instead of EGM-
MV.  HUVEC media consisted of M199 supplemented with 100 
µg/mL heparin (Sigma), 20% heat-inactivated fetal bovine 
serum (FBS, Atlanta Biologicals), 2mmol/L L-glutamine 
(Sigma), 100 U/mL penicillin and 100 mg/mL streptomycin 
(Sigma), and 25 mg/mL endothelial cell growth factor (ECGF, 
Roche).   
 
3.1.3  Storage 
 For storage, endothelial cells at passage 5 or 6 were 
passaged as described above.  After centrifugation, cells 
were resuspended in 3 mL freezing solution rather than EGM-
MV.  Freezing solution consisted of 10% dimethylsulfoxide 
(DMSO, Sigma) in FBS.  Three cryovials were each filled 
with 1 mL of the freezing solution.  The vials were placed 
in a cell freezing container with an isopropanol 
refrigerant jacket which was placed in a -70°C or -80°C 
freezer for 24 hrs.  The cells were then transferred to 
liquid nitrogen for long-term storage. 
 When cells were needed for experiments, one cryovial 
was unthawed and allowed to grow to confluency on T75 
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flasks as described in Section 3.1.1.  After reaching 
confluency, cells were passaged as described in the next 
section for use in experiments. 
 
3.1.4  Cell Culture for Use in Experiments 
 For all experiments, frozen MECs were thawed and grown 
to confluency on T75 flasks as described in Section 3.1.3.  
For flow assays, the confluent T75 was then passaged as 
described in Section 3.1.2, but after centrifugation, the 
cell pellet was resuspended in 32 mL EGM-MV.  Two mL of the 
cell suspension was then placed in a single-well Nunc 
Permanox Lab Tek chamber slide that had been coated 
overnight with 5 µg/mL fibronectin (Sigma) in DPBS.  Thus 
up to 16 slides for flow adhesion assays could be prepared 
from one confluent T75.  The chamber slides were then 
tilted to one side by propping one end of each slide on a 1 
mL pipette.  After 6 minutes, the other end of the slide 
was propped up by the pipette for 6 minutes.  This tilting 
allowed media to cover only half the chamber slide at one 
time and allowed for more even distribution of the 
endothelial cells over the surface of the chamber slide.  
Failure to tilt resulted in congregation of the MECs toward 
the middle of the slide, with many fewer cells attaching to 
the ends of the slides.  Cells grew to confluency in 2 to 3 
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days.  EGM-MV media was exchanged every 48 hrs during 
growth. 
 For ELISA experiments, 96-well tissue culture coated 
plates (Corning) were coated overnight with 0.1% porcine 
gelatin in DPBS.  The available surface area for tissue 
culture for a single 96-well plate was either 30 cm2 or 15 
cm2, depending on whether a full area or a half-area plate 
was used.  To seed full area plates, a confluent T75 of 
MECs or HUVECs was passaged as described in Section 3.1.2.  
After centrifugation, the cell pellet was resuspended in 3 
mL of either EGM-MV (MECs) or HUVEC growth media (HUVECs).  
1 mL of cell suspension was then placed in 30 mL of media.  
100 µL of diluted cell suspension was placed in each well.  
For half-area plates, only 50 uL of cell suspension was 
placed in each well.  Media was exchanged every 48 hrs and 
cells reached confluency after 3 to 4 days. 
 For cAMP assays, MECs were grown to confluency on T75 
flasks and passaged as described in Section 3.1.2.  After 
centrifugation, the cell pellet was resuspended in 36 mL 
EGM-MV.  Cells were seeded onto 6-well tissue culture 
coated dishes (Corning) coated overnight with 0.1% gelatin 
in DPBS.  Two mL of cell suspension was placed in each 
well.  Media was exchanged every 48 hours and cells grew to 
confluency in 3 to 4 days.   
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 For viability assays, MECs were grown to confluency on 
T75 flasks and passaged as described in Section 3.1.2.  
After centrifugation, the cell pellet was resuspended in 36 
mL EGM-MV.  Cells were seeded onto round glass coverslips 
(VWR) placed in 12-well dishes (Corning) and coated 
overnight with 0.1% gelatin in DPBS.  One mL of cell 
suspension was placed in each well.  Media was exchanged 
every 48 hours and cells grew to confluency in 3 to 4 days.   
 
3.2  Sickle Erythrocytes 
 
Blood samples were collected by venipuncture from 
asymptomatic, homozygous sickle patients during regular 
visits to the Georgia Comprehensive Sickle Cell Center at 
Grady Memorial Hospital (Atlanta, GA) into heparin or EDTA-
charged Vacutainer tubes.  Patients did not show signs of 
infection or thromboembolic or liver disease, were not 
pregnant, and were not receiving hydroxyurea therapy.  
Protocols for drawing of blood were approved by the 
Institutional Review Boards of Emory University and Georgia 
Institute of Technology and the Research Oversight 
Committee at Grady Memorial Hospital.  Experiments 
involving blood samples were completed between 2 to 56 from 
the time the blood was drawn.   
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To isolate erythrocytes, blood samples were 
centrifuged at 100g for 10 min at 25°C.  The plasma layer 
and buffy coat were removed, and the erythrocyte-rich layer 
was resuspended to the original sample volume in DPBS 
supplemented with 0.2% (w/v) human albumin, 5 µg/mL human 
transferrin, and 5 µg/mL bovine insulin (all from Sigma).  
The washing process was repeated 2 more times.  The 
hematocrit concentration of the red cell suspension was 
measured using a hematocytometer (Damon/IEC) and recorded.  
Samples were then stored at 4°C until 1 hr prior to use in 
flow assays. 
 
3.3  Flow Adhesion Assays 
 
3.3.1  System Description 
A parallel plate flow chamber was used to quantify 
sickle erythrocyte adhesion to MECs.  A diagram of the flow 
chamber and the assay system is given in Figure 3.1.  Panel 
B shows the components of the actual flow chamber.  The 
bottom plate of the chamber consisted of a confluent 
monolayer of MECs on a Lab-Tek Permanox plate.  The bottom 
plate was separated from the top one by a plastic gasket of 
0.004 in. thickness (Precision Brand, Downers Grove, IL).  
The inside perimeter of the gasket measured 1 cm by 4 cm.  
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The top plate of the chamber consisted of a polypropylene 
block with holes to allow flow of a sickle erythrocyte 
suspension between the two plates.  The bottom plate, 
gasket, and top plate were held together by a thin layer of 
vacuum grease (Dow Corning).  For additional stability, the 
plates were encompassed by aluminum brackets that were 
screwed tightly together. 
To assemble the flow chamber confluent monolayers of 
MECs on Permanox Lab-Tek chamber slides were rinsed twice 
with 2 mL MCDB131 then covered with 1 mL fresh EGM-MV.  The 
walls of the chamber were removed, and the slide was placed 
on top of the gasket and the polypropylene top plate.  The 
holes in the top plate were filled with EGM-MV prior to 
flow chamber assembly to keep air out of the system.  The 
flow chamber assembly was inverted and secured with the 
aluminum brackets.  Tubing was used to connect the flow 
chamber entrance to a reservoir of serum-free media (SFM), 
consisting of MCDB 131 (GIBCO) containing  0.292 mg/mL L-
glutamine (Sigma), 0.1 mg/mL each penicillin-streptomyocin 
(GIBCO), 5 µg/mL human transferrin, 5 µg/mL bovine insulin, 
0.2% (w/v) human albumin, and 0.01 µg/mL endothelial growth 
factor (EGF, Clonetics).  The exit port of the flow chamber 
was connected by tubing to a 60 mL syringe (Becton 
Dickinson), which when attached to a syringe pump (Harvard 
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Apparatus) drew media through the flow chamber (Figure 3.1, 
Panel A).  The assembled flow chamber was placed on an 
inverted microscope (Nikon Diaphot, Tokyo, Japan), and the 
temperature of the chamber was maintained at 37°C by an air 
curtain incubator (Nicholson Precision Instruments, 
Bethesda, MD).  The MECs were rinsed with SFM for 10 
minutes prior to erythrocyte perfusion to remove proteins 
secreted by the endothelial cells.  The temperature of the 
SFM and the erythrocyte suspension was maintained at 37°C 
by a water bath.  
The shear stress at the walls of the flow chamber was 
maintained at 1 dyne/cm2.  This shear stress was chosen 
because it represents the typical wall shear stress in the 
post-capillary venules where occlusion is thought to occur 
in vivo (Goldsmith & Karino, 1987; Karino et al., 1987; 
Turitto, 1982).  Shear stress in the flow chamber was 
determined using the momentum balance for fully developed 
Newtonian flow and parallel plate geometry (Bird et al., 







τ =  
 
where: 
 τwall  =  shear stress (1 dyne/cm2) 
 Q = volumetric flow rate (0.171 mL/min) 
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 µ = fluid viscosity (0.75 cpoise) 
 b = flow chamber width (1.0 cm) 
 h = flow chamber gap height (110 µm) 
 
Fully developed Newtonian flow was assumed due to low 
Reynolds number and low hematocrit.  Reynolds number was 







Re ==  
where: 
 Re = Reynolds number (0.81) 
 h = flow chamber gap height (110 µm) 
 v = average velocity (m/s) 
 Q = volumetric flow rate (0.171 mL/min) 
 ρ = fluid density (1 g/cm3) 
 b = flow chamber width (1.0 cm) 
 µ = fluid viscosity (0.75 cpoise) 
 
 
After a 10 minute rinse with SFM at 1 dyne/cm2 shear 
stress, sickle erythrocytes were perfused over MECs for 40 
minutes.  Sickle erythrocytes were washed as discussed in 
Section 3.2, then suspended at 0.22% hematocrit in 9 mL 
SFM.  The number of firmly adherent sickle erythrocytes was 
counted in 20 random microscopic fields at 400x 
magnification at approximately 1, 3, 5, 10, 20, 30, and 40 
minutes after initiation of erythrocyte perfusion.  The 
number of adherent endothelial cells in a field was 
determined visually, then recorded by the experimenter in a 
Microsoft Excel spreadsheet.  Macros were used to record 
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the clock time each data point was taken and the time after 
initiation of erythrocyte perfusion.  Macros are given in 
Appendix A.  Results at each time point were averaged and 
normalized to adherent erythrocytes per square millimeter 
of endothelium.  Experiments were also recorded by a camera 
(CCD72, MTI) attached to a television (Trinitron) and video 
cassette recorder (JVC). 
For some experiments MECs or sickle erythrocytes were 
treated prior to the flow adhesion assay.  Treatments are 
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Figure 3.1  Flow adhesion assay system.  A) A parallel 
plate flow chamber mounted on a microscope attached to a 
camera, TV, and VCR.   A syringe pump draws an erythrocyte 
suspension through the flow chamber.  The system is warmed 
by a water bath and an air curtain incubator.  B) 
Components of the parallel plate flow chamber. 
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3.3.2  Endothelial Treatments 
To test mechanisms of binding of sickle erythrocytes 
to endothelium, MECs were stimulated with TNF-α (500 U/mL) 
for 2 or 6 hrs prior to sickle erythrocyte perfusion.  Some 
MECs were simultaneously treated with monoclonal antibodies 
to block adhesion molecules and inhibit sickle erythrocyte 
adhesion.  Antibodies for adhesion molecules of interest 
included anti-VCAM-1 antibody (20 µg/mL, Beckman Coulter) 
and anti-E-selectin antibody (30 µg/mL, Beckman Coulter).  
Antibody concentrations used were chosen due to their 
effectiveness in similar experiments in literature and also 
due to practical limits of expense.  To test for antibody 
and adhesion molecule specificity, control antibodies that 
were not expected to inhibit sickle erythrocyte adhesion 
were also used.  These included anti-ICAM-1 antibody (20 
µg/mL, BD Bioscience) and anti-IgGκ antibody (30 µg/mL, 
Sigma). 
In addition to monoclonal antibodies, a synthetic 
peptide (100 µM; higher concentrations were not used due to 
solubility limits) was also used to block E-selectin and 
inhibit sickle erythrocyte adhesion.  The peptide sequence 
was H2N-DITWDQLWDLMK-COOH and was previously shown to 
inhibit neutrophil adhesion to E-selectin (Martens et al., 
1995).  In experiments using the synthetic peptide, the 
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peptide was added not only to the endothelial media 
solution during TNF-α stimulation, but also to the sickle 
erythrocyte suspension to ensure continuous availability of 
the peptide during flow. To control for the addition of 
peptide to the erythrocyte suspension, in some experiments 
peptide was added to the erythrocyte suspension for 40 
minutes, then erythrocytes were centrifuged at 100g for 10 
minutes and resuspended in peptide-free SFM.  Also, to 
control for peptide specificity, a scrambled version of the 
peptide (H2N-QLITWDMDDKWL-COOH) was used. 
 To test the ability of cAMP to regulate adhesion 
molecule expression and sickle erythrocyte adhesion, some 
endothelial monolayers were treated with 100 µM forskolin 
(Fsk), 500 µM isobutylmethylxanthine (IBMX), or 500 µM 
dibutyryladenosine 3’5’-cyclic monophosphate (dibutyryl 
cAMP or Bt2cAMP, all from Sigma) for 30 minutes prior to and 
during 6 hrs TNF-α stimulation to elevate cAMP levels.  In 
addition, some endothelial monolayers were pretreated with 
100 µM Fsk, then stimulated with TNF-α alone (without Fsk) 
for 2 or 6 hrs.  The negative controls for all experiments 
were adhesion of sickle erythrocytes to unstimulated MECs 
and adhesion to MECs treated with Fsk, IBMX, or Bt2cAMP 
alone for 30 minutes or 6.5 hrs. 
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To test the ability of NO to regulate adhesion 
molecule expression and sickle erythrocyte adhesion, some 
endothelial monolayers were treated with 500 µM sodium 
nitroprusside (SNP, Sigma) or 500 µM 2,2'-
(Hydroxynitrosohydrazono)bis-ethanimine (DETA-NO, Sigma) to 
increase endothelial NO content for 30 minutes prior to and 
during 6 hrs of TNF-α stimulation.  Controls for all 
experiments were adhesion of sickle erythrocytes to 
unstimulated MECs and adhesion to MECs treated with SNP or 
DETA-NO alone for 6.5 hrs. 
 
3.3.3  Sickle Erythrocyte Treatments 
To test for binding ligands on sickle erythrocytes, 
erythrocytes were treated with anti-α4 antibody (50 µg/mL, 
Beckman Coulter) to block erythrocyte α4β1 or neuraminidase 
(300 µM Beckman Coulter) to cleave sialic acid residues for 
40 minutes, centrifuged at 100g for 10 minutes, and 
resuspended in SFM prior to perfusion over MECs stimulated 
with TNF-α for 6 hrs.   
To test the effects of reagents that affect 
erythrocyte cAMP or NO concentrations on adhesion of sickle 
erythrocytes, sickle erythrocytes were incubated with 100 
µM Fsk, 500 µM IBMX, 500 µM Bt2cAMP, 500 µM SNP, or 500 µM 
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DETA-NO for 40 minutes, centrifuged at 100g for 10 minutes, 
and resuspended in SFM prior to perfusion over unstimulated 
MECs or MECs stimulated with TNF-α for 6 hrs.   
 
3.4  Enzyme Linked Immunosorbant Assay 
 
To test the effects of cytokine stimulation on 
endothelial adhesion molecule expression, confluent 
monolayers of MECs and HUVECs in 96 well dishes were 
stimulated with TNF-α (500 U/mL) for times ranging from 0 
to 24 hrs.  Enzyme linked immunosorbant assay (ELISA) was 
used to measure VCAM-1, E-selectin, and ICAM-1 expression 
as described below. 
To test the effects of reagents that alter cAMP or NO 
concentrations on endothelial adhesion molecule expression, 
MECs were pretreated with Fsk, IBMX, Bt2cAMP, SNP, or DETA-
NO, then stimulated with TNF-α plus or minus the 
aforementioned reagents for 2 or 6 hrs.  Pretreatment times 
ranged from 0 to 2 hrs and concentrations of reagents used 
varied from 0 to 1000 µM.   
After treatment, all cells were fixed with 10% 
formalin (Fisher) and refrigerated overnight in 1% bovine 
serum albumin (BSA) in DPBS.  Cells were then incubated for 
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1 hr with either anti-VCAM-1, anti-E-selectin, or anti-
ICAM-1 primary antibody (1 µg/mL) in the BSA solution.  
Wells were then rinsed 3 times with BSA and treated with 
peroxidase conjugated sheep anti-mouse IgG secondary 
antibody (Sigma) at 1 µg/mL in BSA.   Secondary antibody 
binding was detected by reaction of o-phenylenediamine 
dihydrochloride (OPD) with H2O2 (SIGMA FAST™ OPD tablets, 
Sigma) for 30 minutes.  Wells treated with secondary 
antibody only served as controls for each plate.  Optical 
density at 450 nm was measured by a Spectramax Plus 384 
Microplate Reader (Molecular Devices). 
 
3.5  cAMP Measurement 
 
To correlate cAMP concentrations with adhesion 
molecule expression and sickle erythrocyte adhesion, 
confluent monolayers of MECs in 6-well dishes were 
pretreated with Fsk for 30 minutes, then stimulated with 
TNF-α with or without Fsk for times ranging from 0 to 6 
hrs.  Intracellular endothelial cAMP was measured using a 
Correlate-EIA™ Direct Cyclic AMP Enzyme Immunoassay Kit 
(AssayDesigns, Ann Arbor, MI).  Confluent and appropriately 
stimulated endothelial cells were lysed by incubation in 
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0.1 M HCl, the lysate was centrifuged at 600g for 10 min, 
and supernatant was used in the assay.  The kit used 
polyclonal antibody to cAMP to competitively bind either 
cAMP in the sample or cAMP molecules conjugated to alkaline 
phosphatase provided in the kit.  100 µL of sample, 50 µL 
of conjugated cAMP, and 50 µL cAMP antibody were added to 
individual wells of a 96-well dish coated with goat anti-
rabbit IgG and shaken on a plate shaker at 500 rpm for 2 
hours.  Wells were washed with 200 µL of supplied wash 
solution 3 times, and then 200 µL of the supplied p-
nitrophenyl phosphate substrate wass added to each well.  
After incubation for 1 hour, 50 µL of supplied stop 
solution was added to each well, and the plate was read at 
405 nm on a Power WaveX 340 Microplate Reader.  Comparison 
of optical density with that of provided standards allowed 
for quantification of cAMP in endothelial supernatant 
samples. 
3.6  Cell Viability Assay 
 
Viability of cell cultures was evaluated by visual 
inspection of endothelial monolayers by light microscopy 
and by a Live/Dead Viability/Cytotoxicity kit (Molecular 
Probes, Eugene, OR).  For this assay, endothelial 
monolayers were rinsed in DPBS 3 times for 10 minutes each, 
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incubated with a dye solution at 37°C for 30 minutes, 
rinsed three more times in DPBS, and stored away from light 
until microscope viewing.  Live cells were stained green 
with calcein AM dye (ex/em 495 nm/515 nm), and dead cells 
were stained red with ethidium homodimer-1 (ex/em 495 
nm/635 nm).  Fluorescence was detected by a Zeiss LSM 510 
confocal microscope (Carl Zeiss Inc., Thornwood, NY). 
 
3.7  Statistical Analysis 
 
One-factor analysis of variance (ANOVA) was used to 
test differences between levels of adherence of sickle 
erythrocytes under various endothelial treatment 
conditions, between differences in levels of adhesion 
molecule expression under various endothelial treatment 
conditions, and differences in endothelial cAMP 
concentrations due to forskolin treatment.  Fisher’s 
pairwise comparisons were used to test for differences in 
individual treatment means when ANOVA yielded statistical 
difference.  Analyses were completed using MINITAB™ 







CELL ADHESION MOLECULES SUPPORTING ADHESION OF SICKLE 
ERYTHROCYTES TO TNF-α STIMULATED ENDOTHELIUM 
 
As discussed in more detail in section 2.2.3, vascular 
occlusion is a cause of many of the clinical manifestations 
associated with sickle cell anemia.  The abnormal adherence 
of sickle erythrocytes to the endothelium likely 
contributes to occlusive events; however, mechanisms of 
adhesion are still under investigation.  Several previous 
studies have demonstrated increased sickle erythrocyte 
adherence to cytokine-stimulated endothelium, most of which 
used cultured HUVECs, or large vessel endothelial cells, as 
a representative endothelial model.  Occlusion, however, 
often occurs in the microcirculation where endothelial 
cells are phenotypically different (H. A. Brittain et al., 
1992; Swerlick et al., 1992).  The following studies 
compare adhesion molecule expression on microvascular 
endothelial cells (MECs) with that of HUVECs and 
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demonstrate mechanisms of sickle erythrocyte adhesion to 
MECs. 
 
4.1  Endothelial Cell Adhesion Molecule Expression 
  
4.1.1  TNF-α Stimulated Microvascular Endothelial Cells 
 Stimulation of endothelial cells with cytokines such 
as TNF-α induces expression of VCAM-1, E-selectin, and 
ICAM-1, although expression profiles with increased 
stimulation time may be different depending on endothelial 
cell phenotype.  ELISA was used to measure expression of 
these receptors on MECs.  Results are shown in Figure 4.1. 
 Panel A of Figure 4.1 shows minimal expression of 
VCAM-1 on unstimulated MECs, and expression is not 
significantly upregulated until 6 hrs of TNF-α stimulation.  
This delay is consistent with reports in literature for 
this cell type (Swerlick et al., 1992).  E-selectin 
expression, however, is significantly increased after only 
two hours of TNF-α stimulation (Panel B).  Unlike VCAM-1 
and E-selectin, ICAM-1 is constitutively expressed on 
unstimulated MECs, and TNF-α stimulation for 4 or more 
hours further increases expression (Panel C). 
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Figure 4.1  Adhesion molecule expression on MECs.  A) VCAM-
1, B) E-selectin, and C) ICAM-1 expression on MECs as a 
function of TNF-α (500 U/mL) stimulation time.  *Indicates 
significant difference from 0 hrs stimulation (n=9).  Data 








0 2 4 6 8










0 2 4 6 8












0 2 4 6 8























4.1.2  Comparison of Adhesion Molecule Expression on MECs 
and HUVECs 
 To determine phenotypic differences in expression of 
adhesion molecules, expression of VCAM-1, E-selectin, and 
ICAM-1 was measured by ELISA for up to 24 hrs of TNF-α 
stimulation.  Figure 4.2 shows results for VCAM-1.  For 
MECs, upregulation of VCAM-1 is apparent after 6 hrs of 
TNF-α stimulation and continues to increase until it peaks 
at 16 hrs (Panel A).  After this time, VCAM-1 expression 
begins to decrease, consistent with literature (Swerlick et 
al., 1992).  VCAM-1 expression is increased on HUVECs after 
6 hrs of stimulation; however, expression then plateaus 
until 20 hrs of stimulation (Panel B).  At 24 hrs of 
stimulation, expression begins to increase again. 
 E-selectin expression profiles are similar between 
MECs and HUVECs (Figure 4.3), but differ from those of 
VCAM-1 for either cell type.  Upregulation of E-selectin is 
evident after only 2 hrs of TNF-α stimulation, but 
expression peaks at 6 hrs (HUVECs) or 8 hrs (MECs).  After 
this, surface expression declines steadily but does not 
reach baseline (expression levels on unstimulated cells) 
after 24 hrs of stimulation. 
78 
 ICAM-1 expression profiles are shown in Figure 4.4.  
Both MECs and HUVECs express ICAM-1 under unstimulated 
conditions, but HUVECs demonstrate higher optical densities 
than MECs.  Expression of ICAM-1 on MECs increases sharply 
for the first 12 hrs of TNF-α stimulation, then plateaus 
out to 24 hrs (Panel A).  On HUVECs, ICAM-1 expression is 
high on unstimulated cells and increases less sharply in 
response to TNF-α stimulation than MECs (Panel B). 
 Together these data demonstrate phenotypic differences 
between HUVECs and MECs with regard to TNF-α stimulated 
adhesion molecule expression.  These differences suggest 
that the choice of an endothelial model for in vitro flow 
studies of sickle erythrocytes needs to be undertaken with 
care and attention to mimicking as closely as possible the 
in vivo environment one wishes to study.  Because many of 
the clinical manifestations of sickle cell anemia result 
from microvascular occlusion, microvascular endothelial 








Figure 4.2  VCAM-1 expression on MECs and HUVECs.  VCAM-1 
expression on MECs (A) and HUVECs (B) as a function of TNF-
α stimulation time (n=2).  Data from individual experiments 
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Figure 4.3  E-selectin expression on MECs and HUVECs.  E-
selectin expression on MECs (A) and HUVECs (B) as a 
function of TNF-α stimulation time (n=2).  Data from 
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Figure 4.4  ICAM-1 expression on MECs and HUVECs.  ICAM-1 
expression on MECs (A) and HUVECs (B) as a function of TNF-
α stimulation time (n=2).  Data from individual experiments 
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4.2  Sickle Erythrocyte Adhesion to TNF-α Stimulated MECs 
  
Increased endothelial adhesion molecule expression due 
to TNF-α stimulation suggests that adhesion of sickle 
erythrocytes increases in response to such stimulation.  To 
test this hypothesis, MECs were stimulated with TNF-α for 
either 2 or 6 hours.  Sickle erythrocytes were perfused 
over the MECs at 1 dyne/cm2 shear stress and adherent 
erythrocytes counted for up to 40 minutes of perfusion (see 
Section 3.3 for more details).   
Results are shown in Figure 4.5 below.  Adhesion of 
sickle erythrocytes to unstimulated MECs is minimal, 
reaching only 7.0 ± 2.8 cells/mm2 after 40 minutes of 
perfusion.  Stimulation of MECs with TNF-α for 2 hrs 
increases adhesion to 18 ± 1.9 cells/mm2; however, this 
increase does not achieve statistical significance.  
Stimulation of MECs with TNF-α for 6 hrs further increases 
adhesion to 44 ± 8.0 cells/mm2.  This value is significantly 
higher than that for both unstimulated MECs and those 
stimulated with TNF-α for 2 hrs.  For both 2 and 6 hrs of 
TNF-α stimulation, sickle erythrocyte adhesion increases 
sharply at short erythrocyte perfusion times, then reaches 
a plateau after 30 to 40 minutes of perfusion. 
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Comparing Figure 4.1 and Figure 4.5 suggests possible 
mechanisms of sickle erythrocyte adhesion.  Unstimulated 
MECs express only ICAM-1 (not VCAM-1 or E-selectin), 
indicating that adherent erythrocytes might be bound to 
ICAM-1.  However, since only small numbers of sickle 
erythrocytes adhere to unstimulated MECs it is unlikely 
that ICAM-1 supports adhesion of sickle erythrocytes.  That 
ICAM-1 is not involved in sickle erythrocyte adhesion is 
confirmed by others (Montes et al., 2002) and by antibody 
blocking studies presented in Section 4.3.3.  After 2 hrs 
of TNF-α stimulation, E-selectin expression, but not VCAM-1 
expression is upregulated.  This suggests that sickle 
erythrocyte adhesion above levels on unstimulated MECs 
results from binding of sickle erythrocytes to E-selectin.  
After 6 hrs of TNF-α stimulation, expression of both VCAM-1 
and E-selectin is upregulated, and the increase in sickle 
erythrocyte adhesion may be due to binding of erythrocytes 
to either E-selectin or VCAM-1.  Mechanisms of adhesion of 
sickle erythrocytes to TNF-α stimulated MECs are further 
tested using monoclonal antibodies to block adhesion via 
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Figure 4.5  Adhesion of SSRBCs to TNF-α stimulated MECs.  
Sickle erythrocyte adhesion to MECs increases with TNF-α 
stimulation time(n=8).  *Indicates statistical difference 
from unstimulated MECs.  #Indicates statistical difference 
from MECs stimulated with TNF-α for 2 hrs.  Data from 




4.3  Blocking of Adhesion Molecules with Monoclonal 
Antibodies 
  
 As mentioned in Section 4.2, mechanisms of sickle 
erythrocyte adhesion to MECs are elucidated by incubating 
endothelial cells with monoclonal antibodies against VCAM-
1, E-selectin, or both during TNF-α stimulation.  
Antibodies specifically fill the binding pocket of the 
adhesion molecule against which they are raised (i.e. VCAM-
















from binding to the endothelial cells via the adhesion 
molecule.   Because monoclonal antibodies are relatively 
large and VCAM-1 and E-selectin are likely in close 
proximity on the endothelial surface, one concern in using 
monoclonal antibodies is that attachment of an antibody to 
one type of adhesion molecule might sterically hinder 
access of sickle erythrocytes to the other type.  Thus to 
verify results obtained using monoclonal antibodies, some 
endothelial monolayers are also treated with a synthetic 
peptide (12 amino acids in length) which blocks E-selectin 
and is only about 1% of the size of a typical antibody, 
lessening the chance of sterically hindering VCAM-1.  
Because ICAM-1 is not expected to support sickle 
erythrocyte adhesion, only a select few experiments are 
completed using anti-ICAM-1 antibodies.  They are presented 
as control data in Section 4.3.3.  Antibody blocking 
experiments using anti-VCAM-1 and anti-E-selectin 
antibodies are completed for both 2 and 6 hrs of TNF-α 
stimulation and results are shown below. 
 
4.3.1  Monoclonal Antibodies Blocking Adhesion Molecules on 
MECs Stimulated with TNF-α for 2 hrs 
Panel A of Figure 4.6 shows that treatment of MECs 
with anti-VCAM-1 antibody does not inhibit sickle 
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erythrocyte adhesion on MECs stimulated with TNF-α for 2 
hrs, suggesting that VCAM-1 does not support adhesion of 
sickle erythrocytes at this time.   
While Panel A represents average data for 8 blood 
samples, individual samples varied greatly in levels of 
adhesion, thus resulting in large error bars.  Adhesion to 
TNF-α stimulated MECs varied from 8 to 229 cells/mm2 after 
40 minutes of perfusion, depending on the blood sample (See 
Table B.7 for the complete data set).  For clarity, Panel B 
of Figure 4.6 shows results from individual blood samples 
comprising the averages shown in Panel A at the 40 minute 









For the 8 blood samples tested, 6 showed a 1.5 fold or 
greater increase in adherent sickle erythrocytes due to 2 
hrs of TNF-α stimulation.  Treatment of MECs with anti-
VCAM-1 antibody inhibited adhesion in only 2 of the samples 
(S38 and S45).  Results from individual blood samples as 









































Figure 4.6  Blocking of sickle erythrocyte adhesion to MECs 
stimulated with TNF-α for 2 hrs by anti-VCAM-1 antibody.  
A)  Average data for n=8 blood samples.  B)  Fold change in 
adhesion after 40 minutes of perfusion for individual blood 
samples comprising the average shown in Panel A.  Data for 



































promote adhesion of sickle erythrocytes to MECs after 2 hrs 
of TNF-α stimulation.  These results are expected, since 
ELISA data shown in Figure 4.1 demonstrate that VCAM-1 is  
not upregulated on the endothelial cell surface after only 
2 hrs of stimulation. 
Figure 4.7 shows blocking of endothelial E-selectin.  
In Panel A, a small synthetic peptide which binds to E-
selectin inhibits adhesion of sickle erythrocytes by 49%.  
Again, these results are not statistically significant due 
to large variability in absolute numbers of adhesive 
erythrocytes between blood samples.  Panel B shows fold 
changes in adhesion for all blood samples tested after 40 
minutes of perfusion.  Of the 8 samples tested, 6 
demonstrate a 1.5 fold or higher increase in sickle 
erythrocyte adhesion due to TNF-α stimulation.  Of these 6, 
5 show a decrease in sickle erythrocyte adhesion due to 
treatment with the E-selectin blocking peptide.  For three 
samples, treatment of MECs with the peptide results in a 
fold change that is less than one, meaning that adhesion is 
less than that for unstimulated MECs.  While not 
statistically significant, these results suggest that E-
selectin may mediate adhesion of sickle erythrocytes to 
MECs in some patients.  These results are further supported 
by data showing that treatment of MECs with anti-E-selectin 
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antibody reduces adhesion of sickle erythrocytes by 49% 
(Figure 4.8).  Testing of a larger patient pool may help to 
clarify the role of E-selectin in promoting adhesion at 
this early TNF-α stimulation time. 
Interesting to note is that blocking with either the 
E-selectin peptide or the E-selectin antibody does not 
completely inhibit adhesion of sickle erythrocytes.  These 
data are consistent with the only other report of E-
selectin mediated adhesion of sickle erythrocytes available 
in the literature to date (Natarajan et al., 1996).  One 
potential explanation for incomplete inhibition of adhesion 
is that too little reagent (either peptide or antibody) was 
used.  More peptide could not be used due to solubility 
limits of the peptide in media.  More antibody was not used 
due to practical limits of expense.  Another potential 
explanation for incomplete inhibition is that an unknown 
adhesion molecule other than E-selectin promotes sickle 
erythrocyte adhesion.  However, this seems unlikely given 
the current body of literature suggesting that the primary 
adhesion molecules upregulated by TNF-α stimulation are 
VCAM-1, E-selectin, and ICAM-1. 
Also important to note is that treatment of MECS with 
both the E-selectin blocking peptide and anti-VCAM-1 
antibody simultaneously inhibits adhesion of sickle 
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erythrocytes by 71%, or 22% more than blocking with the E-
selectin peptide alone.  For the given data set, these 
results are not statistically different; however, they 
invite speculation as to how the antibody and the peptide 
might interact with one another when VCAM-1 is not present 
on the endothelial cell surface and how their interaction 
might affect experimental outcomes.  To date, no studies 
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Figure 4.7  Blocking of sickle erythrocyte adhesion to MECs 
stimulated with TNF-α for 2 hrs by E-selectin blocking 
peptide and anti-VCAM-1 antibody.  A)  Average data for n=8 
blood samples.  B)  Fold change in adhesion after 40 
minutes of perfusion for individual blood samples 
comprising the average shown in Panel A.  Data for 
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Figure 4.8  Blocking of sickle erythrocyte adhesion to MECs 
stimulated with TNF-α for 2 hrs by anti-E-selectin 
antibody.  Average data for n=2 blood samples.  Data for 
individual blood samples are given in Table B.11. 
 
 
4.3.2  Monoclonal Antibodies Blocking Adhesion Molecules on 
MECs Stimulated with TNF-α for 6 hrs 
After 6 hrs of TNF-α stimulation, both VCAM-1 and E-
selectin are upregulated on MECs (Figure 4.1).  Blocking 
studies using antibodies and peptides are conducted to 
determine which adhesion molecules support sickle 
erythrocyte adhesion.  Panel A of Figure 4.9 shows that 
treatment of MECs with anti-VCAM-1 antibody inhibits 
adhesion of sickle erythrocytes by 72%, suggesting that 
VCAM-1 is a dominant adhesion molecule supporting sickle 
erythrocyte adhesion after 6 hrs of TNF-α stimulation.  
















sickle erythrocyte adhesion by 59%, while blocking with an 
anti-E-selectin antibody inhibits adhesion by 67%, 
demonstrating that E-selectin also contributes to sickle 
erythrocyte adhesion (Figure 4.9, Panels B and C).  
Treatment of MECs with both anti-VCAM-1 antibody and E-
selectin blocking peptide simultaneously inhibits adhesion 
of sickle erythrocytes 82% (Figure 4.9, Panel B).   
Together these data demonstrate that both VCAM-1 and 
E-selectin support sickle erythrocyte adhesion to MECs 
stimulated with TNF-a for 6 hrs.  Blocking both adhesion 
molecules together more effectively inhibits sickle 
erythrocyte adhesion than blocking either VCAM-1 or E-
selectin alone, suggesting that adhesion via both molecules 
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Figure 4.9  Blocking of sickle erythrocyte adhesion to MECs 
stimulated with TNF-α for 6 hrs.  Blocking with A) anti-
VCAM-1 antibody (n=13), B) E-selectin blocking peptide 
and/or anti-VCAM-1 antibody (n=9), and C) anti-E-selectin 
antibody (n=10).  *Indicates statistical difference from 
TNF-a (6 hrs).  For Panel B, statistical significance is 
indicated for both E-sel pep and E-sel pep + a-VCAM-1.  













































4.3.3  Control Studies with Non-blocking Antibodies and 
Peptides 
To ensure that the effectiveness of VCAM-1 and E-
selectin antibodies at inhibiting sickle erythrocyte 
adhesion is due to specific binding of the antibodies to 
the adhesion molecule against which they were raised and 
not due to non-specific binding, MECs stimulated with TNF-α 
for 6 hrs are treated with either anti-ICAM-1 antibody or 
anti-IgGκ antibody, then perfused with sickle erythrocytes 
as previously described.  As mentioned earlier in Section 
4.3, ICAM-1 is a specific adhesion molecule not thought to 
support adhesion of sickle erythrocytes.  The IgGκ antibody 
is a non-specific antibody.  The results shown in Figure 
4.10 show that treatment with either anti-ICAM-1 antibody 
or anti-IgGκ antibody does not inhibit sickle erythrocyte 
adhesion, suggesting that inhibition of adhesion due to 
treatment with anti-VCAM-1 or anti-E-selectin antibodies is 
due to specific inhibition of VCAM-1 and E-selectin on 
MECs. 
Control experiments are also performed for the E-
selectin blocking peptide.  The procedure used to generate 
the results in Figures 4.7 and 4.9 includes incubation of 
MECs with the E-selectin blocking peptide during TNF-α 
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stimulation and inclusion of the peptide in the erythrocyte 
suspension perfused over the cells.  The inclusion of the 
peptide in the erythrocyte suspension is necessary to 
inhibit adhesion.  To control for the possibility that the 
ability of the peptide to inhibit adhesion results from 
binding of the peptide to the sickle erythrocytes rather 
than the MECs, sickle erythrocytes are incubated with the 
peptide for 30 minutes, centrifuged, and resuspended in 
peptide-free media for perfusion over MECs stimulated with 
TNF-α for 6 hrs.  Results shown in Figure 4.11, Panel A 
demonstrate that sickle erythrocyte adhesion is not 
inhibited by this method, suggesting that the peptide is 
not bound to the erythrocytes at the time of perfusion.  
The necessity of including the E-selectin blocking peptide 
in the sickle erythrocyte suspension to inhibit adhesion is 
possibly due to low affinity of the peptide for E-selectin.  
That is, the peptide may wash away from E-selectin under 
the flow conditions of the experiment, necessitating 
constant replenishment of the peptide to inhibit adhesion. 
The E-selectin blocking peptide was developed from a 
recombinant library and had the highest affinity for E-
selectin of all members of the library (Martens et al., 
1995).  A peptide containing the same amino acids as the E-
selectin blocking peptide but with a scrambled sequence was 
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generated and used like the original peptide to serve as a 
control.  The results shown in Panel B of Figure 4.11 show 
that the scrambled peptide does not inhibit adhesion of 
sickle erythrocytes, likely because it does not have 
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Figure 4.10  Sickle erythrocyte adhesion to MECs stimulated 
with TNF-α for 6 hrs and treated with anti-ICAM-1 or anti-
IgGκ antibodies.  Sickle erythrocyte adhesion to MECs 
treated with A) anti-ICAM-1 antibody (n=4) or B) anti-IgGκ 
antibody (n=9).  Data for individual blood samples are 












































0 5 10 15 20 25 30 35 40
Perfusion Time (min)
Unstimulated
E-sel pep washed away





















Figure 4.11  Sickle erythrocyte adhesion to MECs stimulated 
with TNF-α for 6 hrs and treated with control peptides.  A)  
Sickle erythrocyte adhesion when erythrocytes were 
incubated with E-selectin blocking peptide, centrifuged, 
and resuspended in peptide-free media prior to perfusion 
(n=3).  B)  Sickle erythrocyte adhesion when a scrambled 
version of the E-selectin blocking peptide was used to 
treat MECs and included in the erythrocyte suspension for 
flow (n=3).  Data for individual blood samples are given in 
































4.4  Blocking of Sickle Erythrocyte Ligands 
  
 As discussed in Section 2.4, adhesion of sickle 
erythrocytes to vascular endothelium results from binding 
of ligand molecules on sickle erythrocytes to adhesion 
molecules or receptors on the endothelial cell surface.  
The integrin α4β1 has previously been identified as a 
specific ligand on sickle erythrocytes that binds to 
endothelial VCAM-1 (Swerlick et al., 1993).  A specific 
erythrocyte ligand for E-selectin has not been identified, 
but others have suggested that sialic acid on sickle 
erythrocytes contributes to their adhesion to endothelial 
cells and another member of the selectin family, P-
selectin, under conditions of low (0.1 dyne/cm2 shear 
stress) or no flow (Matsui et al., 2001; Montes et al., 
2002).  However, several studies have also shown that 
membrane sialic acid content is lower for sickle 
erythrocytes than for non-sickle erythrocytes (Aminoff et 
al., 1980; Ekeke & Ibeh, 1988; Westerman et al., 1979). 
To determine which erythrocyte ligands support 
adhesion of sickle erythrocytes to TNF-α stimulated MECs, 
sickle erythrocytes are incubated with either anti-alpha 4 
antibody or neuraminidase, which cleaves sialic acid 
(Uchida et al., 1979), for 40 minutes at 37°C.  
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Erythrocytes incubated with neuraminidase are then 
centrifuged and resuspended in neuraminidase-free media.  
Treated erythrocytes are perfused over endothelial cells 
stimulated with TNF-α for 6 hrs.  Results are shown in 
Figure 4.12.  Panel A shows that treatment of erythrocytes 
with anti-alpha 4 antibody does not significantly inhibit 
adhesion.  Panel B shows that treatment with neuraminidase 
also does not inhibit sickle erythrocyte adhesion.   
The inability of these treatments to reduce sickle 
erythrocyte adhesion is potentially explained by two 
hypotheses.  First, simultaneous inhibition of both the 
VCAM-1 ligand and the E-selectin ligand on sickle 
erythrocytes may be necessary for inhibition of erythrocyte 
adhesion to TNF-α stimulated MECs.  Second, sialic acid may 
not support adhesion of sickle erythrocytes to E-selectin 
under a physiological shear stress of 1 dyne/cm2.  To test 
these hypotheses, an E-selectin ligand might be identified 
by testing treated erythrocyte adhesion to MECs stimulated 
with TNF-α for only 2 hrs, a stimulation time for which 
VCAM-1 is not upregulated on MECs.  Identification of an E-
selectin ligand would allow for simultaneous inhibition of 
it and erythrocyte α4β1 and testing of the first hypothesis.  
Alternatively, perfusion experiments in which sickle 
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erythrocytes treated with anti-α4 antibody were perfused 
over MECs treated with anti-E-selectin antibody or peptide 
and TNF-α could be performed to determine whether mutual 
inhibition of both adhesion pathways is necessary.  
Blocking of a single pathway (i.e. use of one antibody or 



















































Figure 4.12  Adhesion of sickle erythrocytes treated with 
anti-alpha 4 antibody or neuraminidase to MECs stimulated 
with TNF-α for 6 hrs.  Sickle erythrocyte adhesion when 
erythrocytes were treated with A) anti-alpha 4 antibody 
(n=5) or B) neuraminidase (n=4).  Data for individual blood 






























4.5  Chapter Summary 
  
 Vascular occlusion by sickle erythrocytes results 
in many of the clinical manifestations associated with 
sickle cell anemia.  Stimulation of endothelial cells with 
cytokines such as TNF-α increases adhesion molecule 
expression and sickle erythrocyte adhesion in vitro; 
however, expression profiles of VCAM-1, E-selectin, and 
ICAM-1 vary with endothelial phenotype.  The data presented 
in this chapter demonstrate that VCAM-1 and E-selectin 
support adhesion of sickle erythrocytes, whereas ICAM-1 
does not.  For microvascular endothelial cells, sickle 
erythrocyte adhesion to unstimulated endothelium is 
minimal.  Stimulation with TNF-α for 2 hrs increases E-
selectin, but not VCAM-1 expression, and increases sickle 
erythrocyte adhesion by 2.6-fold.  Antibody and peptide 
blocking studies are inconclusive, but suggest that E-
selectin may support adhesion of sickle erythrocytes at 
this stimulation time.  Stimulation of MECs with TNF-α for 
6 hrs results in significant expression of both VCAM-1 and 
E-selectin and sickle erythrocyte adhesion is increased 
6.3-fold.  Antibody and peptide blocking studies show that 
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both VCAM-1 and E-selectin support adhesion of sickle 
erythrocytes at this stimulation time. 
Together these data show that sickle erythrocyte 
adhesion is complex in vitro.  Dominant mechanisms of 
adhesion vary with cytokine stimulation time, indicating 
that strategies to inhibit adhesion in vivo may need to 
encompass multiple adhesive mechanisms to be effective.  
Taking this into account, the following chapters explore 
inhibition of sickle erythrocyte adhesion by interruption 
of the common intracellular signaling cascades initiated by 












INHIBITION OF CYTOKINE INDUCED SICKLE ERYTHROCYTE ADHESION 
BY ELEVATION OF ENDOTHELIAL INTRACELLULAR cAMP 
 
As discussed previously in Sections 2.4 and 2.5, 
inhibition of sickle erythrocyte adhesion to vascular 
endothelial cells is a potential therapeutic strategy for 
preventing or treating occlusive events in sickle cell 
anemia, but currently no such therapies exist.  One way to 
inhibit sickle erythrocyte adhesion is to physically block 
adhesion molecules and ligands supporting adhesion using 
antibodies or peptides.  However, each antibody or peptide 
is specific for an individual adhesion molecule.  The data 
shown in Chapter 4 and elsewhere in literature (H. A. 
Brittain et al., 1993; Hebbel, 1997, 2000; Kumar, 1995) 
suggest that sickle erythrocyte adhesion in vivo may be 
complex, with multiple endothelial adhesion molecules and 
erythrocyte ligands supporting adhesion simultaneously or 
at different times during the course of an occlusive event.  
Thus for physical blocking of sickle erythrocyte adhesion 
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to be effective, development of a complex cocktail of 
antibodies and peptides blocking several adhesion molecules 
and ligands may be necessary. 
An alternative strategy to preventing sickle 
erythrocyte adhesion to endothelial cells is to inhibit the 
expression of endothelial adhesion molecules by 
interruption of the intracellular signaling cascades 
leading to their expression.  Many of the known endothelial 
adhesion molecules supporting sickle erythrocyte adhesion, 
including VCAM-1 and E-selectin, are upregulated in 
response to infection and inflammation.  Cytokines, 
including TNF-α, that are released into the blood stream 
during inflammation initiate cell signaling resulting in 
adhesion molecule expression.  Several studies have 
demonstrated that the ubiquitous intracellular signaling 
molecule cAMP suppresses inflammatory response (Galea & 
Feinstein, 1999; Otsuki et al., 2001; Pober et al., 1993) 
by controlling endothelial cell signaling.  The mechanisms 
by which these effects occur are outlined in more detail in 
Section 2.6.  The studies presented in this chapter explore 
how elevated endothelial cAMP affects TNF-α induced VCAM-1, 
E-selectin, and ICAM-1 expression on MECs, and how 
regulation of these adhesion molecules affects sickle 
erythrocyte adhesion.  
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5.1  The Effect of Reagents that Increase Intracellular 
cAMP on TNF-α Induced Adhesion Molecule Expression 
  
Elevated endothelial intracellular cAMP is thought to 
suppress inflammatory response, particularly cytokine-
induced adhesion molecule expression.  In vitro, cAMP 
levels can be elevated primarily by 1) activating adenylate 
cyclase with forskolin (Fsk) to produce more cAMP, 2) 
inhibiting the phosphodiesterases that break down cAMP with 
various reagents, including the methyl xanthine derivative 
isobutylmethylxanthine (IBMX), and 3) applying cell-
permeable cAMP analogues such as dibutyryl cAMP (Bt2cAMP).  
The effects of increasing cAMP by each of these methods on 
adhesion molecule expression are shown in the following 
section. 
 
5.1.1  The Effect of Forskolin on VCAM-1, E-selectin, and 
ICAM-1 Expression 
Figure 5.1 shows the effects of forskolin on VCAM-1, 
E-selectin, and ICAM-1 expression on MECs.  The first bar 
in each panel shows expression on unstimulated MECs, and 
the second bar shows increased expression due to 6 hrs of 
TNF-α stimulation.  The remaining bars show expression when 
MECs are pretreated with the given concentration of 
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forskolin for 30 minutes prior to TNF-α stimulation.  Panel 
A shows that VCAM-1 expression is reduced in a 
concentration dependent manner due to forskolin 
pretreatment.  The reduction becomes statistically 
significant, but does not return to baseline, with 1000 µM 
forskolin.  Results follow a similar trend for E-selectin 
(Panel B).  Forskolin pretreatment at concentrations as low 
as 10 µM significantly inhibits E-selectin expression, with 
greater inhibition occurring at higher concentrations.  
Panel C shows that ICAM-1 expression is not significantly 
altered by pretreatment with forskolin. 
In addition to the concentration of forskolin used, 
another important parameter to consider is the time of 
application.  Figure 5.2 shows the effect of forskolin 
pretreatment times ranging from 0 to 120 minutes on VCAM-1, 
E-selectin, and ICAM-1 expression induced by TNF-α 
stimulation for 6 hrs.  In addition, the last two bars on 
each panel show expression when MECs are pretreated with 
forskolin for either 30 or 120 minutes, and forskolin is 
also applied continuously through the duration of TNF-α 
stimulation.  A forskolin concentration of 100 µM was used 
for experiments shown in Figure 5.2.  Panel A indicates 
that TNF-α induced VCAM-1 expression is significantly 
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inhibited by as little as 15 minutes of pretreatment with 
forskolin.  Pretreatment for longer times does not further 
repress VCAM-1 expression.  However, pretreatment and 
continuous presence of forskolin during TNF-α stimulation 
reduces VCAM-1 levels to baseline (levels on unstimulated 
MECs).  Panel B of Figure 5.2 shows a similar trend for E-
selectin. 
Pretreatment with forskolin significantly inhibits E-
selectin expression, but greater inhibition is achieved 
when forskolin is also present during TNF-α stimulation.  
Even continous presence of forskolin, however, is not 
sufficient to completely inhibit E-selectin expression.  
Again, Panel C shows that ICAM-1 expression is not 
significantly inhibited by treatment of MECs with 
forskolin. 
 Together these data demonstrate that forskolin 
inhibits VCAM-1 and E-selectin, but not ICAM-1 expression 
on TNF-α stimulated MECs.  Forskolin is most effective when 
it is applied both prior to and during TNF-α stimulation, 
suggesting that treatment time is more important than 
treatment concentration.  Possible explanations for the 
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Figure 5.1  Effect of forskolin pretreatment concentration 
on TNF-α induced adhesion molecule expression.  Surface 
expression of A) VCAM-1, B) E-selectin, and C) ICAM-1 on 
MECs treated with forskolin for 30 min then TNF-α for 6 hrs 
(n=6).  *Indicates statistically significant difference 
from MECs treated with only TNF-α (0 µM forskolin).  Data 
































































Figure 5.2  Effect of forskolin pretreatment time on TNF-α 
induced adhesion molecule expression.  Surface expression 
of A) VCAM-1, B) E-selectin, and C) ICAM-1 on MECs 
pretreated with 100 µM forskolin for the indicated time 
then TNF-α and/or forskolin for 6 hrs (n=4).  *Indicates 
statistically significant difference from MECs treated with 











































































































5.1.2  The Effect of IBMX on VCAM-1, E-selectin, and ICAM-1 
Expression 
The ability of forskolin to regulate adhesion molecule 
expression is likely due to elevation of intracellular cAMP 
levels.  To further demonstrate the role of cAMP in 
regulating adhesion molecule expression, MECs are treated 
with IBMX, which elevates cAMP by a different mechanism 
(inhibition of phosphodiesterases) than forskolin, for 30 
minutes prior to and during 6 hrs of TNF-α stimulation.  
Results are shown in Figure 5.3. 
Panel A of Figure 5.3 shows that pretreatment and 
continuous presence of IBMX at concentrations of 50 µM or 
greater significantly inhibits TNF-α induced VCAM-1 
expression, and degree of inhibition appears concentration 
dependent.  Panel B shows that E-selectin expression is not 
significantly inhibited at concentrations less than 1000 
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Figure 5.3  Effect of IBMX concentration on TNF-α induced 
adhesion molecule expression. Surface expression of A) 
VCAM-1, B) E-selectin, and C) ICAM-1 on MECs pretreated 
with IBMX for 30 min then TNF-α and IBMX for 6 hrs (n=5).  
*Indicates statistically significant difference from MECs 
treated with only TNF-α (0 µM IBMX).  Data for individual 




















5.1.3  The Effect of Bt2cAMP on VCAM-1, E-selectin, and 
ICAM-1 Expression 
In addition to regulation of the enzymes that make and 
break down cAMP in endothelial cells, another method to 
elevate intracellular cAMP is to supply cell-permeable cAMP 
analogues in the cell culture media, which diffuse into the 
cells and produce physiological responses like cAMP.  The 
effect of pretreatment and continuous presence of one cAMP 
analogue, Bt2cAMP, at varying concentrations on TNF-α 
induced VCAM-1, E-selectin, and ICAM-1 expression is shown 
in Figure 5.4 below.  Panel A shows that Bt2cAMP inhibits 
VCAM-1 expression in a concentration dependent manner, with 
inhibition becoming statistically significant at Bt2cAMP 
concentrations of 100 µM or higher.  E-selectin expression 
is also inhibited by Bt2cAMP (Panel B), while ICAM-1 is not 
except at a concentration of 1000 µM (Panel C). 
Pretreatment and continuous presence of either Fsk, 
IBMX, or Bt2cAMP during TNF-α stimulation inhibits, but does 
not completely abolish, VCAM-1 and E-selectin expression.  
Literature suggests that treatment of endothelial cells 
with both Fsk and cilostazol, a phosphodiesterase inhibitor 
like IBMX, results in greater inhibition of VCAM-1 
expression than treatment with either reagent alone (Otsuki 
et al., 2001).  However, a study of the effects of multiple 
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cAMP-elevating reagents used simultaneously on TNF-α 
induced adhesion molecule expression is not undertaken in 
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Figure 5.4  Effect of Bt2cAMP concentration on TNF-α induced 
adhesion molecule expression.  Surface expression of A) 
VCAM-1 (n=5), B) E-selectin (n=5), and C) ICAM-1 (n=1) on 
MECs pretreated with Bt2cAMP for 30 min then TNF-α and 
Bt2cAMP for 6 hrs.  *Indicates statistically significant 
difference from MECs treated with only TNF-α (0 µM Bt2cAMP).  





















5.1.4  Comparison of Forskolin Effect on MECs stimulated 
with TNF-α for 2 or 6 hrs 
A summary of the effects of forskolin pretreatment and 
continuous presence during 6 hrs of TNF-α stimulation is 
presented in Figure 5.5, Panel A (the full study is shown 
in Figure 5.2).  In Figure 5.5 and all following figures, 
the term “pretreatment,” abbreviated “pre”, refers to a 30 
minute treatment with the specified compound prior to TNF-α 
stimulation.  The term “continuous”, abbreviated “cont,” 
refers to treatment with the specified compound during TNF-
α stimulation.  Figure 5.5, Panel A reiterates that for 6 
hrs of TNF-α stimulation, VCAM-1 and E-selectin expression 
are upregulated.  Pretreatment with forskolin inhibits E-
selectin, but not VCAM-1 expression.  Pretreatment and 
continuous presence of forskolin during TNF-α stimulation 
inhibits VCAM-1 and E-selectin expression, but not ICAM-1. 
Similar experiments were conducted with MECs 
stimulated with TNF-α for 2 hrs, and the results are shown 
in Figure 5.5, Panel B.  The data demonstrate that VCAM-1 
is not upregulated on MECs after 2 hrs of stimulation and 
is not affected by forskolin.  E-selectin is upregulated, 
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Figure 5.5  Comparison of the effect of forskolin on MECs 
stimulated with TNF-α for 2 or 6 hrs.  Surface expression 
of VCAM-1, E-selectin, and ICAM-1 on MECs pretreated with 
Fsk for 30 min then TNF-α alone or TNF-α and Fsk for 2 
(n=6) or 6 (n=4) hrs.  *Indicates statistically significant 
difference from MECs treated with only TNF-α.  Data are 


















and is further inhibited by pretreatment and continuous 
presence of the cAMP-elevating reagent. 
 
5.1.5  Effect of Fsk, IBMX, and Bt2cAMP alone on VCAM-1, E-
selectin, and ICAM-1 expression 
To test for the possibility that increasing cAMP might 
alter adhesion molecule expression on MECs by means other 
than interruption of cytokine induced signaling cascades, 
MECs were treated with Forskolin, IBMX, or Bt2cAMP alone for 
6.5 hours and VCAM-1, E-selectin, and ICAM-1 expression 
were measured.  The results shown in Table 5.1 demonstrate 
that treatment with these reagents alone does not induce 
adhesion molecule expression, since optical density does 
not change with treatment.   
Additionally, to ensure that the ability of cAMP 
elevating reagents to inhibit adhesion molecule expression 
was not due to cell damage or death, endothelial monolayers 
treated or not with reagents that increase cAMP were 
photographed under light microscopy.  Also, a live/dead 
assay was performed as described in Section 3.6, and 
photographs of the cells were taken using confocal 
microscopy.  Live cells are stained green and dead cells 
are stained red.  Pictures are shown in Appendix C and 
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reveal that viability was not affected by endothelial 
treatment with reagents that increase cAMP. 
 
Table 5.1  Effect of Fsk, IBMX, or Bt2cAMP alone on adhesion 
molecule expression.  Surface expression of VCAM-1, E-
selectin, and ICAM-1 on MECs treated with 100 µM Fsk, 500 
µM IBMX, or 500 µM Bt2cAMP for 6.5 hrs (n=2).  Data for 
individual experiments are presented in Table B.26. 
 
 
Endothelial Treatment VCAM-1 E-selectin ICAM-1
Unstimulated 0.019 0.033 0.134
Fsk 0.018 0.027 0.129
IBMX 0.032 0.035 0.104
Bt2cAMP 0.026 0.069 0.127  
 
 
5.2  The Effect of Reagents that Increase Endothelial 
Intracellular cAMP on TNF-α Induced Sickle Erythrocyte 
Adhesion 
  
 The data presented in Section 5.1 demonstrate that 
interruption of cytokine induced cell signaling cascades is 
achieved by elevation of endothelial intracellular cAMP.  
Such interruption inhibits TNF-α induced VCAM-1 and E-
selectin expression, but not ICAM-1 expression.  Data 
presented in Section 5.2 translate from the biochemical 
ELISA assay to the functional adhesion assay.  That is, in 
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this section, the effects of increased endothelial cAMP on 
TNF-α induced sickle erythrocyte adhesion are examined. 
 
5.2.1  Inhibition of Sickle Erythrocyte Adhesion to MECs 
stimulated with TNF-α for 2 hrs 
 Figure 5.6 demonstrates the effects of 30 minute 
pretreatment with forskolin on sickle erythrocyte adhesion 
induced by 2 hrs of TNF-α stimulation.  Pretreatment with 
forskolin inhibits sickle erythrocyte adhesion by 74% after 
20 minutes of erythrocyte perfusion, 63% after 30 minutes, 
and 48% after 40 minutes.  Inhibition is statistically 
significant at 20 and 30 minutes of perfusion.  That 
forskolin pretreatment inhibits, but does not completely 
abolish sickle erythrocyte adhesion is potentially 
explained by comparison of Figure 5.6 with Figure 5.5, 
Panel B.  Pretreatment alone does not completely inhibit E-
selectin expression, thus it is likely that residual E-
selectin contributes to sickle erythrocyte adhesion after 
forskolin pretreatment.  In addition, it is possible that 
blood age (that is, the amount of time that passes between 
when the blood is drawn from the patient and when it is 
used for flow experiments) contributes to incomplete 
inhibition.  Blood samples were over 16 hrs old when used 
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in the flow adhesion assays presented in this section.  A 
more detailed analysis of the effect of blood age on 
adhesion is given in Section 5.4. 
 
5.2.2  Inhibition of Sickle Erythrocyte Adhesion to MECs 
stimulated with TNF-α for 6 hrs 
 The data presented in Figure 5.7, Panel A demonstrate 
the effects of forskolin pretreatment and/or continuous 
presence when MECs are stimulated with TNF-α for 6 hrs.  
Unlike the data shown in Figure 5.6 for 2 hrs of TNF-α 
stimulation, pretreatment alone of MECs with forskolin 
prior to 6 hrs of TNF-α stimulation does not significantly 
inhibit sickle erythrocyte adhesion.  However, when 
forskolin is present both prior to and during TNF-α 
stimulation, adhesion is inhibited by 59% after 40 minutes 
of perfusion.  Panels B and C of Figure 5.7 show similar 
results with pretreatment and continuous presence of IBMX 
or Bt2cAMP, with IBMX inhibiting adhesion by 64% and Bt2cAMP 
by 64%.  Together these data show that sickle erythrocyte 
adhesion to TNF-α stimulated MECs is inhibited by elevation 
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Figure 5.6  Effect of 100 µM forskolin pretreatment on 
sickle erythrocyte adhesion induced by 2 hrs TNF-α 
stimulation.  *Indicates statistically significant 
difference from MECs treated with only TNF-α (n=5).  Data 
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Figure 5.7  Effect of reagents that elevate endothelial 
cAMP on sickle erythrocyte adhesion induced by 6 hrs TNF-α 
stimulation. Pretreatment and/or continuous presence of A) 
100 µM Forskolin (n=10), B) 500 µM IBMX (n=8), or C) 500 µM 
Bt2cAMP (n=8) inhibits sickle erythrocyte adhesion.  
*Indicates statistically significant difference from MECs 
treated with only TNF-α.  Data for individual blood samples 












































 The need for continuous presence of forskolin during 6 
hrs of TNF-α stimulation may be explained by the data 
presented in Figures 5.8 and 5.9.  Figure 5.8 shows 
endothelial cAMP concentrations when MECs are pretreated 
with 100 µM forskolin for 30 minutes, then stimulated with 
TNF-α alone for 6 hrs.  The first bar in Figure 5.8 shows 
cAMP levels in quiescent, untreated MECs.  The second bar 
shows that treatment of MECs with 100 µM forskolin for 30 
minutes induces a 4-fold increase in cAMP concentration.  
However, the remaining bars show that when forskolin is 
removed and MECs are then stimulated with TNF-α alone for 6 
hrs, cAMP levels are significantly diminished within 0.5 
hrs of forskolin removal and return to baseline within 2 
hrs.  On the other hand, Figure 5.9 shows that when MECs 
are pretreated with forskolin and it is also present during 
TNF-α stimulation, cAMP levels attenuate much more slowly, 
reaching a trough at 2 hrs of stimulation and then climbing 
again at 4 and 6 hrs.  Concentrations never reach those of 
untreated MECs.  Thus one reason that forskolin may need to 
be continuously present to inhibit adhesion molecule 
expression and sickle erythrocyte adhesion long-term is 
that cAMP levels must be elevated through the duration of 



























Figure 5.8  Effect of forskolin pretreatment on endothelial 
cAMP concentration over 6 hrs of TNF-α stimulation. 
*Indicates statistically significant difference from cAMP 
concentration just after pretreatment (n=3).  Data for 




























































































































Figure 5.9  Effect of forskolin pretreatment and continous 
presence on endothelial cAMP concentration over 6 hrs of 
TNF-α stimulation. *Indicates statistically significant 
difference from cAMP concentration just after pretreatment 























































































































































Figure 5.10  Effect of reagents that increase endothelial 
intracellular cAMP on sickle erythrocyte adhesion.  A)  100 
µM forskolin (n=4), B) 500 µM IBMX, and 500 µM Bt2cAMP (n=3) 
alone (without TNF-α) do not affect sickle erythrocyte 
adhesion to MECs.  Data for individual blood samples are 



































molecules.  A one-time spike in cAMP concentration may 
delay expression of VCAM-1 and E-selectin, but this delay 
is less noticeable after 6 hrs of TNF-α stimulation than 
after 2 hrs.  Also, it is interesting to note that despite 
continuous presence of forskolin, Figure 5.9 shows that 
cAMP levels are highest after 30 minutes of forskolin 
treatment and decline thereafter.  This may be due to 
activation of phosphodiesterases, which break down cyclic 
AMP to AMP.  It is not clear from these experiments how 
high cAMP levels must be to sustain suppression of adhesion 
molecule expression in the presence of cytokines or if 
adhesion molecule suppression is sustainable over longer 
cytokine stimulation times.  More detailed experiments need 
be undertaken to determine kinetics of suppression (See 
Section 8.1). 
 Also important to note is that despite continuous 
presence of cAMP-elevating reagents, complete inhibition of 
sickle erythrocyte adhesion is not achieved (Figure 5.7).  
The inability these reagents to completely inhibit adhesion 
of sickle erythrocytes is potentially explained by three 
theories.  First, while increasing cAMP inhibits TNF-α 
induced VCAM-1 and E-selectin expression, it could 
potentially upregulate expression of unknown receptors that 
promote adhesion.  This scenario is unlikely, however, 
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since Figure 5.10 demonstrates that treatment of MECs with 
Forskolin, IBMX, or Bt2cAMP alone for 30 min or 6.5 hrs does 
not increase sickle erythrocyte adhesion.  Another 
possibility is that the age of the blood reduces the 
percent inhibition achieved by cAMP elevating compounds.  
The effect of blood age on adhesion is discussed in Section 
5.4.   
A likely theory is that incomplete inhibition of 
sickle erythrocyte adhesion is due to incomplete inhibition 
of VCAM-1 and E-selectin expression.  This theory could be 
tested in experiments in which endothelial cells are 
treated with cAMP-elevating reagents and monoclonal 
antibodies to block residual adhesion molecules during TNF-
α stimulation.  ELISA data (Figures 5.2-5.4) demonstrate 
that treatment of MECs with any of the cAMP-inducing 
reagents does not completely abolish receptor expression.  
One potential explanation for incomplete inhibition of 
receptor expression is that others have shown that chronic 
exposure to cAMP (> 6-8 hrs) may result in a refractory 
period in which cells are no longer responsive to cAMP 
stimulation (Krall & Jamgotchian, 1987; Montminy, 1997).  
Regardless, the data suggest presence of a relatively small 
number of VCAM-1 or E-selectin molecules may be sufficient 
to support significant erythrocyte adhesion, indicating 
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that greater understanding of the biophysics of sickle cell 
adhesion to VCAM-1 and E-selectin is important to its 
prevention.   
 
5.3  The Effect of Reagents that Increase Intracellular 
cAMP in Sickle Erythrocytes on Their Adhesion to MECs 
  
 Since in vivo modulation of endothelial intracellular 
cAMP would likely require concomitant modulation of sickle 
erythrocyte cAMP concentrations, it is important to 
understand the effects of cAMP-elevating agents on sickle 
erythrocytes and their adhesion to MECs.  Others have shown 
that treatment of sickle erythrocytes, rather than the 
endothelium, with forskolin can increase adhesion to 
endothelial αςβ3 by activation of ICAM-4 on sickle 
erythrocytes (Zennadi et al., 2004).  Those results were 
obtained by statically incubating erythrocytes with 
endothelial cells, then rinsing at 1 dyne/cm2 shear stress.  
The results presented in the following section demonstrate 
the effects of treatment of sickle erythrocyte with 
reagents that increase cAMP on adhesion to MECs under 




5.3.1  Adhesion of SSRBCs Treated with cAMP Elevating 
Reagents to Unstimulated MECs 
 Figure 5.11 shows the effects of sickle erythrocyte 
treatment with reagents that increase cAMP on adhesion to 
unstimulated MECs.  Because some blood samples respond to 
treatment with these reagents and others do not, results 
are shown for individual blood samples, rather than the 
average of all samples.  Data shown are for 40 minutes of 
erythrocyte perfusion.  A complete table of all data for 
each blood sample (that is, numbers of adherent 
erythrocytes at all perfusion time points) as well as the 
averages is given in Appendix B, Tables B.33 and B.34. 
Also, because blood age might affect the ability of 
erythrocytes to respond to treatment with cAMP elevating 
reagents, only blood samples for which experiments were 
completed within 16 hrs of blood drawing are shown in 
Figure 5.11.  The effect of blood age on sickle erythrocyte 
adhesion is discussed in Section 5.4.    
 Panel A of Figure 5.11 shows the effect of 
pretreatment of sickle erythrocytes for 40 minutes with 100 
µM forskolin prior to perfusion on their adhesion to 
unstimulated MECs.  For the four blood samples tested, two 
respond to forskolin pretreatment, resulting in increased 
adhesion to MECs.  Similarly, panel B shows that 
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pretreatment of sickle erythrocytes with IBMX results in 
increased adhesion for 2 out of 3 blood samples, whereas 
Panel C shows increased adhesion due to erythrocyte 
pretreatment with Bt2cAMP in 1 out of 3 blood samples.   
These results are partially consistent with those 
obtained by Zennadi, et al.  While their data do not show 
non-responsive patient samples, it is important to note 
that the flow conditions of the two experiments were not 
identical.  Rather, Zennadi, et al. followed a pattern of 
static attachment followed by detachment under flow, while 
the data presented in Figure 5.11 were gathered under 
conditions of continuous flow for attachment.  As 
established in Section 2.4.3, low or no flow conditions 
tend to promote higher numbers of adherent sickle 
erythrocytes via lower-affinity binding mechanisms; thus by 
corollary it is reasonable to believe that the flow regime 
established by Zennadi, et al. would result in more sickle 
erythrocyte adhesion in more patients than the flow regime 
established in this work.  Regardless, both the data 
presented in Figure 5.11 and by Zennadi, et al. suggest 
that increased cAMP in sickle erythrocytes may promote 
their adhesion to unstimulated MECs in some patients.  Thus 
more experiments are necessary to more clearly define flow 
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conditions and red cell activation states under which this 
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Figure 5.11  Effect of reagents that increase intracellular 
cAMP in sickle erythrocytes on adhesion to unstimulated 
MECs.  Treatment of SSRBCS with A) 100 µM forskolin (n=4), 
B) 500 µM IBMX, and C) 500 µM Bt2cAMP (n=3) prior to 
perfusion increases adhesion to MECs in some patients after 
40 minutes of erythrocyte perfusion.  Complete data sets 












































5.3.2  Adhesion of SSRBCs Treated with cAMP Elevating 
Reagents to MECs Stimulated with TNF-α 
 Figure 5.12 shows the effects of reagents that 
increase cAMP in sickle erythrocytes on their adhesion to 
MECs stimulated with TNF-α.  Panel A and panel B 
demonstrate that treatment of sickle erythrocytes with 
either 100 µM forskolin or 500 µM Bt2cAMP does not alter 
adhesion to TNF-α stimulated MECs.  Data sets represent the 
average of several blood samples, because analysis of 
results from individual blood samples reveals virtually 
homogeneous results.  Only one blood sample responded to 
treatment with forskolin, resulting in a 1.5-fold increase 
in adhesion of sickle erythrocytes.  None of the samples 
treated with Bt2cAMP responded to treatment.  Results for 
individual samples as well as the averages are given in 
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Figure 5.12  Effect of reagents that increase intracellular 
cAMP in sickle erythrocytes on adhesion to MECs stimulated 
with TNF-α for 6 hrs.  Treatment of SSRBCS with A) 100 µM 
forskolin (n=4) or B) 500 µM Bt2cAMP (n=3) prior to 
perfusion does not affect adhesion.  Data for individual 


































5.4  The Effect of Blood Sample Age on Adhesion of Sickle 
Erythrocytes 
  
 Data shown in Chapters 4 and 5 were generated in flow 
adhesion assays in which blood varied in age from 0 to 56 
hrs.  Blood age is defined as the time elapsed between 
drawing of blood from the patient to the time flow adhesion 
assays are completed.  In this section, retrospective 
analysis of the effect of blood age on sickle erythrocyte 
adhesion is undertaken. 
 
5.4.1  Effect of Blood Age on Adhesion of Sickle 
Erythrocytes to Unstimulated and TNF-α Stimulated MECs 
 Figure 5.13 shows the effect of blood age on sickle 
erythrocyte adhesion to unstimulated and TNF-α stimulated 
MECs.  It shows all blood samples used to generate data in 
Chapters 4 through 6 in which adhesion to MECs stimulated 
with TNF-α for 6 hrs was measured.  The values shown are 
numbers of adherent erythrocytes after 40 minutes of 
perfusion.  The samples are ordered from least to greatest 
numbers of adhesive erythrocytes to unstimulated MECs, 
shown by the orange bars.  On top of the orange bars, 
numbers of adhesive erythrocytes to TNF-α stimulated MECs 
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are shown for each blood sample.  The color of the top bar 
indicates the age of the blood sample when adhesion to 
unstimulated and TNF-α stimulated MECs was measured.  The 
freshest samples (2-16 hrs old) are shown in green, the 
middle samples (18-36 hrs) are shown in red, and the oldest 
samples (44 to 56 hrs) are shown in blue.  Qualitatively, 
Figure 5.13 shows an absence of green, or fresh, samples at 
the left end of the graph and a higher concentration of 
fresh samples at the right end of the graph, indicating 
that sickle erythrocyte adhesion to unstimulated MECs is 
higher for the freshest samples.  This result is confirmed 
by ANOVA, which indicates a statistically significant 
difference between numbers of adherent erythrocytes to 
unstimulated MECs for the green and the blue groups (the 
freshest versus the oldest samples).  The average numbers 
of adherent sickle erythrocytes for both unstimulated and 
TNF-α stimulated MECs for each color/age group are given in 
Figure 5.15, where the statistical difference is indicated.  
 The reason that sickle erythrocyte adhesion to 
unstimulated MECs is higher for fresher blood samples is 
unknown.  Fresh erythrocytes from sickle patients have been 
shown to be more adherent to unstimulated endothelial cells 
than non-sickle erythrocytes, possibly due to the increased 
presence of ligands on sickle erythrocytes that bind to the 
141 
endothelial cells.  However, the receptors and ligands 
promoting this abnormal adhesion under unstimulated 
conditions are not well understood.  One potential 
explanation for decreased adhesion of sickle erythrocytes 
as blood ages is that the ligands on sickle erythrocytes 
that promote adhesion to unstimulated MECs may be shed into 
the plasma over time.  When the blood samples are washed to 
isolate the erythrocytes, the shed receptors may be 
discarded. 
 As reticulocytes mature, they produce exosomes, the 
major known function of which is clearing of membrane 
proteins.  One major component these exosomes is the 
transferrin receptor (Johnstone et al., 1987).  However, a 
smaller component is α4β1.  One study suggests that in vitro 
maturation of reticulocytes for 48 hours at 37°C results in 
almost complete clearing of α4β1 from the surface of 
reticulocytes. Interestingly, the α4β1 in exosomes remains 
active, as exosomes containing α4β1 are more adherent to 
fibronectin (Rieu et al., 2000).  It is not clear that α4β1 
is shed from the sickle reticulocytes used in the 
experiments presented in this document during the storage 
period, especially given that externalization of membrane 
proteins appears temperature dependent and the sickle blood 
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is refrigerated at 4°C prior to use (Orr et al., 1987).  It 
is also not clear that removal of reticulocyte α4β1 would 
affect adhesion to unstimulated MECs.  However, these 
studies do invite speculation that storage of sickle blood 
prior to use in flow assays results in exosomal removal of 
membrane proteins such as α4β1 that are important to sickle 
cell adhesion. 
 In Figure 5.14 the same data set as shown in Figure 
5.13 is rearranged to show increasing sickle erythrocyte 
adhesion to MECs stimulated with TNF-α for 6 hrs.  
Qualitatively, no particular color trend is evident, and 
ANOVA results indicate no statistical difference between 
numbers of adherent erythrocytes to TNF-α stimulated MECs 
between the three color/age groups. 
 
5.4.2  Effect of Blood Age on cAMP Inhibition of Sickle 
Erythrocyte Adhesion to TNF-α Stimulated MECs 
 Only minimal data exist to test whether or not blood 
age affects the ability of cAMP elevating agents to inhibit 
sickle erythrocyte adhesion.  Table 5.2 shows that 10 blood 
samples were used to test the effects of forskolin 
treatment of MECs on TNF-α induced adhesion.  Of the ten 
samples, two were used within 16 hrs, and the other eight 
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were used within 56 hours of drawing.  The average for the 
two fresh samples shows higher unstimulated sickle 
erythrocyte adhesion and higher percent inhibition of 
adhesion due to forskolin treatment than the average of the 
eight older samples.  On the other hand, eight blood 
samples were used to test the effects of IBMX and Bt2cAMP on 
sickle cell adhesion, one of which was used within 16 hrs 
of drawing and the others of which were used within 36 hrs.  
These data demonstrate that adhesion and percent inhibition 
were similar regardless of blood age.  Given the small 
sample size of the freshest blood samples, whether or not 
blood age affects the ability of cAMP-elevating reagents to 












































































































































































































































































































































































































































































































































































































































































































TNF-a (6 hrs) when:
blood age = 2-16 hrs (n=11)
blood age = 18-36 hrs (n=18)





Figure 5.15  Average adhesion to unstimulated and TNF-α 
stimulated MECs as a function of blood age.  The color of 
top bars indicates the age of the blood sample when flow 
adhesion assay was completed.  *Indicates statistical 
difference from unstimulated adhesion when blood age was 44 
to 56 hrs.  Data for individual blood samples are also 











































Table 5.2  Effect of blood age on percent inhibition in 
sickle erythrocyte adhesion caused by cAMP-elevating 
agents.  Data for individual blood samples are given in 




Endothelial Treatment 18-56 hrs 2-16 hrs All Samples
(n=8) (n=2) (n=10)
Unstimulated 13.8 21.8 15.4
Fsk (pre + cont) + TNF-a (6  hrs) 47.0 30.2 43.7
TNF-a ( 6  h r s ) 87.1 70.0 83.7
% Inhibition
Fsk (pre + cont) + TNF-a (6  hrs) 54.7 82.5 58.6
Blood Age
Endothelial Treatment 18-36 hrs 2-16 hrs All Samples
(n=7) (n=1) (n=8)
Unstimulated 8.9 13.0 9.4
IBMX (pre + cont) + TNF-a ( 6  h r s ) 22.6 23.7 22.8
Bt2cAMP (pre + cont) + TNF-a ( 6  h r s ) 22.6 24.7 22.9
TNF-a ( 6  h r s ) 47.1 42.7 46.5
% Inhibition
IBMX (pre + cont) + TNF-a ( 6  h r s ) 64.0 64.0 64.0
Bt2cAMP (pre + cont) + TNF-a ( 6  h r s ) 64.0 60.6 63.7  
 
 
5.4.3  Effect of Blood Age on Adhesion of Forskolin Treated 
Sickle Erythrocytes to MECs 
 As shown in Table 5.3, treatment of sickle 
erythrocytes with forskolin prior to perfusion does not 
affect adhesion to unstimulated MECs when the sickle 
erythrocytes are 44 to 56 hours old (n=4).  However, as 
noted in Section 5.3.1, treatment of sickle erythrocytes 
that are less than 16 hrs old with forskolin induces 
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adhesion to unstimulated MECs two of four samples tested.  
These results are reflected in the increased average 
adhesion for forskolin-treated erythrocytes that are 2-16 
hrs old as compared to untreated sickle erythrocytes of the 
same age.  Also, it is worth noting that the adhesion of 
unstimulated sickle erythrocytes is higher for fresh 
samples as compared to older samples, as noted in Section 
5.4.1.  Adhesion of fresh sickle erythrocytes is also 
increased by treatment with IBMX or Bt2cAMP. 
 
 
Table 5.3  Effect of blood age on sickle erythrocyte 
adhesion induced by treatment of erythrocytes with reagents 




Erythrocyte 44-56 hrs 2-16 hrs All Samples
Treatment (n=4) (n=4) (n=8)
Untreated 9.8 17.3 13.5
Fsk 9.4 25.7 17.6
Blood Age
Erythrocyte 44-56 hrs 2-16 hrs All Samples
Treatment (n=0) (n=3) (n=3)
Untreated 19.5 19.5
IBMX 32.0 32.0




5.5  Chapter Summary 
  
 The data presented in Chapter 5 demonstrate that 
inhibition of endothelial adhesion molecule expression and 
sickle erythrocyte adhesion is achieved by elevation of 
endothelial intracellular cAMP levels.  The expression of 
VCAM-1 and E-selectin, but not ICAM-1 on TNF-α stimulated 
MECs is reduced by treatment of MECs with Forskolin, IBMX, 
or Bt2cAMP, which increase endothelial cAMP levels by 
different mechanisms.  The degree of reduction depends 
primarily on the length of treatment time with cAMP-
elevating reagents and, to a lesser extent, on the 
concentration of reagent used.  While significant 
reductions in adhesion molecule expression are achieved by 
pretreatment of MECs with cAMP-elevating reagents, the 
largest reductions in expression are seen when the reagents 
are present both prior to and during TNF-α stimulation.   
 Pretreatment and continuous presence of cAMP-elevating 
reagents during TNF-α stimulation of MECs also results in 
significantly decreased sickle erythrocyte adhesion.  
Adhesion is not, however, completely attenuated, with 
percent inhibition of adhesion varying from 59% to 64%, 
depending on the cAMP-elevating reagent used.  Incomplete 
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inhibition of sickle erythrocyte adhesion may result from 
incomplete inhibition of adhesion molecule expression. 
 Experiments in which sickle erythrocytes, rather than 
endothelial cells, are treated with cAMP-elevating reagents 
prior to perfusion show that adhesion to TNF-α stimulated 
MECs is not altered.  However, adhesion to unstimulated 
MECs is increased for some blood samples.  These results 
are consistent with other reports in literature (Zennadi et 
al., 2004). 
 In addition to the effects of cAMP-elevating reagents 
on sickle erythrocyte adhesion, the preceding chapter also 
addresses the effect of blood age after drawing from the 
patient.  Retrospective analysis demonstrates that adhesion 
of sickle erythrocyte to unstimulated MECs is higher for 
fresher blood samples than for older ones.  Levels of TNF-α 
induced adhesion are not significantly altered.  It is 
unclear whether or not blood age affects the ability of 
cAMP elevating reagents on MECs to inhibit TNF-α induced 
sickle erythrocyte adhesion.  However, it appears as though 
treatment of some fresh sickle erythrocytes with cAMP-
elevating reagents increases adhesion to unstimulated MECs, 
whereas older blood samples are not affected by treatment. 
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 Together these data demonstrate that cAMP is an 
effective inhibitor of TNF-α induced adhesion molecule 
expression and sickle erythrocyte adhesion.  While the data 
presented in this chapter were obtained under in vitro 
conditions, it is also important to consider what is known 
from literature about in vivo effects of elevated cAMP in 
animals and humans with and without sickle cell anemia.  
Pentoxifylline, a methyl xanthine derivative, has been used 
to treat peripheral vascular disease in humans for over 30 
years, and the generally accepted mechanism of its action 
is increasing levels of intracellular cAMP by inhibition of 
phosphodiesterases (Windmeier & Gressner, 1997).  Clinical 
trials in which the drug was administered to sickle 
patients either three times daily or at presentation of 
pain episodes showed the groups taking pentoxifylline to 
have fewer patients experiencing pain episodes, fewer total 
pain episodes, shorter duration of pain events, and shorter 
duration of inpatient treatment than groups on placebo 
(Manrique, 1987; Teuscher et al., 1989).  The therapeutic 
benefit of this drug is thought to be primarily due to 
reduced platelet aggregation and blood viscosity (Windmeier 
& Gressner, 1997), as well as increased erythrocyte 
flexibility caused in part by inhibition of cell 
dehydration and sickling (Ambrus et al., 1988; Stuart et 
152 
al., 1987).  However, administration of pentoxifylline to 
non-sickle patients has also resulted in decreases in 
circulating TNF-α and soluble VCAM-1, E-selectin, and ICAM-
1 in patient plasma (Boldt et al., 1996; Noel et al., 
2000), implying that pentoxifylline suppresses endothelial 
cell activation.  While similar studies have not been 
conducted in sickle patients, the data presented in this 
chapter suggest that one of the beneficial effects of 
pentoxifylline in sickle cell anemia may be reduction in 
adhesion molecule expression and sickle erythrocyte 
adhesion. 
 In addition to regulating expression of endothelial 
adhesion molecules, elevated cAMP also causes vasodilation 
in rabbit spinal arterioles (Yashiro & Ohhashi, 2002) and 
transgenic sickle mice (Kaul et al., 2000), a response 
generally attributed to production of endothelial nitric 
oxide.  The following chapter explores the role of nitric 
oxide in regulating endothelial adhesion molecule 







REGULATION OF CYTOKINE INDUCED ADHESION MOLECULE EXPRESSION 
AND SICKLE ERYTHROCYTE ADHESION BY ELEVATION OF ENDOTHELIAL 
NITRIC OXIDE 
 
As outlined in Section 2.7, nitric oxide is a soluble 
gas synthesized upon activation of nitric oxide synthase in 
endothelial cells.  The most notable physiologic effect of 
nitric oxide release is vasodilation.  However, nitric 
oxide also appears to have anti-coagulatory and anti-
inflammatory properties (Gladwin & Schechter, 2001).  
Nitric oxide bioavailability in sickle patients, especially 
men, is reduced (Gladwin et al., 2003), suggesting that 
strategies to improve NO bioavailability may be of benefit 
to sickle patients.   
Several studies indicate that nitric oxide inhibits 
inflammation-induced VCAM-1 (and possibly E-selectin) 
expression on endothelial cells.  The ability of NO to 
regulate adhesion molecule expression and sickle 
erythrocyte adhesion is the subject of this chapter. 
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6.1  Regulation of Endothelial Adhesion Molecule Expression 
by Reagents that Increase Nitric Oxide 
  
 Panel A of Figure 6.1 shows adhesion molecule 
expression on unstimulated MECs (white bars), MECs 
stimulated with TNF-α for 6 hrs (black bars), and MECs 
treated with 500 µM sodium nitroprusside (a nitric oxide 
donor) for 30 minutes prior to and during 6 hrs of TNF-α 
stimulation (gray bars).  Sodium nitroprusside 
significantly inhibits TNF-a induced VCAM-1 expression, but 
not E-selectin or ICAM-1 expression.  These results are 
mimicked by treatment of MECs with 500 µM DETA-NO, a 
different nitric oxide donor (Panel B).  Several other 
reports in literature confirm that nitric oxide partially, 
but not completely, inhibits VCAM-1 mRNA and protein 
expression (De Caterina et al., 1995; Khan et al., 1996; 
Spiecker et al., 1997).  However, literature regarding the 
effects of NO on E-selectin and ICAM-1 is conflicting, with 
some authors suggesting an inhibition in expression (De 
Caterina et al., 1995) and others suggesting no effect 
(Khan et al., 1996).  Figure 6.1 indicates a small, 
statistically insignificant inhibition.  To ensure that the 
ability of these reagents to inhibit VCAM-1 expression is 
not due to cell death, flurorescent cell viability assays 
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were performed as described above.  Light and confocal 
microscopy photographs of MECs treated with NO donors and 
TNF-α are given in Appendix C. 
That VCAM-1, but not E-selectin, expression is 
significantly inhibited by nitric oxide indicates a 
divergence in the cell signaling cascades leading to 
expression of these two receptors.  As more is learned 
about the transcription factors and co-factors that 
regulate receptor transcription, it may be possible to 
locate the point of divergence and tailor receptor 
expression or inhibition therapies to specific molecules. 
In addition to their effects on TNF-α induced adhesion 
molecule expression, the effects of treatment of 
endothelial cells with SNP and DETA-NO alone (without TNF-
α) are of interest.  Table 6.1 shows that for the adhesion 
molecules tested, expression is not upregulated by 
treatment of MECs with reagents that increase NO.  
The data presented in this section suggest that 
increasing endothelial nitric oxide with SNP or DETA-NO 
will inhibit TNF-α induced sickle erythrocyte adhesion but 
will not affect unstimulated adhesion.  The results 
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Figure 6.1  Inhibition of TNF-α induced adhesion molecule 
expression by reagents that increase intracellular nitric 
oxide.  VCAM-1 expression, but not E-selectin or ICAM-1 
expression, is significantly inhibited by pretreatment and 
continuous presence of A) SNP (n=6) or B) DETA-NO (n=4) 
during 6 hrs of TNF-α stimulation.  *Indicates 
statistically significant difference from MECs treated with 
only TNF-α.  Data for individual experiments are presented 

















Table 6.1  Adhesion molecule expression on MECs treated 
with SNP or DETA-NO alone.  Adhesion molecule expression is 
not significantly upregulated by treatment of MECs with SNP 
or DETA-NO alone for 6.5 hrs (n=3).  Data for individual 




Endothelial Treatment VCAM-1 E-selectin ICAM-1
Unstimulated 0.01 ± 0.01 0.02 ± 0.02 0.18 ± 0.01
SNP 0.01 ± 0.01 0.05 ± 0.05 0.13 ± 0.03
TNF-α 0.15 ± 0.06 0.48 ± 0.14 0.68 ± 0.13
Endothelial Treatment VCAM-1 E-selectin ICAM-1
Unstimulated 0.01 ± 0.01 0.03 ± 0.03 0.18 ± 0.06
DETA-NO 0.02 ± 0.02 0.04 ± 0.04 0.33 ± 0.07




6.2  Effect of Reagents that Increase Endothelial Nitric 
Oxide on Sickle Erythrocyte Adhesion 
 
 The data presented in Section 6.1 demonstrate that NO 
donors partially inhibit endothelial expression of VCAM-1 
induced by TNF-α.  To test their effects on sickle 
erythrocyte adhesion, MECs were treated with 500 µM SNP or 
500 µM DETA-NO for 30 minutes prior to and during 6 hrs of 
TNF-α stimulation, mimicking the conditions outlined in 
Section 6.1.  Panel A of Figure 6.2 demonstrates that SNP 
inhibits TNF-α induced adhesion by 71% after 40 minutes of 
erythrocyte perfusion.  Similar results are obtained with 
DETA-NO, which inhibits adhesion by 79%. 
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 Like the results obtained when MECs were treated with 
cAMP, inhibition of TNF-α induced adhesion by NO donors is 
partial, but not complete.  Incomplete inhibition of sickle 
erythrocyte adhesion may be due to incomplete inhibition of 
adhesion molecule expression on MECs, since VCAM-1 is only 
partially reduced and E-selectin expression is not changed 
by NO donors.  Partial inhibition of adherence of 
leukocytes (De Caterina et al., 1995; M. Z. Jiang et al., 
2005), non-sickle erythrocytes (Space et al., 2000), and 
Plasmodium falciparum-infected erythrocytes (Serirom et 
al., 2003) to cytokine stimulated endothelial cells by 
exogenous NO donors has been observed by others in vitro. 
In addition to partial inhibition of endothelial 
receptors by NO donors, the age of the blood samples, or 
time elapsed between drawing from the patient and perfusion 
over MECs may affect adhesion.  This possibility is further 
discussed in Section 6.4.   
While the data in Figure 6.2 demonstrate that 
treatment of endothelial cells with NO donors inhibits TNF-
α induced sickle erythrocyte adhesion, the data in Figure 
6.3 show that treatment of MECs with NO donors alone 
(without TNF-α) for 6.5 hrs does not affect adhesion to 
otherwise untreated endothelial cells.  That is, 
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unstimulated adhesion of erythrocytes, which is elevated in 
sickle patients when compared to non-sickle patients, is 
not affected by NO donors under conditions of continuous 
flow.  These results are in conflict with those of Space, 
et al., who show the nitric oxide donor DETA-NO decreases 
adhesion of sickle erythrocytes to unstimulated endothelial 
cells by 54% (Space et al., 2000).  However, three main 
differences in experimental protocols may explain the 
results.  First, Space, et al. use a higher concentration 
of DETA-NO than is used to produce the results of Figure 
6.3 (2000 µM versus 500 µM).  This higher concentration may 
result in an effect not seen with a lower concentration.  
Second, numbers of adherent erythrocytes in this work are 
counted under conditions of continous flow, whereas Space, 
et al. work under conditions of intermittent flow.  As 
discussed in Section 2.4.3, adhesion of sickle erythrocytes 
is higher under static conditions than under flow.  This 
may account for the high numbers of adherent erythrocytes 
to unstimulated MECs that Space, et al. show (387 ± 111 
erythrocytes/mm2 versus 17 ± 3 erythrocytes/mm2) and for the 
ability of the NO donor DETA-NO to inhibit this adhesion.  
Finally, it is important to note that the data presented in 
Figure 6.3 were generated under conditions in which only 
the MECs, and not the erythrocytes, are treated with an NO 
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donor, whereas Space, et al. treat both the MECs and the 
erythrocytes with DETA-NO.  The effect of treatment of 
sickle erythrocytes with NO donors on their adhesion to 












































Figure 6.2  Inhibition of TNF-α induced sickle erythrocyte 
adhesion by reagents that increase intracellular nitric 
oxide.  Treatment of MECs with A) 500 µM SNP (n=10) or B) 
500 µM DETA-NO (n=11) before and during 6 hrs of TNF-α 
stimulation inhibits adhesion of sickle erythrocytes.  
*Indicates statistically significant difference from MECs 
treated with only TNF-α.  Data for individual blood samples 
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Figure 6.3  Effect of reagents that increase endothelial 
intracellular NO on sickle erythrocyte adhesion.  A)  500 
µM SNP (n=8) and DETA-NO (n=7) alone (without TNF-α) do not 
affect sickle erythrocyte adhesion to MECs.  Data for 
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6.3  Treatment of Sickle Erythrocytes with Nitric Oxide 
Donors 
 
 Figure 6.4 shows adhesion of sickle erythrocytes 
treated with either 500 µM SNP (Panel A) or DETA-NO (Panel 
B) for 40 minutes prior to perfusion over unstimulated 
MECs.  The data demonstrate that treatment of sickle 
erythrocytes with NO donors does not affect their adhesion 
to unstimulated endothelial cells.   Figure 6.5 shows 
adhesion of sickle erythrocytes treated with NO donors to 
MECs stimulated with TNF-α for 6 hrs.  Treatment of 
erythrocytes with SNP inhibits adhesion 28% (Panel A), 
while treatment with DETA-NO inhibits adhesion by 50% 
(Panel B), although these results are not statistically 
significant.   
 Little information exists in the literature to support 
or explain the results shown in Figure 6.5. Space et. al. 
report inhibition of TNF-α induced adhesion when both 
endothelial cells and erythrocytes are treated with the NO 
donor DETA-NO, but it is not clear whether the effect is on 
the endothelium, the erythrocytes, or both (Space et al., 
2000).  However, treatment of neutrophils with reagents 
that inhibit nitric oxide induces expression of α4β1, which 
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binds to VCAM-1, possibly through mobilization of 
neutrophil granules and cytoskeletal rearrangement (Conran 
et al., 2003). It is not clear, though, that NO donors 
affect α4β1 expression on neutrophils or that the response 
to NO extends to erythrocytes.  In addition, patients 
taking hydroxyurea, which generates NO, show fewer 
erythrocytes expressing α4β1 and fewer α4β1 molecules per 
erythrocyte than sickle patients not taking hydroxyurea 
(Styles et al., 1997).  Although this effect may not result 
from NO exposure, it invites speculation that one 
beneficial effect of NO for sickle patients may be 
reduction in α4β1 expression on sickle erythrocytes and 





























Figure 6.4  Adhesion of sickle erythrocytes treated with NO 
donors to unstimulated MECs.  Treatment of sickle 
erythrocytes with A) 500 µM SNP (n=7) or B) 500 µM DETA-NO 
(n=5) prior to perfusion does not affect adhesion to 
unstimulated MECs.  Data for individual blood samples are 





















































































Figure 6.5  Adhesion of sickle erythrocytes treated with NO 
donors to TNF-α stimulated MECs.  Treatment of sickle 
erythrocytes with A) 500 µM SNP (n=8) or B) 500 µM DETA-NO 
(n=7) prior to perfusion over TNF-α stimulated MECs.  Data 
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6.4  Effect of Blood Age on Sickle Erythrocyte Adhesion 
 
 Data presented in Chapter 6 were obtained in flow 
assays in which blood samples were 2 to 36 hours old at the 
time of erythrocyte perfusion.  Here the effect of blood 
age on sickle erythrocyte adhesion is discussed. 
 
6.4.1  Sickle Erythrocyte Adhesion to MECs Treated with 
Reagents that Increase Nitric Oxide 
 Table 6.2 shows numbers of adherent erythrocytes to 
unstimulated and TNF-α stimulated MECs and also to MECs 
exposed to nitric oxide donors before and during TNF-α 
stimulation after 40 minutes of erythrocyte perfusion.  
Blood samples are categorized by age, and the average of 
all blood samples of a given age is shown.  The far right 
column represents the average of all blood samples tested.  
The data show that numbers of adherent erythrocytes do not 
vary with blood age for MECs stimulated with TNF-α, SNP + 
TNF-α, or DETA-NO + TNF-α.  However, unstimulated adhesion 
tends to be higher for younger blood samples than older 
ones, consistent with the data in Section 5.4.   
 Table 6.3 shows adhesion of sickle erythrocytes to 
MECs treated with SNP or DETA-NO alone.  The fold change in 
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adhesion due to treatment with these reagents as compared 
to unstimulated MECs varies from 0.6 to 1.5 depending on 
the reagent and age of blood.  However, these results do 
not change the overall conclusion that nitric oxide donors 
alone on MECs do not significantly affect sickle 
erythrocyte adhesion. 
 
Table 6.2  Blood age and adhesion of sickle erythrocytes to 
MECs stimulated with TNF-α and nitric oxide donors.  
Numbers of adherent erythrocytes after 40 minutes of 
perfusion are shown.  Average data for all blood samples 
are represented graphically in Figure 6.2, and data for 




Endothelial Treatment 18-36 hrs 2-16 hrs All
(n=6) (n=4) (n=10)
Unstimulated 9.8 28.2 17.1
TNF-α (6 hrs) 53.4 51.6 52.7
SNP (pre + cont) + TNF-α (6 hrs) 26.7 28.6 27.4
% Inhibition 61.2 98.6 71.0
Endothelial Treatment 18-36 hrs 2-16 hrs All
(n=7) (n=4) (n=11)
Unstimulated 13.5 28.2 18.9
TNF-α 6 hrs 46.1 51.6 48.1
DETA-NO (pre + cont) + TNF-α (6 hrs) 24.4 25.8 24.9









Table 6.3  Blood age and adhesion of sickle erythrocytes to 
MECs treated with nitric oxide donors.  Numbers of adherent 
erythrocytes after 40 minutes of perfusion are shown.  
Average data for all blood samples are represented 
graphically in Figure 6.3, and data for individual blood 
samples are presented in Tables B.44 and B.45. 
 
 
Endothelial Treatment 18-36 hrs 2-16 hrs All
(n=3) (n=5) (n=8)
Unstimulated 13.9 26.1 21.5
TNF-α (6 hrs) 33.4 41.6 38.5
SNP 11.5 16.0 14.3
Fold change 0.8 0.6 0.7
Endothelial Treatment 18-36 hrs 2-16 hrs All
(n=4) (n=3) (n=7)
Unstimulated 16.9 16.2 16.6
TNF-α (6 hrs) 65.1 44.8 56.4
DETA-NO 19.8 25.0 22.0






6.4.2  Adhesion of Sickle Erythrocytes Treated with Nitric 
Oxide Donors 
 Table 6.4 shows the same data presented in Figure 6.4 
for 40 minutes of perfusion, but samples are separated by 
blood age.  While it appears as though sickle erythrocyte 
adhesion to unstimulated MECs is higher for younger blood 
samples than for older ones (regardless of whether or not 
the sickle erythrocytes are treated with NO donors), the 
overall conclusion that increased NO in sickle erythrocytes 
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does not affect adhesion to unstimulated MECs remains the 
same. 
 Table 6.5 shows the data presented in Figure 6.5, but 
again samples are divided by blood age.  Significant 
differences between younger and older blood samples cannot 
be determined due to the small number of older blood 
samples, and it is unclear whether blood age affects the 







































Table 6.4  Blood age and adhesion of sickle erythrocytes 
treated with nitric oxide donors to MECs.  Numbers of 
adherent erythrocytes after 40 minutes of perfusion are 
shown.  Average data for all blood samples are represented 
graphically in Figure 6.4, and data for individual blood 
samples are presented in Tables B.46 and B.47. 
 
 
Endothelial Treatment 18-36 hrs 2-16 hrs All
(n=3) (n=4) (n=7)
Unstimulated SSRBCs, 13.6 27.7 21.7
Unstimulated MECs
Unstimulated SSRBCs, 58.4 45.1 50.8
TNF-α (6 hrs) on MECs
SNP on SSRBCs, 21.6 30.2 26.5
Unstimulated MECs
Fold change 1.6 1.1 1.2
Endothelial Treatment 18-36 hrs 2-16 hrs All
(n=2) (n=3) (n=5)
Unstimulated SSRBCs, 15.4 31.4 25.0
Unstimulated MECs
Unstimulated SSRBCs, 39.6 41.8 41.0
TNF-α (6 hrs) on MECs
DETA-NO on SSRBCs, 15.3 32.0 25.3
Unstimulated MECs


















Table 6.5  Blood age and adhesion of sickle erythrocytes 
treated with NO donors to TNF-α stimulated MECs.  Numbers 
of adherent erythrocytes after 40 minutes of perfusion are 
shown.  Average data for all blood samples are represented 
graphically in Figure 6.5, and data for individual blood 





Endothelial Treatment 18-36 hrs 2-16 hrs All
(n=2) (n=6) (n=8)
Unstimulated SSRBCs, 12.0 24.9 21.7
Unstimulated MECs
Unstimulated SSRBCs, 83.5 48.1 57.0
TNF-α (6 hrs) on MECs
SNP on SSRBCs, 67.6 40.0 46.9
TNF-α (6 hrs) on MECs
% Inhibition 22.3 34.8 28.4
Endothelial Treatment 18-36 hrs 2-16 hrs All
(n=1) (n=6) (n=7)
Unstimulated SSRBCs, 8.0 24.9 22.5
Unstimulated MECs
Unstimulated SSRBCs, 41.7 48.1 47.2
TNF-α (6 hrs) on MECs
DETA-NO on SSRBCs, 41.7 33.7 34.8
TNF-α (6 hrs) on MECs















6.5  Chapter Summary 
 
 The results presented in Chapter 6 explore how nitric 
oxide treatment affects sickle erythrocyte adhesion.  ELISA 
assays demonstrate that TNF-α induced VCAM-1 surface 
expression, but not E-selectin or ICAM-1 expression, is 
inhibited by pretreatment with and continuous presence of 
reagents that increase intracellular nitric oxide during 
TNF-α stimulation.  Nitric oxide donors alone (without TNF-
α) do not affect VCAM-1, E-selectin, or ICAM-1 surface 
expression.  These biochemical observations translate well 
to functional observations measuring sickle erythrocyte 
adhesion.  Two different nitric oxide donors inhibit TNF-α 
induced adhesion by 71% and 79%, presumably by inhibiting 
VCAM-1 expression.  These results are mimicked when TNF-α 
stimulated MECs are treated with VCAM-1 antibody, which 
inhibits adhesion by 72% (See Section 4.3.2).  Treatment of 
MECs with NO donors alone (without TNF-α) does not affect 
sickle erythrocyte adhesion. 
 Also explored in Chapter 6 is whether treatment of 
sickle erythrocytes with nitric oxide donors affects their 
adhesion to endothelial cells.  Nitric oxide donors do not 
affect adhesion to unstimulated endothelial cells.  
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However, a substantial (28% to 50%), but not statistically 
significant, inhibition of adhesion to TNF-α stimulated 
endothelial cells is shown, suggesting that more studies 
need to be undertaken to establish if and how nitric oxide 
affects sickle erythrocytes (See Chapter 8). 
 Together these data demonstrate anti-inflammatory and 
anti-adhesive properties of nitric oxide.  In vivo, soluble 
VCAM-1 is elevated in sickle patients, compared to non-
sickle controls, and soluble VCAM-1 levels correlate 
significantly with endogenous NO bioavailability. That is, 
patients with lower NO levels show the higher soluble VCAM-
1 levels (Gladwin et al., 2003).  Furthermore, higher NO 
metabolite levels in sickle patients experiencing pain 
episodes correlate with lower pain scores (Lopez et al., 
1996).  Overall, the data presented in this chapter and 
elsewhere suggest that the benefits of nitric oxide to 
















Sickle cell anemia is caused by the homozygous 
inheritance of the sickle β hemoglobin gene.  Symptoms of 
the conditions include reversible aggregation of hemoglobin 
inside erythrocytes upon deoxygenation, hemolytic anemia, 
and vaso-occlusion resulting in painful crises, acute chest 
syndrome, stroke, retinopathy, priapism, and other 
complications.  In sickle patients, both endothelial cells 
and erythrocytes exhibit abnormalities that likely 
contribute to patient clinical symptoms.  The sickle 
endothelium shows dimished capacity to regulate vascular 
tone and is also chronically activated to express proteins 
and receptors involved in coagulation and inflammation.  
One of the most important sickle erythrocyte abnormalities 
is increased adhesion to endothelial cells and endothelial 
matrix proteins, which likely initiates or propagates vaso-
occlusion.  Strategies to inhibit abnormal erythrocyte 
adhesion to endothelial cells may benefit sickle patients, 
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but current therapies for sickle cell anemia patients do 
not directly address adhesion.   
The chronic activation of endothelial cells to express 
and display inflammatory markers may contribute to abnormal 
sickle erythrocyte adhesion and clinical symptoms.  The 
data presented in the preceding chapters demonstrates that 
stimulation of endothelial cells with inflammatory 
cytokines such as TNF-α increases adhesion molecule 
expression and sickle erythrocyte adhesion in vitro; 
however, expression profiles of adhesion molecules VCAM-1, 
E-selectin, and ICAM-1 vary with endothelial phenotype.  
VCAM-1 and E-selectin support adhesion of sickle 
erythrocytes, whereas ICAM-1 does not.  For microvascular 
endothelial cells, sickle erythrocyte adhesion to 
unstimulated endothelium is minimal.  Stimulation with TNF-
α for 2 hrs increases E-selectin, but not VCAM-1 
expression, and increases sickle erythrocyte adhesion.  
Antibody and peptide blocking studies are inconclusive, but 
suggest that E-selectin may support adhesion of sickle 
erythrocytes at this stimulation time.  Stimulation of MECs 
with TNF-α for 6 hrs results in significant expression of 
both VCAM-1 and E-selectin and sickle erythrocyte adhesion 
is further increased.  Antibody and peptide blocking 
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studies show that both VCAM-1 and E-selectin support 
adhesion of sickle erythrocytes at this stimulation time. 
Together these data show that sickle erythrocyte 
adhesion is complex in vitro, and suggest that adhesion is 
likely also complex in vivo.  Dominant mechanisms of 
adhesion vary with cytokine stimulation time, indicating 
that strategies to inhibit adhesion in vivo may need to 
encompass multiple adhesive mechanisms to be effective.   
Taking this into account, inhibition of sickle 
erythrocyte adhesion by interruption of the common 
intracellular signaling cascades initiated by cytokines 
that lead to expression of endothelial adhesion molecules 
was studied.  Cyclic AMP is a ubiquitous regulator of many 
intracellular processes and has been shown by others to 
have many anti-inflammatory properties.  The data presented 
in this work demonstrate that inhibition of endothelial 
adhesion molecule expression and sickle erythrocyte 
adhesion is achieved by elevation of endothelial 
intracellular cAMP levels.  The expression of VCAM-1 and E-
selectin, but not ICAM-1 on TNF-α stimulated MECs is 
reduced by treatment of MECs with Forskolin, IBMX, or 
Bt2cAMP, which increase endothelial cAMP levels by different 
mechanisms.  The degree of reduction depends primarily on 
the length of treatment time with cAMP-elevating reagents 
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and, to a lesser extent, on the concentration of reagent 
used.  While significant reductions in adhesion molecule 
expression are achieved by pretreatment of MECs with cAMP-
elevating reagents, the largest reductions in expression 
are seen when the reagents are present both prior to and 
during TNF-α stimulation.   
 Pretreatment and continuous presence of cAMP-elevating 
reagents during TNF-α stimulation of MECs also results in 
significantly decreased sickle erythrocyte adhesion.  
Adhesion is not, however, completely attenuated, with 
percent inhibition of adhesion varying from 59% to 64%, 
depending on the cAMP-elevating reagent used.  Incomplete 
inhibition of sickle erythrocyte adhesion may result from 
incomplete inhibition of adhesion molecule expression. 
 Experiments in which sickle erythrocytes, rather 
than endothelial cells, are treated with cAMP-elevating 
reagents prior to perfusion show that adhesion to TNF-α 
stimulated MECs is not altered.  However, adhesion to 
unstimulated MECs is increased for some blood samples, 
consistent with other reports in the literature. 
Like cAMP, nitric oxide also shows potential as an 
anti-inflammatory molecule as well as a vasodilator.  ELISA 
assays demonstrate that TNF-α induced VCAM-1 surface 
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expression, but not E-selectin or ICAM-1 expression, is 
significantly inhibited by pretreatment with and continuous 
presence of reagents that increase intracellular nitric 
oxide during TNF-α stimulation.  Nitric oxide donors alone 
(without TNF-α) do not affect VCAM-1, E-selectin, or ICAM-1 
surface expression.  These biochemical observations 
translate well to functional observations measuring sickle 
erythrocyte adhesion.  Two different nitric oxide donors 
inhibit TNF-α induced adhesion by 71% and 79%, presumably 
by inhibiting VCAM-1 expression.  Treatment of MECs with NO 
donors alone (without TNF-α) does not affect sickle 
erythrocyte adhesion. 
 Also explored in this work is whether or not nitric 
oxide in sickle erythrocytes affects their adhesion to 
endothelial cells.  Elevated nitric oxide does not affect 
adhesion to unstimulated endothelial cells.  However, a 
substantial (28% to 50%), but not statistically 
significant, inhibition of adhesion to TNF-α stimulated 
endothelial cells is shown, suggesting that more studies 
need to be undertaken to establish if and how nitric oxide 
affects sickle erythrocytes. 
In summary, the data presented in this work suggest 
that cAMP and nitric oxide and their associated signaling 
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may significantly affect the pathology of sickle cell 
anemia.  Using an endothelial model in which both VCAM-1 
and E-selectin support adhesion of sickle erythrocytes, it 
is demonstrated that increases in cAMP and NO regulate TNF-
α induced expression of one or both receptors and result in 
reduced sickle erythrocyte adhesion, which may be of 
benefit to sickle patients.  The work suggests that in 
addition to antibody blocking, interruption of the 
signaling cascades leading to surface expression of 
receptors may be effective to control sickle cell adhesion 
and vaso-occlusion.  The effects of cAMP and NO described 
here, along with those described by others, suggest that 
cAMP and nitric oxide-dependent signaling may be an 
important therapeutic target in the prevention or treatment 
















RECOMMENDATIONS AND FUTURE STUDIES 
 
8.1  Inhibition of Adhesion Molecule Expression and Sickle 
Erythrocyte Adhesion at Long Cytokine Stimulation Times 
  
 As discussed in Section 5.2.2, treatment of 
endothelial cells with reagents that increase intracellular 
cAMP partially, but not completely, inhibits TNF-α induced 
VCAM-1 and E-selectin expression and sickle erythrocyte 
adhesion.  To be effective for 6 hrs of TNF-α stimulation, 
the cAMP-elevating reagents must be available for the 
duration of TNF-α stimulation.  This is likely the case 
because cAMP levels quickly return to baseline after 
reagents are removed from contact with endothelial cells, 
presumably because cAMP is broken down to AMP by 
phosphodieasterases.  Also, literature suggests that 
continuously elevated levels of cAMP in endothelial cells 
can result in a period of refractoriness, in which 
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endothelial cells are no longer responsive to cAMP (Krall & 
Jamgotchian, 1987).   
 One limitation of the studies presented in the 
preceding chapters is that they do not address the effects 
of cAMP-elevating reagents at long cytokine stimulation 
times.  In vivo, sickle patients exhibit signs of chronic 
elevation of cytokine levels which are further elevated 
during symptomatic events.  Thus for a therapy aiming to 
limit or control the inflammatory process or cytokine-
induced cell signaling to be of benefit in vivo, it may 
need to be effective over long periods of time.  ELISA or 
flow cytometry assays should be performed to determine the 
effect of continous presence of cAMP-elevating reagents on 
both endothelial cAMP concentrations and cytokine-induced 
adhesion molecule expression at longer (1-3 days) cytokine 
stimulation times. 
 
8.2  Inhibition of Leukocyte Rolling and Adhesion by cAMP 
and NO 
  
 Recent reports in literature suggest that in addition 
to sickle erythrocytes, sickle leukocytes are also 
abnormally adherent to the endothelium (Kaul et al., 2004; 
Okpala, 2004).  Thus therapies to control adhesion or vaso-
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occlusion in sickle cell patients may need to account for 
both cell types.  Since E-selectin on endothelial cells 
contributes to rolling of leukocytes and cAMP inhibits TNF-
α induced E-selectin expression, it is hypothesized that 
elevated endothelial cAMP inhibits sickle leukocyte rolling 
and adhesion.  This hypothesis could be tested in flow 
assays similar to those which measure sickle erythrocyte 
adhesion, except that leukocytes, rather than erythrocytes 
would be isolated from sickle blood and perfused over 
treated endothelial cells.  In addition to counting 
adherent leukocytes, numbers and velocities of rolling 
leukocytes could be measured in the presence and absence of 
cAMP elevating reagents.  Similar experiments could be 
conducted with NO elevating reagents; however, it is not 
clear from the data presented in previous chapters that 
nitric oxide would affect E-selectin expression or 
leukocyte rolling and adhesion. 
 
8.3  Effect of cAMP and NO on Other Adhesion Molecules 
Supporting Sickle Erythrocyte Adhesion 
  
 The data presented in this document suggest that cAMP 
and nitric oxide inhibit expression of VCAM-1 and/or E-
selectin and sickle erythrocyte adhesion.  However, these 
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are just two of several receptors on endothelial cells 
shown to support sickle erythrocyte adhesion, and 
literature indicates that cAMP and nitric oxide may affect 
surface expression of other receptors important to sickle 
cell anemia.  One study suggests that cAMP alone induces a 
delayed release of vWF and, to a much lesser extent, P-
selectin from Weibel-Palade bodies in endothelial cells 
(Cleator et al., 2005). Another, however, demonstrates that 
elevated cAMP actually inhibits histamine-induced P-
selectin surface expression (Easton & Dorovini-Zis, 2001).  
Several in vivo studies also suggest that elevated nitric 
oxide inhibits P-selectin expression (Barbato et al., 
2005), while lowering nitric oxide levels induces 
expression (Nabah et al., 2005). 
In addition to endothelial receptors, it is likely 
that cAMP and nitric oxide also play a role in regulating 
the ligands on sickle erythrocytes that promote adhesion. 
In fact, recent research indicates a role for cAMP in 
regulating expression of ICAM-4 on sickle erythrocytes, 
which binds to endothelial αVβ3 (Zennadi et al., 2004).  
Also, the results presented in this document suggest that 
nitric oxide may regulate α4β1 expression (See Section 6.3).  
In order to better understand how cAMP or nitric oxide 
would affect sickle patients in vivo, it is necessary to 
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understand their effects on the adhesion molecules that 
promote sickle erythrocyte adhesion.  ELISA and flow assays 
could be used to study how these intracellular signaling 
molecules affect many of the adhesion molecules important 
to sickle cell anemia patients. 
 
 8.4  Regulation of α4β1 Expression on Sickle Erythrocytes 
  
 The data presented in Section 6.3 suggest that 
increasing nitric oxide in sickle erythrocytes may inhibit 
their adhesion to endothelial cells stimulated with 
inflammatory cytokines, inviting speculation that nitric 
oxide may regulate sickle erythrocyte α4β1 expression.  
Little is known about how nitric oxide affects ligands on 
sickle erythrocytes.  However, treatment of neutrophils 
with reagents that inhibit nitric oxide induces expression 
of α4β1, which binds to VCAM-1, possibly through 
mobilization of neutrophil granules and cytoskeletal 
rearrangement (Conran et al., 2003). It is not clear, 
though, that NO donors affect α4β1 expression on neutrophils 
or that the response to NO extends to erythrocytes.  In 
addition, sickle cell patients taking hydroxyurea, which 
generates NO, show fewer erythrocytes expressing α4β1 and 
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fewer α4β1 molecules per erythrocyte than sickle patients 
not taking hydroxyurea (Styles et al., 1997).  Although 
this effect may not result from NO exposure, it invites 
speculation that one beneficial effect of NO for sickle 
patients may be reduction in α4β1 expression on sickle 
erythrocytes and reduced sickle erythrocyte adhesion.  To 
test this hypothesis directly, α4β1 expression on sickle 
erythrocytes exposed or not to nitric oxide donors could be 
measured using flow cytometry.  In addition, the effect of 
suppression of nitric oxide synthase enzymes on α4β1 
expression and activation could be determined.  The 
determination that nitric oxide affects α4β1 expression 
would invite further study into the mechanism of action of 
nitric oxide on sickle erythrocytes. 
 
8.5  Trials of cAMP or Nitric Oxide Elevating Reagents in 
Sickle Mice 
  
 While the studies presented in this document look 
solely at adhesion molecule expression and sickle 
erythrocyte adhesion in closely controlled in vitro 
systems, the effects of cAMP and nitric oxide elevating 
reagents in vivo remain to be seen.  The development of 
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sickle transgenic mice allows for study of these two 
intracellular signaling molecules and their effects on 
adhesion in vivo.  To date, many in vivo studies in which 
cAMP or NO elevating reagents are inhaled or injected into 
sickle mice look only at regulation of vascular tone.  Both 
cAMP-elevating reagents such as forskolin and inhaled 
nitric oxide appear to improve vascular tone in sickle mice 
(Kaul et al., 2000).  However, it is hypothesized that 
these reagents may also have anti-inflammatory properties.  
To test this hypothesis intravital fluorescence microscopy 
could be used to examine endothelial markers of 
inflammation such as VCAM-1, E-selectin, ICAM-1, and P-
selectin in sickle mice presented with inflammatory 
challenge or not.  The same could be examined after 
administration of cAMP or nitric oxide elevating reagents.  
Alternatively, mice could be sacrificed after treatment and 
tests for endothelial inflammatory markers could be 
conducted ex vivo.   
 
8.6  Effect of cAMP on Endothelial Permeability 
  
 Appropriate permeability of endothelial cells is 
crucial to the regulation of vascular tone and function.  
The endothelium allows exchange of small molecules such as 
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water, oxygen, and carbon dioxide between blood and 
tissues, but prevents exchange of some other, larger 
molecules.  The permeability of endothelial cells varies 
largely with the type of vessel and the organ system in 
which they lie.  An increase in endothelial permeability 
due to endothelial damage is a major dysfunction that is 
part of the common stroke pathogenesis pathway.  Thus one 
hypothesis regarding the pathogenesis of stroke in sickle 
patients is that sickle erythrocytes damage endothelial 
cells in such a way as to increase permeability.  Lola 
Brown demonstrates preliminary data suggesting that sickle 
erythrocytes loosen endothelial adherens junctions, 
supporting this hypothesis (L. A. Brown, 2005).  While much 
more work is necessary to confirm an effect of sickle 
erythrocytes on endothelial permeability, confirmation begs 
the question, “Could prevention of increased endothelial 
permeability in the sickle vasculature reduce the incidence 
of stroke in sickle patients, and, if so, how can increased 
endothelial permeability be prevented?”  
Many recent studies indicate that cyclic nucleotides 
such as cAMP play an important role in the regulation of 
endothelial permeability.  Several in vitro assays suggest 
that cAMP works to tighten endothelial adherens junctions 
and decrease endothelial permeability.  The effect is 
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independent of endothelial phenotype and has been tested in 
brain endothelial cells (Bruckener et al., 2003; Chong & 
Victorino, 2005; Deli et al., 1995; Kooistra et al., 2005; 
Krizbai & Deli, 2003; Rist et al., 1997).  These studies 
suggest that elevated cAMP, in addition to the effects 
demonstrated in this document, could potentially reduce the 
effects of sickle erythrocytes on endothelial permeability.  
This could be tested in experiments in which endothelial 
cells grown on polyester membranes are exposed or not to 
sickle erythrocytes and exposed or not to cAMP-elevating 
reagents such as Forskolin.  Permeability of fluorescently 
labeled small molecules such as dextran could be measured 
as previously described (L. A. Brown, 2005).  
 
8.7  Expedition of Endothelial Receptor Shedding 
  
 The studies presented in this document have 
focused on strategies to prevent or inhibit receptor 
expression and sickle erythrocyte adhesion.  However, it is 
likely that a patient who presents him or herself at a 
hospital seeking treatment for clinical symptoms associated 
with sickle cell anemia may already have expressed adhesion 
molecules, and, thus a preventive strategy may not be 
effective.   
190 
Once receptors are expressed on the endothelial 
surface, they are displayed for a time, then are shed into 
the circulation.  Another potential treatment strategy, 
then, may be to expedite the receptor shedding process. An 
understanding of how receptors are shed is just beginning 
to develop.  It appears that shedding is caused by cleavage 
of transmembrane proteins by proteases.  However, the 
specific proteases responsible for cleavage of receptors of 
interest in sickle cell anemia are not well known.  Matrix 
metallo-proteinases are responsible for shedding of most 
membrane proteins studied to date.  Metalloproteinases, 
possibly the tumor necrosis factor alpha converting 
enzymes, are responsible for endothelial VCAM-1 shedding 
(Garton et al., 2003).  As more is learned about the 
enzymes responsible for receptor shedding and the 
intracellular signaling responsible for their activation, 
it may be possible to harness their activity for use in 






MACROS FOR RECORDING ADHERENCE DATA 
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' initialtime Macro 
' Macro recorded 8/22/2002 by aowings 
' 
' Keyboard Shortcut: Ctrl+q 
' 
    ActiveCell.FormulaR1C1 = "=NOW()" 
    ActiveCell.Select 
    Selection.Copy 
    Selection.PasteSpecial Paste:=xlPasteValues, 
Operation:=xlNone, SkipBlanks _ 
        :=False, Transpose:=False 
    Application.CutCopyMode = False 
    Selection.NumberFormat = "h:mm:ss" 









' datetime Macro 
' Macro recorded 8/22/2002 by aowings 
' 
' Keyboard Shortcut: Ctrl+s 
' 
    ActiveCell.Offset(-1, -2).Range("A1").Select 
    ActiveCell.FormulaR1C1 = "=NOW()" 
    ActiveCell.Select 
    Selection.Copy 
    Selection.PasteSpecial Paste:=xlPasteValues, 
Operation:=xlNone, SkipBlanks _ 
        :=False, Transpose:=False 
    Application.CutCopyMode = False 
    Selection.NumberFormat = "h:mm:ss" 
    ActiveCell.Offset(0, 1).Range("A1").Select 
    ActiveCell.FormulaR1C1 = "=(RC[-1]-R6C1)*1440" 























































































































































































































































































































































































































































































































































































































































































































































Table B.2  Sample Calculations for single factor ANOVA and 
Fisher’s Pairwise Comparisons.  ELISA data presented in 
Table B.1 and graphically in Figure 4.1 are used for sample 
calculations.  MINITAB™ Statistical Software is used for 
all calculations, and software output is shown below.  
Statistical differences are achieved when ANOVA returns 
P<0.05 and when the intervals returned by Fisher’s pairwise 
comparisons do not contain zero.  Statistical differences 




One-way ANOVA: O.D. 450 nm (VCAM-1) versus TNF stimulation time 
 
Analysis of Variance for O.D. 450 
Source     DF        SS        MS        F        P 
TNF stim    4   0.10733   0.02683    11.37    0.000 
Error      40   0.09439   0.00236 
Total      44   0.20172 
                                   Individual 95% CIs For Mean 
                                   Based on Pooled StDev 
Level       N      Mean     StDev  ---+---------+---------+---------+--- 
0           9   0.02624   0.01751    (----*-----)  
2           9   0.02039   0.01614   (----*-----)  
4           9   0.05217   0.03437        (-----*----)  
6           9   0.11021   0.06157                  (----*-----)  
8           9   0.14496   0.07911                        (----*-----)  
                                   ---+---------+---------+---------+--- 
Pooled StDev =  0.04858             0.000     0.060     0.120     0.180 
 
Fisher's pairwise comparisons 
 
    Family error rate = 0.275 
Individual error rate = 0.0500 
 
Critical value = 2.021 
 
Intervals for (column level mean) - (row level mean) 
 
                   0           2           4           6 
 
       2    -0.04042 
             0.05213 
 
       4    -0.07220    -0.07806 
             0.02036     0.01450 
 
       6    -0.13024    -0.13610    -0.10432 
            -0.03768    -0.04354    -0.01176 
 
       8    -0.16499    -0.17085    -0.13907    -0.08103 









One-way ANOVA: O.D. 450 nm (E-selectin) versus TNF stimulation time 
 
Analysis of Variance for O.D. 450 
Source     DF        SS        MS        F        P 
TNF stim    4    1.2608    0.3152    23.37    0.000 
Error      40    0.5396    0.0135 
Total      44    1.8004 
                                   Individual 95% CIs For Mean 
                                   Based on Pooled StDev 
Level       N      Mean     StDev  -----+---------+---------+---------+- 
0           9    0.0077    0.0197   (---*----)  
2           9    0.1259    0.1108          (----*----)  
4           9    0.3422    0.1552                       (----*----)  
6           9    0.4282    0.1423                             (----*----)  
8           9    0.4131    0.1023                            (----*----)  
                                   -----+---------+---------+---------+- 
Pooled StDev =   0.1161               0.00      0.16      0.32      0.48 
 
Fisher's pairwise comparisons 
 
    Family error rate = 0.275 
Individual error rate = 0.0500 
 
Critical value = 2.021 
 
Intervals for (column level mean) - (row level mean) 
 
                   0           2           4           6 
 
       2     -0.2289 
             -0.0076 
 
       4     -0.4452     -0.3269 
             -0.2238     -0.1056 
 
       6     -0.5312     -0.4129     -0.1967 
             -0.3099     -0.1916      0.0246 
 
       8     -0.5161     -0.3979     -0.1816     -0.0956 
             -0.2948     -0.1766      0.0397      0.1257 
 
One-way ANOVA: O.D. 450 nm (ICAM-1) versus TNF stimulation time 
 
Analysis of Variance for O.D. 450 
Source     DF        SS        MS        F        P 
TNF stim    4    3.4570    0.8643    21.55    0.000 
Error      40    1.6039    0.0401 
Total      44    5.0609 
                                   Individual 95% CIs For Mean 
                                   Based on Pooled StDev 
Level       N      Mean     StDev  ---------+---------+---------+------- 
0           9    0.1863    0.1454   (---*----)  
2           9    0.3183    0.1793       (----*---)  
4           9    0.6000    0.2380                 (---*---)  
6           9    0.8499    0.1597                         (---*----)  
8           9    0.8772    0.2551                          (---*----)  
                                   ---------+---------+---------+------- 






Fisher's pairwise comparisons 
 
    Family error rate = 0.275 
Individual error rate = 0.0500 
 
Critical value = 2.021 
 
Intervals for (column level mean) - (row level mean) 
 
                   0           2           4           6 
 
       2     -0.3228 
              0.0588 
 
       4     -0.6044     -0.4725 
             -0.2229     -0.0909 
 
       6     -0.8544     -0.7224     -0.4407 
             -0.4728     -0.3408     -0.0592 
 
       8     -0.8816     -0.7497     -0.4680     -0.2181 








Table B.3  VCAM-1 expression on TNF-α stimulated MECs and 




VCAM-1 (MECs) Experiment Number
TNF-a Stim Time (hrs) E4 E5 Average
0 0.030 0.028 0.029
1 0.020 0.014 0.017
2 0.019 0.016 0.017
3 0.026 0.017 0.021
4 0.076 0.019 0.047
6 0.187 0.073 0.130
8 0.254 0.183 0.218
12 0.439 0.334 0.387
16 0.516 0.427 0.472
20 0.464 0.380 0.422
24 0.443 0.368 0.406
VCAM-1 (HUVECs) Experiment Number
TNF-a Stim Time (hrs) E4 E5 Average
0 0.015 0.015 0.015
1 0.005 0.016 0.010
2 0.005 0.010 0.007
3 0.014 0.025 0.020
4 0.036 0.055 0.045
6 0.157 0.184 0.171
8 0.108 0.194 0.151
12 0.212 0.065 0.139
16 0.200 0.136 0.168
20 0.204 0.228 0.216










Table B.4  E-selectin expression on TNF-α stimulated MECs 






E-selectin (MECs) Experiment Number
TNF-a Stim Time (hrs) E4 E5 Average
0 0.000 0.008 0.004
1 0.006 0.011 0.009
2 0.059 0.023 0.041
3 0.194 0.089 0.141
4 0.397 0.199 0.298
6 0.504 0.284 0.394
8 0.484 0.471 0.477
12 0.548 0.259 0.404
16 0.500 0.212 0.356
20 0.349 0.119 0.234
24 0.328 0.054 0.191
E-selectin (HUVECs) Experiment Number
TNF-a Stim Time (hrs) E4 E5 Average
0 0.000 0.006 0.003
1 0.009 0.006 0.007
2 0.008 0.036 0.022
3 0.037 0.087 0.062
4 0.062 0.106 0.084
6 0.088 0.214 0.151
8 0.058 0.155 0.107
12 0.098 0.036 0.067
16 0.074 0.049 0.062
20 0.042 0.013 0.028















Table B.5  ICAM-1 expression on TNF-α stimulated MECs and 






ICAM-1 (MECs) Experiment Number
TNF-a Stim Time (hrs) E4 E5 Average
0 0.326 0.229 0.278
1 0.252 0.212 0.232
2 0.415 0.265 0.340
3 0.576 0.443 0.509
4 0.732 0.452 0.592
6 0.979 0.814 0.896
8 1.251 0.993 1.122
12 1.267 1.175 1.221
16 1.377 1.173 1.275
20 1.455 1.194 1.324
24 1.503 1.184 1.343
ICAM-1 (HUVECs) Experiment Number
TNF-a Stim Time (hrs) E4 E5 Average
0 0.630 0.809 0.719
1 0.598 0.817 0.708
2 0.631 0.768 0.700
3 0.799 0.837 0.818
4 0.781 0.862 0.822
6 0.921 1.025 0.973
8 0.985 1.126 1.056
12 1.041 0.935 0.988
16 1.008 1.029 1.018
20 1.013 1.061 1.037




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table B.11  Blocking of sickle erythrocyte adhesion to MECs 
stimulated with TNF-α for 2 hrs by anti-E-selectin 





Perfusion Time (min) S26 S68 Average
1 0.8 1.9 1.4
3 6.5 4.3 5.4
5 6.4 6.4 6.4
10 3.2 7.2 5.2
20 8.0 13.2 10.6
30 5.6 16.8 11.2
40 8.0 6.2 7.1
a- E- s e l e c t i n Experiment Number
Perfusion Time (min) S26 S68 Average
1 0.8 0.9 0.8
3 3.7 2.3 3.0
5 2.4 9.1 5.7
10 11.2 10.7 10.9
20 16.8 17.3 17.0
30 20.8 19.7 20.2
40 21.6 17.3 19.4
TNF-a (2 hrs) Experiment Number
Perfusion Time (min) S26 S68 Average
1 1.8 2.4 2.1
3 8.7 11.2 10.0
5 7.2 9.9 8.6
10 21.6 12.4 17.0
20 28.8 24.7 26.7
30 32.0 21.1 26.6



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table B.15  Sickle erythrocyte adhesion to MECs stimulated 
with TNF-α for 6 hrs and treated with anti-ICAM-1.  Average 
data are presented graphically in Figure 4.10, Panel A. 
 
Unstimulated Experiment Number
Perfusion Time (min) S40 S42 S47 S48 Average SEM
1 0.8 1.9 7.7 3.8 3.5 1.5
3 8.0 6.6 6.9 5.3 6.7 0.5
5 6.1 5.3 20.4 5.1 9.2 3.7
10 16.0 9.1 14.3 5.9 11.3 2.3
20 10.9 5.1 21.8 6.4 11.0 3.8
30 22.6 6.4 9.8 10.4 12.3 3.5
40 13.7 7.6 18.3 6.4 11.5 2.8
a- I CAM- 1 Experiment Number
Perfusion Time (min) S40 S42 S47 S48 Average SEM
1 2.8 0.0 4.8 5.6 3.3 1.2
3 7.5 7.6 28.2 9.4 13.2 5.0
5 6.4 12.2 22.4 36.7 19.4 6.6
10 16.7 13.9 19.2 36.9 21.7 5.2
20 40.5 26.9 29.8 60.8 39.5 7.7
30 49.1 64.8 40.9 80.8 58.9 8.8
40 62.7 51.4 39.6 112.0 66.4 15.9
TNF-a (6 hrs) Experiment Number
Perfusion Time (min) S40 S42 S47 S48 Average SEM
1 0.0 6.0 1.9 1.1 2.2 1.3
3 4.6 9.8 6.2 0.0 5.1 2.0
5 13.7 22.4 28.4 14.2 19.7 3.5
10 36.6 19.6 28.5 32.8 29.4 3.7
20 41.0 56.8 48.8 37.6 46.1 4.3
30 46.2 54.1 54.5 66.4 55.3 4.2























































































































































































































































































































































































































































































































































































































































































































































































































Table B.17  Sickle erythrocyte adhesion when erythrocytes 
were incubated with E-selectin blocking peptide, 
centrifuged, and resuspended in peptide-free media prior to 
perfusion. Average data are presented graphically in Figure 




Perfusion Time (min) S42 S60 S62 Average SEM
1 1.9 0.0 2.5 1.4 0.7
3 6.6 6.5 3.4 5.5 1.0
5 5.3 4.9 4.8 5.0 0.2
10 9.1 8.0 8.0 8.4 0.4
20 5.1 11.9 9.6 8.8 2.0
30 6.4 7.0 5.1 6.2 0.5
40 7.6 13.6 16.0 12.4 2.5
E-sel pep washed away Experiment Number
Perfusion Time (min) S42 S60 S62 Average SEM
1 2.5 1.0 2.7 2.1 0.5
3 9.6 10.0 0.7 6.8 3.0
5 33.6 3.0 3.1 13.2 10.2
10 32.0 9.6 6.8 16.1 8.0
20 65.9 18.1 10.9 31.6 17.3
30 94.3 18.1 20.0 44.1 25.1
40 78.4 12.6 22.0 37.7 20.5
TNF-a (6 hrs) Experiment Number
Perfusion Time (min) S42 S60 S62 Average SEM
1 6.0 3.6 0.7 3.5 1.5
3 9.8 12.7 4.7 9.1 2.3
5 22.4 10.0 5.9 12.8 5.0
10 19.6 33.3 14.2 22.3 5.7
20 56.8 39.0 9.7 35.2 13.7
30 54.1 33.9 23.3 37.1 9.0






Table B.18  Sickle erythrocyte adhesion to MECs stimulated 
with TNF-α for 6 hrs and treated with scrambled peptide.  






Perfusion Time (min) S40 S42 S47 Average SEM
1 0.8 1.9 7.7 3.5 2.1
3 8.0 6.6 6.9 7.1 0.4
5 6.1 5.3 20.4 10.6 4.9
10 16.0 9.1 14.3 13.2 2.1
20 10.9 5.1 21.8 12.6 4.9
30 22.6 6.4 9.8 12.9 4.9
40 13.7 7.6 18.3 13.2 3.1
Scrambled pep Experiment Number
Perfusion Time (min) S40 S42 S47 Average SEM
1 4.2 1.9 6.3 4.1 1.3
3 15.0 5.9 16.0 12.3 3.2
5 25.8 8.0 23.1 19.0 5.5
10 41.8 28.0 24.8 31.5 5.2
20 32.7 35.8 33.7 34.1 0.9
30 50.5 59.4 26.9 45.6 9.7
40 54.6 61.7 32.0 49.4 9.0
TNF-a (6 hrs) Experiment Number
Perfusion Time (min) S40 S42 S47 Average SEM
1 0.0 6.0 1.9 2.6 1.8
3 4.6 9.8 6.2 6.9 1.6
5 13.7 22.4 28.4 21.5 4.3
10 36.6 19.6 28.5 28.2 4.9
20 41.0 56.8 48.8 48.9 4.6
30 46.2 54.1 54.5 51.6 2.7













Table B.19  Adhesion of sickle erythrocytes treated with 
anti-alpha 4 antibody to MECs stimulated with TNF-α for 6 
hrs.  Average data are presented graphically in Figure 






Perfusion Time (min) S53 S54 S55 S58 S65 Average SEM
1 4.4 4.2 0.0 0.8 0.0 1.9 1.0
3 5.3 0.6 2.0 0.8 3.2 2.4 0.9
5 7.1 2.6 4.0 3.0 2.9 3.9 0.8
10 11.8 0.7 3.0 3.6 8.0 5.4 2.0
20 12.0 1.4 4.4 9.9 4.1 6.4 2.0
30 18.1 4.2 4.7 8.3 11.6 9.4 2.6
40 15.3 0.7 2.8 6.4 16.6 8.4 3.2
a- a4 Experiment Number
Perfusion Time (min) S53 S54 S55 S58 S65 Average SEM
1 0.0 0.6 0.8 0.0 3.4 0.9 0.6
3 6.9 4.3 3.8 4.2 5.1 4.8 0.5
5 10.7 2.1 5.5 9.6 12.2 8.0 1.8
10 17.5 8.3 9.5 8.3 19.0 12.5 2.3
20 36.4 12.5 16.0 16.0 32.9 22.8 4.9
30 41.0 13.9 18.9 33.5 84.6 38.4 12.5
40 45.7 10.9 25.8 46.4 65.6 38.9 9.4
TNF-a (6 hrs) Experiment Number
Perfusion Time (min) S53 S54 S55 S58 S65 Average SEM
1 7.0 4.2 3.4 1.5 1.5 3.5 1.0
3 14.1 2.2 8.0 6.0 9.3 7.9 2.0
5 23.5 5.6 9.6 7.4 8.5 10.9 3.2
10 29.2 17.2 16.0 12.5 20.4 19.1 2.8
20 36.7 24.3 19.6 13.7 32.0 25.3 4.1
30 29.2 46.1 32.0 14.5 51.0 34.6 6.5








Table B.20  Adhesion of sickle erythrocytes treated with 
neuraminidase to MECs stimulated with TNF-α for 6 hrs.  





Perfusion Time (min) S53 S54 S55 S65 Average SEM
1 4.4 4.2 0.0 0.0 2.2 1.3
3 5.3 0.6 2.0 3.2 2.8 1.0
5 7.1 2.6 4.0 2.9 4.1 1.0
10 11.8 0.7 3.0 8.0 5.9 2.5
20 12.0 1.4 4.4 4.1 5.5 2.3
30 18.1 4.2 4.7 11.6 9.6 3.3
40 15.3 0.7 2.8 16.6 8.8 4.1
Neuraminidase Experiment Number
Perfusion Time (min) S53 S54 S55 S65 Average SEM
1 6.0 0.7 0.9 1.8 2.4 1.2
3 6.7 5.8 6.0 13.3 7.9 1.8
5 16.6 6.9 14.6 25.1 15.8 3.8
10 20.2 15.3 21.6 36.0 23.3 4.4
20 32.8 37.9 40.0 40.6 37.8 1.8
30 32.0 38.8 47.3 55.4 43.4 5.1
40 41.5 46.6 52.4 32.0 43.1 4.3
TNF-a (6 hrs) Experiment Number
Perfusion Time (min) S53 S54 S55 S65 Average SEM
1 7.0 4.2 3.4 1.5 4.0 1.1
3 14.1 2.2 8.0 9.3 8.4 2.5
5 23.5 5.6 9.6 8.5 11.8 4.0
10 29.2 17.2 16.0 20.4 20.7 3.0
20 36.7 24.3 19.6 32.0 28.2 3.8
30 29.2 46.1 32.0 51.0 39.6 5.3


















































































































































































































































































































































































































































































































































































































































































































































































































Table B.22  Effect of forskolin treatment time on TNF-α 
induced adhesion molecule expression.  Average data are 




Endothelial Treatment E8 E10 E11 E12 Average SEM
Unstimulated 0.000 0.019 0.071 0.071 0.040 0.018
TNF-a (6 hrs) 0.184 0.217 0.366 0.366 0.283 0.048
Fsk (15 min pre) 0.113 0.186 0.191 0.191 0.170 0.019
Fsk (30 min pre) 0.098 0.223 0.334 0.334 0.247 0.056
Fsk (60 min pre) 0.084 0.202 0.220 0.220 0.181 0.033
Fsk (90 min pre) 0.057 0.147 0.221 0.221 0.161 0.039
Fsk (120 min pre) 0.090 0.188 0.199 0.199 0.169 0.027
Fsk (30 min pre + cont) 0.024 0.032 0.040 0.040 0.034 0.004
Fsk (120 min pre + cont) 0.030 0.042 0.074 0.074 0.055 0.011
E-selectin Experiment Number
Endothelial Treatment E8 E10 E11 E12 Average SEM
Unstimulated 0.000 0.003 0.007 0.007 0.004 0.002
TNF-a (6 hrs) 0.536 0.418 0.489 0.489 0.483 0.024
Fsk (15 min pre) 0.334 0.264 0.339 0.339 0.319 0.018
Fsk (30 min pre) 0.380 0.366 0.368 0.368 0.370 0.003
Fsk (60 min pre) 0.383 0.299 0.315 0.315 0.328 0.019
Fsk (90 min pre) 0.267 0.308 0.382 0.382 0.335 0.029
Fsk (120 min pre) 0.380 0.338 0.402 0.402 0.381 0.015
Fsk (30 min pre + cont) 0.153 0.134 0.210 0.210 0.177 0.020
Fsk (120 min pre + cont) 0.114 0.146 0.286 0.286 0.208 0.046
ICAM-1 Experiment Number
Endothelial Treatment E8 E10 E11 E12 Average SEM
Unstimulated 0.231 0.124 0.222 0.222 0.200 0.025
TNF-a (6 hrs) 0.875 0.887 0.978 0.978 0.930 0.028
Fsk (15 min pre) 0.631 0.793 0.987 0.987 0.850 0.086
Fsk (30 min pre) 0.762 0.750 0.933 0.933 0.845 0.051
Fsk (60 min pre) 0.690 0.699 0.933 0.933 0.814 0.069
Fsk (90 min pre) 0.562 0.777 0.972 0.972 0.821 0.098
Fsk (120 min pre) 0.710 0.796 0.934 0.934 0.843 0.055
Fsk (30 min pre + cont) 0.533 0.606 0.885 0.885 0.727 0.092








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table B.26  Effect of Fsk, IBMX, or Bt2cAMP alone on 
adhesion molecule expression.  Average data are presented 




Endothelial Treatment E30 E31 Average
Unstimulated 0.026 0.011 0.019
Fsk 0.026 0.026 0.018
IBMX 0.038 0.038 0.032
Bt2cAMP 0.035 0.035 0.026
E-selectin Experiment Number
Endothelial Treatment E30 E31 Average
Unstimulated 0.030 0.036 0.033
Fsk 0.041 0.012 0.027
IBMX 0.046 0.025 0.035
Bt2cAMP 0.086 0.051 0.069
ICAM-1 Experiment Number
Endothelial Treatment E30 E31 Average
Unstimulated 0.123 0.145 0.134
Fsk 0.159 0.098 0.129
IBMX 0.103 0.106 0.104













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table B.30  Effect of forskolin on endothelial cAMP 
concentration. Data are given as pmol cAMP per well.  





Endothelial Treatment C1 C2 C3 Average SEM
Unstimulated 1.08 2.76 2.85 2.23 0.57
Fsk (pre) 1.30 8.70 16.76 8.92 4.47
Fsk (pre) + TNF-a (0.5 hrs) 1.28 3.39 3.89 2.85 0.80
Fsk (pre) + TNF-a (1 hr) 1.22 3.30 4.01 2.84 0.84
Fsk (pre) + TNF-a (2 hrs) 1.25 2.33 3.11 2.23 0.54
Fsk (pre) + TNF-a (4 hrs) 1.40 2.53 2.85 2.26 0.44
Fsk (pre) + TNF-a (6 hrs) 1.46 2.10 4.11 2.55 0.80
Experiment Number
Endothelial Treatment C1 C2 C3 Average SEM
Unstimulated 1.08 2.76 2.85 2.23 0.57
Fsk (pre) 1.30 8.70 16.76 8.92 4.47
Fsk (pre + cont) + TNF-a (0.5 hrs) 1.52 8.34 9.36 6.41 2.46
Fsk (pre + cont) + TNF-a (1 hr) 1.24 6.34 9.42 5.67 2.38
Fsk (pre + cont) + TNF-a (2 hrs) 1.03 3.71 6.52 3.75 1.59
Fsk (pre + cont) + TNF-a (4 hrs) 1.63 4.28 8.59 4.83 2.03










Table B.31  Effect of forskolin alone on sickle erythrocyte 




Perfusion Time (min) S21 S22 S23 S24 Average SEM
1 4.4 0.0 4.0 2.5 2.7 1.0
3 4.8 0.0 6.7 6.7 4.5 1.6
5 6.4 5.3 8.3 28.4 12.1 5.5
10 16.0 5.6 11.3 27.2 15.0 4.6
20 23.2 9.6 8.0 36.0 19.2 6.6
30 22.5 6.4 16.0 59.2 26.0 11.5
40 14.5 9.6 14.7 52.8 22.9 10.0
Fsk Experiment Number
Perfusion Time (min) S21 S22 S23 S24 Average SEM
1 0.0 0.0 6.9 0.0 1.7 1.7
3 1.5 5.3 7.4 9.8 6.0 1.8
5 0.6 7.1 11.3 13.8 8.2 2.9
10 3.2 1.6 18.4 20.9 11.0 5.0
20 4.0 11.2 19.8 23.2 14.6 4.3
30 8.8 8.8 21.1 40.8 19.9 7.6
40 4.8 4.8 19.2 22.9 12.9 4.7
TNF-a (6 hrs) Experiment Number
Perfusion Time (min) S21 S22 S23 S24 Average SEM
1 4.8 5.9 4.2 5.0 0.5
3 12.7 21.3 23.6 19.2 3.3
5 16.9 69.1 45.1 43.7 15.1
10 27.8 129.6 54.4 70.6 30.5
20 74.4 220.8 116.8 137.3 43.5
30 103.2 251.2 121.6 158.7 46.6





Table B.32  Effect of IBMX and Bt2cAMP alone on sickle 
erythrocyte adhesion.  Average data are presented in Figure 




Perfusion Time (min) S58 S59 S63 Average SEM
1 0.8 0.0 0.0 0.3 0.3
3 0.8 3.6 8.0 4.2 2.1
5 3.0 2.9 6.2 4.0 1.1
10 3.6 4.7 21.6 10.0 5.8
20 9.9 9.4 23.0 14.1 4.4
30 8.3 8.9 24.5 13.9 5.3
40 6.4 8.0 26.0 13.5 6.3
IBMX Experiment Number
Perfusion Time (min) S58 S59 S63 Average SEM
1 2.4 3.7 0.0 2.0 1.1
3 3.6 10.3 8.0 7.3 2.0
5 6.7 14.5 12.0 11.1 2.3
10 5.8 13.9 16.0 11.9 3.1
20 6.5 16.0 28.0 16.8 6.2
30 9.7 6.4 28.3 14.8 6.8
40 9.7 8.7 32.0 16.8 7.6
Bt2cAMP Experiment Number
Perfusion Time (min) S58 S59 S63 Average SEM
1 1.8 0.0 2.0 1.3 0.6
3 1.1 0.8 12.8 4.9 4.0
5 5.9 1.5 25.1 10.8 7.3
10 2.3 1.6 33.1 12.3 10.4
20 5.3 2.5 40.6 16.1 12.3
30 5.1 2.3 74.2 27.2 23.5
40 5.1 4.0 43.1 17.4 12.8
TNF-a (6 hrs) Experiment Number
Perfusion Time (min) S58 S59 S63 Average SEM
1 1.5 0.0 1.5 1.0 0.5
3 6.0 2.5 30.7 13.0 8.9
5 7.4 5.0 27.4 13.3 7.1
10 12.5 18.6 69.0 33.4 17.9
20 13.7 16.8 104.5 45.0 29.8
30 14.5 28.0 140.4 61.0 39.9










Table B.33  Effect of treatment of sickle erythrocytes with 
forskolin on adhesion to unstimulated MECs.  Data are 




Unstimulated MECs Experiment Number
Perfusion Time (min) S61 S64 S67 S72 Average SEM
1 2.3 1.7 0.8 1.1 1.5 0.3
3 7.6 4.4 7.0 4.6 5.9 0.8
5 12.8 5.3 12.6 12.8 10.9 1.8
10 14.6 10.9 17.7 16.0 14.8 1.4
20 7.0 14.5 14.5 21.3 14.3 2.9
30 8.7 10.7 16.6 27.4 15.9 4.2
40 13.0 10.7 14.8 30.7 17.3 4.5
Fsk on SSRBCs
Unstimulated MECs Experiment Number
Perfusion Time (min) S61 S64 S67 S72 Average SEM
1 0.7 1.5 4.6 1.9 2.2 0.8
3 2.0 4.4 5.1 6.6 4.5 1.0
5 8.7 13.3 9.0 16.8 12.0 1.9
10 11.3 22.0 16.0 24.0 18.3 2.9
20 9.7 31.3 26.4 39.6 26.8 6.3
30 12.5 36.7 15.1 42.0 26.6 7.5











Table B.34  Effect of treatment of sickle erythrocytes with 
IBMX and Bt2cAMP on adhesion to unstimulated MECs.  Data are 




Unstimulated MECs Experiment Number
Perfusion Time (min) S61 S67 S72 Average SEM
1 2.3 0.8 1.1 1.4 0.4
3 7.6 7.0 4.6 6.4 0.9
5 12.8 12.6 12.8 12.7 0.1
10 14.6 17.7 16.0 16.1 0.9
20 7.0 14.5 21.3 14.3 4.2
30 8.7 16.6 27.4 17.6 5.4
40 13.0 14.8 30.7 19.5 5.6
IBMX on SSRBCs
Unstimulated MECs Experiment Number
Perfusion Time (min) S61 S67 S72 Average SEM
1 3.2 2.3 2.0 2.5 0.4
3 4.8 5.1 6.3 5.4 0.4
5 6.0 19.2 9.1 11.4 4.0
10 9.3 29.1 18.4 18.9 5.7
20 12.5 35.2 48.8 32.2 10.6
30 13.4 38.9 22.7 25.0 7.4
40 11.3 42.2 42.4 32.0 10.3
Bt2cAMP on SSRBCs
Unstimulated MECs Experiment Number
Perfusion Time (min) S61 S67 S72 Average SEM
1 3.0 1.4 0.0 1.5 0.9
3 2.4 8.8 10.4 7.2 2.5
5 4.9 14.4 14.3 11.2 3.1
10 5.1 18.0 20.8 14.6 4.8
20 7.3 34.9 48.0 30.1 12.0
30 13.2 24.7 29.7 22.6 4.9






Table B.35  Effect of treatment of sickle erythrocytes with 
forskolin on adhesion to MECs stimulated with TNF-α for 6 





Unstimulated MECs Experiment Number
Perfusion Time (min) S61 S64 S67 S72 Average SEM
1 2.3 1.7 0.8 1.1 1.5 0.3
3 7.6 4.4 7.0 4.6 5.9 0.8
5 12.8 5.3 12.6 12.8 10.9 1.8
10 14.6 10.9 17.7 16.0 14.8 1.4
20 7.0 14.5 14.5 21.3 14.3 2.9
30 8.7 10.7 16.6 27.4 15.9 4.2
40 13.0 10.7 14.8 30.7 17.3 4.5
Fsk on SSRBCs
TNF-a (6 hrs) on MECs Experiment Number
Perfusion Time (min) S61 S64 S67 S72 Average SEM
1 2.8 0.0 1.6 3.2 1.9 0.7
3 11.5 5.1 5.6 7.7 7.5 1.5
5 17.4 5.1 28.8 32.0 20.8 6.1
10 36.6 10.9 26.7 80.9 38.8 15.0
20 43.1 14.7 43.2 88.0 47.2 15.2
30 55.3 22.0 43.1 84.6 51.2 13.1
40 64.7 18.2 41.0 111.0 58.7 19.8
Unstimulated SSRBCs
TNF-a (6 hrs) on MECs Experiment Number
Perfusion Time (min) S61 S64 S67 S72 Average SEM
1 2.9 0.0 0.8 5.6 2.3 1.2
3 3.7 2.8 6.3 10.2 5.7 1.7
5 11.6 23.4 13.9 24.4 18.3 3.2
10 13.9 14.7 13.6 56.0 24.5 10.5
20 20.4 29.2 18.5 75.3 35.8 13.4
30 38.2 24.3 22.4 115.0 50.0 22.0






Table B.36  Effect of treatment of sickle erythrocytes with 
Bt2cAMP on adhesion to MECs stimulated with TNF-α for 6 hrs.  




Unstimulated MECs Experiment Number
Perfusion Time (min) S61 S67 S72 Average SEM
1 2.3 0.8 1.1 1.4 0.4
3 7.6 7.0 4.6 6.4 0.9
5 12.8 12.6 12.8 12.7 0.1
10 14.6 17.7 16.0 16.1 0.9
20 7.0 14.5 21.3 14.3 4.2
30 8.7 16.6 27.4 17.6 5.4
40 13.0 14.8 30.7 19.5 5.6
Bt2cAMP on SSRBCs
TNF-a (6 hrs) on MECs Experiment Number
Perfusion Time (min) S61 S67 S72 Average SEM
1 3.2 4.4 1.9 3.1 0.7
3 3.6 12.8 20.0 12.1 4.8
5 6.0 20.6 38.7 21.8 9.5
10 5.0 44.8 56.0 35.3 15.5
20 4.9 22.2 55.3 27.5 14.8
30 12.5 24.6 83.0 40.1 21.8
40 13.8 48.0 73.0 44.9 17.2
Unstimulated SSRBCs
TNF-a (6 hrs) Experiment Number
Perfusion Time (min) S61 S67 S72 Average SEM
1 2.9 0.8 5.6 3.1 1.4
3 3.7 6.3 10.2 6.7 1.9
5 11.6 13.9 24.4 16.7 3.9
10 13.9 13.6 56.0 27.8 14.1
20 20.4 18.5 75.3 38.0 18.6
30 38.2 22.4 115.0 58.5 28.6




Table B.37  Effect of blood age on sickle erythrocyte 
adhesion to unstimulated and TNF-α stimulated MECs.  Data 
are presented graphically in Figures 5.13 through 5.15. 
 
Adherent Erythrocytes / mm2






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table B.40  Adhesion molecule expression on MECs treated 





Endothelial Treatment E14 E28 E17 Average SEM
Unstimulated 0.000 0.000 0.034 0.011 0.011
SNP 0.000 0.000 0.022 0.007 0.007
TNF-α 0.165 0.233 0.044 0.147 0.055
E-selectin Experiment Number
Endothelial Treatment E14 E28 E17 Average SEM
Unstimulated 0.000 0.000 0.063 0.021 0.021
SNP 0.000 0.000 0.132 0.044 0.044
TNF-α 0.594 0.640 0.206 0.480 0.138
ICAM-1 Experiment Number
Endothelial Treatment E14 E28 E17 Average SEM
Unstimulated 0.183 0.162 0.199 0.182 0.011
SNP 0.180 0.064 0.133 0.126 0.034














Table B.41  Adhesion molecule expression on MECs treated 






Endothelial Treatment E14 E28 E18 Average SEM
Unstimulated 0.000 0.000 0.024 0.008 0.008
DETA-NO 0.000 0.000 0.048 0.016 0.016
TNF-α 0.193 0.281 0.088 0.187 0.056
E-selectin Experiment Number
Endothelial Treatment E14 E28 E18 Average SEM
Unstimulated 0.000 0.000 0.099 0.033 0.033
DETA-NO 0.000 0.000 0.104 0.035 0.035
TNF-α 0.569 0.712 0.462 0.581 0.072
ICAM-1 Experiment Number
Endothelial Treatment E14 E28 E18 Average SEM
Unstimulated 0.150 0.091 0.286 0.176 0.058
DETA-NO 0.275 0.244 0.468 0.329 0.070



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































LIGHT AND CONFOCAL MICROSCOPY PHOTOGRAPHS OF MECS TREATED 






TNF-α (6 hrs) 
 
Figure C.1  Endothelial cells after treatment with various 
reagents.  Panels on the left show live (green) and dead 
cells (red) after treatment with reagents (400X).  Panels 
on the right show light microscopy photographs after 




Fsk (pre + cont) + TNF-α (6 hrs) 
 
IBMX (pre + cont) + TNF-α (6 hrs) 
 




Bt2cAMP (pre + cont) + TNF-α (6 hrs) 
 
SNP (pre + cont) + TNF-α (6 hrs) 
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